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Abstract 
Conventional risk factors for cardiovascular disease, such as age, gender, 
hyperlipidaemia and hypertension are useful clinical markers of coronary artery disease 
(CAD) in asymptomatic patients or those without a prior history of atherosclerosis.  In 
patients referred for a cardiology opinion, modification of risk factors by lifestyle changes 
and cardiac medications as well as confounding co-morbidities limit the value of these 
markers.  Patients are often referred for diagnostic coronary angiography to determine the 
presence and severity of CAD, stratify the risk of future events and determine appropriate 
management.  Despite the use of a variety of tests to best identify those requiring 
angiography, up to half of all patients referred do not have significant disease.   
 Pulse wave analysis (PWA) is a novel method to derive indices of central (aortic) 
blood pressure and arterial stiffness.  Pressure waveforms are obtained non-invasively from 
the radial artery using a simple tonometry method and have been shown to correlate with 
clinical outcomes and cardiovascular events in selected populations.  This thesis will explore, 
for the first time, the clinical potential for PWA as a non-invasive marker of CAD in an 
unselected contemporary cohort of patients referred for elective coronary angiography.  The 
main hypotheses tested are first that PWA is a suitable tool for clinical use, including those 
with cardiac and non-cardiac co-morbidities and second that abnormalities of PWA are 
independent predictors of the presence and severity of CAD.  Data have been derived from a 
prospective, protocol-driven, multi-centre cohort of 550 patients recruited from 2006-8.   
Results suggest that PWA has a useful clinical role in stratifying the risk of coronary 
disease.  PWA variables were independent of conventional blood pressure measurement and 
superior to baseline risk factors, biomarkers and other non-invasive tests. 
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Chapter 1. Introduction 
 
Risk prediction is an important and emerging focus of cardiovascular health care, not 
least because of the perceived benefits in early targeting of high-risk patients but also to 
streamline management and reduce escalating costs.  In asymptomatic patients, risk scoring 
algorithms such as Framingham and the European SCORE project provide validated methods 
to ascertain 10-year risk.1, 2  Patients with pre-existing cardiovascular disease (CVD) are 
specifically excluded from these risk tables, although evaluation is frequently based on the 
same conventional risk factors (age, gender, diabetes, hypertension, total and high-density 
lipoprotein (HDL)-cholesterol, family history and smoking).  Apart from specific groups such 
as acute coronary syndromes, such risk stratification lacks evidence, particularly as risk 
factors are often attenuated by lifestyle changes or cardiac medications.  Many proceed to 
invasive diagnostic coronary angiography, the definitive method for identifying coronary 
artery disease (CAD).  In spite of stress testing with or without echocardiographic or nuclear 
imaging, a significant coronary artery stenosis is not demonstrated in up to half of assessed 
patients.3, 4  Angiographically-normal coronary arteries (NCA) constitute a substantial 
proportion of this group (10-20%), contributing to higher costs and inefficient use of scarce 
resources. 
14 
 
Although a generally safe procedure, complication rates for myocardial infarction 
(MI) and death are approximately 0.1% with bleeding complications quoted as high as 8.8% 
and vascular injury in up to 4%.5-7  Disease severity on angiography is closely linked to long-
term mortality8-10, despite the observation that angiographic severity of coronary lesions 
inaccurately predicts the time and location of a subsequent occlusion.11  Medically treated 
participants in the Coronary Artery Surgery Study Registry had a 12-year survival of 74%, 
59%, and 40% for patients with single, two- and three-vessel disease respectively.9  Patients 
with NCA have a favourable prognosis with similar long-term mortality and coronary 
morbidity to that of the general population, substantially better than for those with minor 
coronary irregularities (30-50% stenoses) or obstructive CAD (≥50%).3, 12, 13  
 
 The limitations of conventional risk markers for symptomatic patients have led to the 
evaluation of a number of novel variables, including biochemical markers and non-invasive 
measurements of endothelial function.  Identification of sub-clinical disease prior to overt 
atherosclerotic events is a key requirement for any biomarker, although the definition also 
includes indices that measure the effect of therapeutic interventions and provide surrogate 
clinical end-points based on scientific evidence.14, 15  Regardless of mechanism, biomarkers 
are expected to optimise patient management by adding, in some way, to standard risk 
stratification.  This thesis will explore the clinical application of pulse wave analysis (PWA), 
a non-invasive method to determine central arterial stiffness and aortic pressures.  Further, 
PWA will be compared with existing risk variables, biomarkers and other novel methods for 
assessing vascular risk.   
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The key hypotheses discussed are that: 
1. Prediction of the presence of CAD using conventional risk factors is inadequate in 
contemporary cardiology referrals due to patient heterogeneity and modification of risk 
factors [Chapter 3]. 
2. High-sensitivity C-reactive protein (CRP) and B-type natriuretic peptide (BNP) can aid in 
clinical determination of the risk of coronary artery disease [Chapter 3]. 
3. PWA is independently associated with the presence of arterial disease on coronary 
angiography [Chapter 4]. 
4. PWA can be used in a clinical setting despite variation in waveform quality due to patient 
co-morbidities [Chapter 5]. 
5. PWA is a superior predictor of CAD as compared with heart rate variability, pulse wave 
velocity and the resting electrocardiogram [Chapter 6]. 
 
[1.1]  Existing Risk Scores for Coronary Artery Disease 
The traditional ‘Framingham’ variables are the cornerstone of risk management and 
are derived from the original Framingham Heart Study data from the middle of the last 
century.  Men and women were enrolled who were free from CVD at the time of assessment.  
The subsequent addition of offspring cohorts and continued long-term monitoring for 
cardiovascular outcomes has provided a unique dataset for exploration of risk and the factors 
determining it.16  Although based on a specific population of largely white Americans, the 
Framingham risk scores have been successfully applied to other populations.  However they 
require recalibration in certain ethnic groups for differing prevalence of risk factors and the 
underlying rate of coronary events.17  As with any risk estimation, application to individuals 
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is not straightforward.  A risk score of 30% over ten years means that 70 out of 100 patients 
will not experience a cardiovascular event. 
An additional limitation of the Framingham algorithm are the small numbers of 
diabetic patients included in the original cohort (4%) and the proprietary definition of 
diabetes based on a random blood glucose of >9mmol/L or the use of anti-diabetic 
medication.  This has resulted in underestimation of risk in diabetics and with falling 
mortality rates from CVD, overestimation in low-risk groups.  A review of over 70000 
participants in 27 studies using Framingham-based charts confirmed that predicted to 
observed ratios for the composite of non-fatal and fatal coronary disease ranged from an 
under-prediction of 0.43 (95% confidence interval [CI] 0.27-0.67) in a high-risk population to 
an over-prediction of 2.87 (1.91-4.31) in a lower-risk population.18  The authors also found 
no evidence that the risk-assessment led to any improvement in outcome, confirmed by a 
Cochrane review assessing multiple risk factor interventions for primary prevention of 
coronary disease.19  Defining the risk for coronary events is demonstrably more difficult than 
mortality.  For example when the Framingham coronary event equation was applied to the 
British Regional Heart Study participants, only 106 of the predicted 677 men with a 10-year 
risk over 30% actually suffered an infarct.20  This sensitivity of 16% compares with 68% for 
CAD mortality. 
Despite these problems, the Framingham calculations remain a widely used tool in 
determining the risk of CAD, with most countries employing modified versions in risk 
calculators and treatment guidelines (for example the Joint British recommendations21, the 
New Zealand Guidelines Group22 and the American Heart Association23).  The discrepancy in 
predicted and observed mortality using Framingham variables have led investigators to 
consider alternative factors that could be of prognostic value and to reassess existing 
variables in contemporary populations.  These include the European SCORE project2 (based 
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on a pooled dataset of 205178 individuals without a history of prior myocardial infarction) 
and QRISK which additionally incorporates body mass index (BMI), family history of CAD, 
measures of social deprivation and existing treatment of hypertension.24  QRISK was derived 
in 1.28 million primary care patients in the UK free of diabetes and CVD and validated in a 
cohort consisting of 0.61 million patients.  As expected, QRISK was better calibrated to the 
UK population than Framingham scores, although surprisingly its ability to discriminate 
CAD was roughly equivalent.  In women, the area under the receiver operator curve (ROC) 
for 10-year risk of CVD was 0.788 for QRISK and 0.774 for Framingham and in men the 
corresponding c-statistics were 0.767 and 0.760.  Neither of the scores predicted more than 
35% of the variability in the risk of CVD24, suggesting other factors unrelated to conventional 
risk predictors are driving the development of atherosclerosis in patients without prior 
disease. 
 
One of the only prospective risk tools to include patients with a previous history of 
CVD was the Epidemiological Prevention Study of Zoetermeer (EPOZ).25   Since 1975, a 
population cohort in the Netherlands has been followed-up, with data at 11.5 years available 
on 6,057 participants of which 9.5% died.  At baseline 2.3% had a prior MI, 0.6% a previous 
stroke, 1.2% a diagnosis of diabetes and 11.9% were on antihypertensive medication.  
Variables related to all-cause mortality in both sexes were age and diabetes.  For men, heart 
rate, smoking, antihypertensive drug use and a history of MI were significant adjusted risk 
factors, whereas for women (accounting for 53% of the cohort) BMI and systolic blood 
pressure (BP) were the only other independent markers of death.  There was no association of 
serum cholesterol with mortality in either gender. 
 
18 
Risk algorithms have also been developed for patients with acute coronary 
syndromes.  The INTERHEART study enrolled 15152 cases of acute MI (symptoms plus 
electrocardiographic changes) and 14820 age and sex-matched controls across 52 countries.26  
The majority of predicted risk was accounted for by hyperlipidaemia, smoking, hypertension, 
diabetes, abdominal obesity, psychosocial factors, regular physical activity and consumption 
of fruits, vegetables, and alcohol.  Similarly the GRACE registry evaluated 43810 patients, 
21688 in the derivation cohort and 22122 in the validation set.27  Recruited participants 
presented with an acute coronary syndrome and had either unstable angina, ST elevation MI 
or non-ST elevation MI.  In the period from admission to six months after discharge, the 
independent predictors of death and the combined end point of death or MI were age, heart 
failure, peripheral vascular disease, systolic BP, Killip class, creatinine, elevated cardiac 
markers, cardiac arrest on admission and ST changes on the electrocardiogram (ECG). 
 
Patients presenting to cardiology often comprise a population that lies between those 
who are asymptomatic with no prior history of major atherosclerotic disease and the group of 
patients with acute coronary syndromes.  These include individuals with typical and atypical 
cardiac symptoms, as well as those with prior CVD who lack the characteristics of an acute 
event.  Commonly this group are actively treated for hypertension, diabetes and other risk 
factors and may have instituted risk-modifying practices such as participation in physical 
exercise, dietary fat reduction and smoking cessation.  Risk prediction in this population has 
been not been extensively studied.  Published data are rarely prospectively validated and 
specific to the group of patients studied and their particular risk factor prevalence.  The true 
benefit of stratification of risk using conventional factors in this population is therefore 
unknown.   
 
19 
Electrocardiograms and Risk Stratification 
 The resting ECG has been used to improve risk prediction in patients suspected of 
coronary disease.  In the Uppsala Swedish cohort, 1139 men assessed at age 50 were re-
evaluated at the age of 70 and followed-up for 32 years.28  The addition of ECG variables 
indicating ischaemia significantly increased the predictive power of the Framingham score 
(c-statistic 0.671 with ECG parameters versus 0.583 without; p=0.001).  Persistent ischaemic 
changes were associated with twice the risk of mortality compared with new ECG changes 
developing between the age of 50 and 70.  However, although ischaemic features at age 50 
had a long-term prognostic value for subsequent fatal and non-fatal MI (hazard ratio 2.27, 
95% CI 1.72-3.00), when re-measured at 70 years of age the significance for prediction of MI 
was lost.  Further, in the British Regional Heart Study of 7735 middle-aged men, serious 
ECG abnormalities were predictors of future coronary events only in men with symptomatic 
disease.29  In those without symptoms, the ECG had little or no value as a screening tool.  
Population studies of healthy men have identified a small but statistically significant 
increase in the risk of death from CAD due to frequent ventricular ectopics, left ventricular 
hypertrophy and ischaemia-related changes.  Unfortunately there is no evidence that early 
detection of these ECG abnormalities can lead to interventions which improve cardiovascular 
outcomes.30  The sensitivity of the resting ECG for future coronary events is too low for use 
as a practical screening tool; as a predictor of mortality sensitivity is 8-18% for ST depression 
and 4-21% for pathological Q-waves.31  ST changes occur not only with myocardial 
ischaemia but also cardiomyopathies, pulmonary thrombo-embolic disease, drugs (for 
example digoxin) and electrolyte abnormalities. 
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[1.2]  Biochemical Markers 
A variety of biochemical markers have been shown to correlate with CAD, coronary 
events and cardiovascular death.  Those with statistically significant associations include 
high-sensitivity CRP and BNP as well as interleukin-632, 33, fibrinogen34, apolipoproteins35, 36, 
serum amyloid A37, 38, platelet activating factors39, activated clotting factors V and VII40, 
phospholipase A241, homocysteine42, sphingomyelin43 and haemoglobin A1c.44, 45  However 
their use in clinical practice is ill-defined and of questionable value when added to traditional 
risk scores.  An evaluation of 10 biomarkers in a community cohort of 3209 Framingham 
Heart Study participants identified only a marginal increase in the ability to classify risk 
above conventional variables.46   
 
CRP has the advantage of being widely available and well-known to clinicians.  It is 
traditionally used as a marker for inflammation but may also have a role in the pathogenesis 
of atherosclerosis via oxidised low-density lipoprotein (LDL) binding, tissue factor 
production, complement activation and stimulation of ICAM-1 expression47, 48.  Highly-
sensitive CRP assays have been shown to correlate with cardiovascular events in healthy 
patients as well as those with established coronary disease.  In a prospective cohort study of 
15632 initially healthy US women aged 45 years or older, the hazard ratio for cardiac events 
in those in the highest quintile of CRP was 2.98 (95% CI 1.90-4.67), after adjustment for age, 
smoking, BP, diabetes and body mass index49.  Zebrack et al found only a weak correlation 
between CRP and the extent of CAD in 2554 patients with angina and a normal creatine 
kinase-MB fraction.50  However in patients with extensive CAD, the risk of death or MI was 
23.5% in those with CRP>2mg/L compared to 8.4% with CRP<1mg/L.   
A number of recent studies have presented less beneficial data on the use of high-
sensitivity CRP.  In meta-analysis of 22 studies and 7068 participants, only a modest 
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correlation between coronary events and CRP was identified with an overall odds ratio (OR) 
of 1.45 (95% CI 1.25-1.68).51  Studies published prior to 2000 showed a much greater 
association than more contemporary trials, most likely a consequence of recent increases in 
statin prescriptions which are known to lower CRP.52, 53  In a study of patients with stable 
coronary disease, those with high-sensitivity CRP>3.8mg/L had an odds ratio of 4.2 for 
exercise-induced ischaemia on stress echocardiography but this was only significant in those 
patients not treated with statins or beta-blockers.54  Elevated CRP levels in the general 
population are largely attributable to abnormalities in traditional risk factors and rarely raised 
in their absence, questioning the clinical usefulness of testing.55 
 
BNP is released from the myocardium in states of wall stress and cardiac 
decompensation.  It has been shown to correlate with the prognosis of both heart failure and 
acute coronary syndromes, and may be of use in assigning treatment strategies.56, 57  The titre 
of BNP can define the mortality risk in unstable coronary disease and the risk of future heart 
failure.58, 59  A recent study of over 1000 patients undergoing coronary angiography 
confirmed that high levels of natriuretic peptide predicted clinically significant coronary 
disease.60  This result was independent of traditional risk-factors and left-ventricular function.  
However the authors comment that due to the low predictive value, BNP was not useful as an 
isolated screening tool for identifying coronary disease.  In contrast, natriuretic peptides can 
assist in risk stratification of acute dyspnoea, guide therapy to improve clinical outcomes and 
are powerful markers of death and re-hospitalisation in patients admitted with heart failure.61 
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[1.3]  Pulse Wave Analysis 
Left ventricular output determines many important characteristics of cardiovascular 
function and hence in determining cardiovascular risk.  The arterial tree is also a complex 
inter-dependent organ that responds in various ways according to its local construction (the 
distribution of smooth muscle, collagen and elastin) with haemodynamic and neurohormonal 
overlay.62  Brachial BP measured using a sphygmomanometer cuff, has been the standard 
method of assessing arterial pressure for many years.  It is technically easy and cheap to 
perform and there is abundant evidence to support its use in predicting cardiovascular risk63-
66, although some controversy remains over the use of systolic and diastolic versus mean and 
pulse pressures (PP).67   As BP is not a static pressure wave, identifying the peak and trough 
values alone is somewhat arbitrary.  Arterial pressure can be considered as having two 
components, a steady pressure determined by cardiac output and peripheral vascular 
resistance and a pulsatile constituent that is dependent on the mechanics of ventricular 
ejection and aortic compliance.68  Work on arterial waveforms has added greatly to our 
knowledge of the latter component with recent technologies now allowing non-invasive 
assessment of previously inaccessible territory.  However to be a functional clinical tool, such 
devices must be simple, validated and refine the risk assessment provided by standard BP 
measurement. 
PWA provides a non-invasive method of assessing central (i.e. aortic) pressure and its 
determinants, using applanation of a peripheral artery.69  In a similar fashion to the 
measurement of intra-ocular pressure, applanation involves the use of a tonometer on the 
radial, femoral or carotid arteries.  By equalising the circumferential stress on the arterial 
wall, a waveform is produced that accurately represents actual arterial pressure.69, 70  PWA 
goes further in using a generalised transfer function to convert this waveform into one 
approximating that in the ascending aorta.  As the primary determinant of left ventricular load 
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and arterial distensibility is central rather than peripheral pressure, PWA seeks to define 
cardiovascular risk over and above that obtained by brachial BP alone. 
 
  High central pulse pressure (cPP) and central augmentation pressure (cAP – see 
Figure 1.1) have been identified as markers of arterial stiffness and are independently 
associated with cardiovascular events.  In both CAFE-ASCOT (Conduit Artery Function 
Evaluation from the Anglo-Scandinavian Cardiovascular Outcomes Trial; n=2073)71 and the 
Strong Heart Study (n=2403)72, these derived pressures were superior to standard BP 
measurement for determining clinical outcomes. 
 
Figure 1.1:  Pulse Wave Analysis – Derived Aortic Pressure Waveform 
 
 
 Examples of PWA-derived aortic pressure waveforms from the ARM-CAD study.  cAP, central augmentation 
pressure; cPP, central pulse pressure; cAI, central augmentation index (cAP/cPP x 100). 
 
As demonstrated in Figure 1.2, publications in this field have increased in the last few 
years, with some notable and large clinical-outcome studies using commercially-available 
devices.  However a number of investigators have questioned this move to clinical use citing 
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issues with the transfer function and validation in the clinical setting.  A further criticism 
involves the generalisability of this technique with most studies excluding patients with 
abnormal ventricular function, arrhythmias or conduction defects and anything greater than 
mild valvular dysfunction.  The scope of this literature review is to assess the validation of 
radial PWA in the clinical setting and provide a summary of the published literature to define 
the presence and severity of coronary artery disease.  As noted, PWA techniques can be 
applied to a number of peripheral arterial sites.  Although the carotid is attractive with regards 
to proximity to the aorta73, clinical use is complicated by more difficult waveform acquisition 
(requiring technical expertise)74, baro-receptor activation and the theoretical possibility of 
carotid plaque disruption.75  Hence this thesis will focus on data for radial PWA as the most 
likely to be applied in future clinical practice. 
 
Figure 1.2:  Citations for Pulse Wave Techniques 
 
 
 Citations per year from the National Library of Medicine's 'PubMed' Service.  Total citations 
in grey (left axis) and percentage of citations matching keyword search for "Pulse Wave" in 
black (right axis).  Significant increasing trend for Pulse Wave citations (p<0.01). 
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Pressure Mechanics of the Aortic Pulse 
The pressure waveform of the aortic pulse is markedly different to that of flow, 
suggesting an additional force is involved in the creation of aortic pressure.  This is supported 
by the rise in pressure during systole while the flow is decreasing, the presence of secondary 
pressure waves in diastole (when flow is effectively zero) and peripheral amplification of the 
pressure waveform.  Work by McDonald, later supported by Nichols, O’Rourke and others 
have provided an elegant solution in the form of wave reflection.  In this model, the 
transmitted aortic pulse is modified by returning reflections, the latter principally determined 
at sites of bifurcation and high-resistance arterioles.69, 76  The summation of the reflecting 
waves from the vascular bed can augment the systolic pressure depending on where in the 
cardiac cycle they return.  As the velocity of the aortic pulse will determine the time it takes 
for these reflections to return, arterial distensibility is a major component of wave reflections.  
Hence the use of PWA as a surrogate measure of ‘arterial stiffness’. 
 
Murgo et al have shown that the aortic waveform is highly dependent on age.77  In 
younger subjects, lower pulse wave velocity (PWV) causes reflected waves to arrive later in 
the cardiac cycle (closer to the time of the incisura caused by aortic valve closure) and may 
act to bolster diastolic pressure.  As the vascular tree ages and becomes less distensible, 
central systolic BP is enhanced due to higher PWV (leading to earlier reflection) and 
increased magnitude of reflected waves.  This augmentation pressure can therefore lead to a 
cycle of enhanced cardiac workload, hypertrophy and eventually cardiac ischaemia.76, 78  The 
drop in diastolic pressure associated with earlier reflectance may diminish coronary perfusion 
adding to this effect (see Figure 1.3).   
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These vascular changes also occur in disease states such as diabetes, hypertension, 
end-stage renal failure and atherosclerosis, a similar scenario of aortic stiffening and 
increased pulse wave velocity.69, 79-83  However recent and evolving data suggest a more 
complex physiology; meta-analysis has identified that summation of reflected waves, even in 
the young, arrives entirely in systole.84  Furthermore, in healthy individuals at least, forward-
travelling waves are predominantly responsible for pulse pressure and impedance mismatch 
between the aorta and its muscular tributaries as age increases causes reflection to occur more 
distally.85, 86  After accounting for volume-related changes in arterial pressure (“reservoir 
pressure”), the contribution of reflected and indeed forward-travelling waves to BP reduces 
Figure 1.3:  Cause and Effects of Earlier Reflected Aortic Waves 
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substantially and may not account for the rise in augmentation associated with age or vascular 
disease.87  These factors may explain the disparity seen in numerous studies between 
reflection timing and augmentation index, requiring new methodological hypotheses. 
 
Practical Application of PWA 
Despite substantial theoretical advantages to analyzing the peripheral artery 
waveform, a number of objections have been raised.  Principal among these is:  1) the use and 
validity of a generalised transfer function (GTF) to convert the peripheral waveform into one 
resembling the aortic without obtaining the central pressure data directly; and 2) that the 
transformation is calibrated by brachial BP.  As depicted in Figure 1.4, the aortic waveform 
has an accentuated peak, higher systolic BP due to reflected waves as noted above, delayed 
timing (dependent on pulse wave velocity) but similar diastolic pressure compared to the 
radial artery.88  The GTF was initially derived on a small number of subjects during cardiac 
catheterisation89, whereby Fourier analysis (a sinusoidal frequency decomposition of the 
waveform) is used to produce individual transfer functions which are summed to produce a 
GTF.69, 90  Commercial devices such as SphygmoCor® have satisfied US Food & Drug 
Administration criteria for “substantial equivalence” with true aortic pressure, although 
whether such a generalisation can apply to individual patients is still unclear.91-94  The use of 
different types of GTF model can lead to varying results, largely due to the components of 
the GTF and how it is derived.95  Gender differences in transfer functions have also been 
noted.96  
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Figure 1.4:  Radial-Aortic Generalised Transfer Function 
 
     
 Example of measured (radial) and derived (aortic) pulse waveforms obtained using a 
generalised transfer function (GTF). 
 
Table 1.1 summarizes five validation studies, each with methodological concerns and 
highlighting the difficulty in achieving consensus on the success of GTFs.  Critics would 
argue that such a concept is ideologically flawed and that a single transfer function cannot 
hope to accommodate variable circumstances, both individual-specific (amount of peripheral 
vascular disease or medication usage for example) and patient-group related (patients with 
and without heart failure).  From the available evidence we can infer that deriving central 
pressures using PWA is better validated than variables such as central augmentation index 
(cAI - augmentation pressure as a percentage of pulse pressure) due to amplification of error 
in brachial BP recording and the high-frequency loss of transfer functions.97  A further issue 
is the difficulty in identifying the inflection in the waveform caused by reflected waves when 
they occur after peak pressure.98, 99  This only tends to occur in younger populations but may 
have important implications in assigning risk to individuals.  Regardless of whether the GTF 
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provides a completely accurate representation of aortic pressure, proponents would argue that 
the method is sufficiently robust to be tested in clinical studies of risk prediction. 
 
Reproducibility of PWA is generally good, with most published studies suggesting 
low intra and inter-operator variability.  Table 1.2 highlights the major studies assessing 
reproducibility of radial assessment.  Missing from the literature however is an analysis of the 
quality of radial waveforms obtained and the impact this might have on predictive capacity.  
Use of this technology in the clinical setting will no doubt result in more variation than is 
typically found in research studies.  For PWA to be accepted in the routine work-up of those 
at risk of cardiovascular disease, it must retain a clinical utility.  Recommendations from 
consensus groups about the need for standardising subject conditions (particularly with 
regards to resting periods and restriction of smoking and food intake prior to assessment)100 
may severely impinge on practical use in an out-patient setting. 
  
 
30 
 
Table 1.1:  Major Studies Assessing Validation of PWA Transfer Function 
N Population Demographics Transfer Function Validation Concerns/issues Reference 
62 Anaesthetised cardiac surgery 
patients 
Mean age 61 
73% male 
Mean LVEF 47% 
Minimal difference in derived aortic pressures from measured. Radial waveforms obtained 
invasively by radial cannulation. 
101 
20 Varied – 12 with CAD,              
2 healthy and 5 post-transplant 
Mean age 59 
80% male 
GTF as good as individual transfer functions in defining aortic 
waveform and accounted for haemodynamic changes. 
cAI lower using GTF (p<0.05). 
Calibrated from invasive aortic 
pressures. 
97 
30 Undergoing angiogram Mean age 56 
70% male 
Mean LVEF 60% 
Strong correlation and little difference in pressures derived from 
PWA and cardiac catheterisation. 
Calibrated from invasive aortic 
pressures. 
Excluded patients with severe 
disease. 
102 
50 Undergoing angiogram;               
21 normal, 2 dilated 
cardiomyopathy, 27 CAD 
Mean age 54 
50% male 
Mean LVEF 60% 
Close correlation in systolic pressure (r=0.89), however difference 
between measured and calculated diastolic pressure was large 
(mean difference -10.4mmHg, r=0.59).   
Brachial pulse pressure closer to 
aortic than calculated by GTF. 
Excluded arrhythmias and 
significant valve disease. 
103 
30 Undergoing angiogram;           
age >65 in 50%, 17 with CAD 
Mean age 64 
60% male 
Marked difference in derived and measured pressures.  GTF 
underestimated central systolic and overestimated diastolic 
pressure. 
Single cuff BP measurement only.  
Brachial pressure closer to aortic 
than GTF-derived. 
104 
78 Undergoing angiogram; 
population undefined 
Mean age 63 
78% male 
Close correlation between measured and calculated pressures 
(p<0.01).  However marked individual scatter resulting in no 
significant association between measured and derived cAI. 
Fluid-filled catheter-manometers 
are known to dampen higher 
frequencies.103 
105 
LVEF, left-ventricular ejection fraction; GTF, generalised transfer function; cAI, central augmentation index. 
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Table 1.2:  Major Studies Assessing Reproducibility of Radial PWA 
N Population Demographics Reproducibility Comments Reference 
25 Healthy volunteers Mean age 33 
60% male 
 
Mean difference ± SD between two operators: cPP 0.1 ± 
0.7mmHg; cAI 0.4% ± 6.4%.  Percentage within two SD of 
mean: cPP 93%; cAI 94%. 
 106 
88 Hospital staff without a history of 
CVD or medication usage 
Mean age 31 
20% male 
Small (2.2%) but significant variation in derived cPP 
between two visits. 
 107 
20 Ambulatory patients, 10 with 
medicated hypertension, 10 
without hypertension or CVD 
Mean age 56 
80% male 
Intra-observer difference 0.1% as a proportion of range.  
Inter-observer difference in heart-rate adjusted cAI 1.0 ± 
2.0% between two operators. 
Two clinical nurses with limited 
previous experience. 
108 
33 5 controls, 12 diabetics and 16 
hypertensive patients 
Mean age 51 Mean intra-observer difference for cAI 0.49 ± 0.93%.        
Inter-observer difference 0.23 ± 0.66% (two operators). 
 109 
534 White Europeans excluding those 
at high risk 
Mean age approx 35 
43% male 
Intra-observer coefficient of variation less than 3%,          
inter-observer approx 5% (3 centres). 
Reproducibility study examined 
10-12 subjects per centre 
110 
19 Intensive care patients with 
cardiogenic shock post-infarct       
(in sinus rhythm) 
Mean age 64 
68% male 
Mean BP (before balloon 
pump) 87.7 / 48.1mmHg 
Intra-observer differences: cAI 0.10 ± 5.82%;                   
cAP 0.02 ± 1.29 mmHg. 
 95% of cAI and 97% of cAP within two SD. 
Reproducibility acceptable in 
different haemodynamic 
conditions. 
111 
439 Attending cardiovascular 
outpatients 
Mean age 59 
53% male 
52% CAD, 11% heart failure 
Transfer function modulus stable between sexes, at different 
blood pressures, across age ranges and when given 
nitroglycerin or midazolam. 
Work from theses, reviews and 
abstracts; original data 
unavailable. 
112 
SD, standard deviation; cPP, central pulse pressure; cAI, central augmentation index; cAP, central augmentation pressure.
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Factors Influencing PWA 
Cardiac risk factors have notable effects on central pressures and augmentation 
indices.  Increasing age, as discussed earlier, is a major determinant of augmentation, with 
lack of large artery distensibility leading to earlier wave reflection.  The relationship between 
age and augmentation pressure is linear, however the association with cAI is not.110, 113  After 
the age of 50 the slope flattens, with a much weaker correlation coefficient.  As this is the 
inverse of the relationship between pulse wave velocity and age, it suggests that 
augmentation index in younger subjects is principally due to the magnitude of wave 
reflection, whereas it constitutes earlier wave reflection in older age-groups.  This has been 
confirmed in a large study of healthy normotensive individuals113 as well as our own cohort 
of symptomatic cardiology patients undergoing coronary angiography (refer to Figure 4.7, 
page 94). 
Augmentation pressures are considerably greater in women as compared to men.80, 110, 
114, 115  Multivariate analysis suggests that lower height in women (and hence reduced arterial 
distance) only partially explains this difference.86, 114  As such there may be other 
confounders at work or a more fundamental difference in the mechanical and/or hormonal 
properties of reflected wave propagation.  
Heart rate and blood pressure are also strongly correlated with augmentation 
pressure.115  Heart rate has a linear inverse relationship with cAP and cAI.116  Physiologically 
as heart rate increases the duration of systole reduces, resulting in later arrival of reflected 
waves and less augmentation of the systolic peak.  Commercial devices often adjust for heart 
rate, although the basis for their adjustment is unknown.  With regards to other cardiac risk 
factors, patients with diabetes, hypercholesterolaemia and renal failure have all shown 
increases in augmentation compared with controls.79, 82, 83 
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Effect of Medications on PWA 
PWA has successfully been used to characterise the effects of different cardiac 
medications and determine their mode of action beyond simple blood pressure lowering.71, 117  
However few clinical studies have adequately accounted for the impact of medications on 
measured variables.  Nitrates have been shown to reduce afterload by arterial dilatation as 
well as their effects on preload through venous dilatation.118  As such cAI and central 
pressure indices are reduced, despite very little effect on brachial BP, aortic 
resistance/compliance measures and pulse wave velocity.119  Both angiotensin converting 
enzyme (ACE) inhibitors and calcium-channel blockers have been shown to benefit arterial 
elasticity, reducing wave velocity and cAI.120  Invasive experimental studies suggest that 
calcium-channel blockers have both an immediate and longer-term effect on aortic 
distensibility whilst ACE inhibitors take time for their effects to manifest, possibly through 
endothelial mechanisms.121, 122   
The consequences of beta-blockers are complicated by their effects on heart rate.  
Magnetic resonance imaging to determine aortic elastic modulus has identified that atenolol 
is as good as cilazapril at improving aortic distensibility123 but due to heart rate reductions 
beta-blockers increase augmentation indices.  This was brought to focus in the CAFE study.  
2073 hypertensive patients from the ASCOT trial were assessed with PWA to determine why 
the amlodopine/perindopril arm of ASCOT had a better clinical outcome than the 
atenolol/thiazide arm.71  The latter group had significantly increased central and 
augmentation pressures despite similar brachial blood pressure.  The authors question 
whether atenolol, by delaying the reflected peak and enhancing afterload, may have led to the 
increased mortality and coronary events of the atenolol/thiazide arm.71  Similar findings were 
reported in the REASON study comparing perindopril/indapamide with atenolol.124  Further 
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work is required to establish if newer third generation beta-blockers may avoid these issues, 
particularly in light of dilating and anti-inflammatory properties.125-127  
 
Correlation with Clinical Endpoints 
A number of studies have highlighted PWA as an independent marker of coronary 
disease, both for mortality prediction and coronary events.  These include studies based on 
populations without pre-existing CVD, as well as those with significant risk factors and 
demonstrated coronary disease. 
The Strong Heart Study examined 2403 American Indians free of overt CVD or atrial 
fibrillation with radial PWA and documented 319 cardiovascular events in the 4.8 years of 
follow-up.  In multivariate Cox models, derived central pulse pressure (adjusted for age, 
gender, BMI, smoking, cholesterol:HDL ratio, creatinine, fibrinogen, diabetes and heart rate) 
had a hazard ratio of 1.15 (1.07-1.24; p<0.001) per 10mmHg.72  Compared to brachial 
measurement, cPP remained significant in those over the age of 62 and when anti-
hypertensive medications were included in the model.  Of note, 47% of the population were 
diabetic; as higher pulse wave velocity and wave reflection can occur in diabetics even with 
no clinical evidence of atherosclerosis82, extrapolation to a more typical population is 
uncertain. 
In the afore-mentioned CAFE-ASCOT trial, hypertensive patients with 3 additional 
risk factors were recruited.  A 10mmHg rise in augmentation pressure related to a hazard 
ratio of 1.21 in an adjusted model for the composite endpoint of cardiovascular events, 
procedures and development of renal impairment (95% confidence interval 1.01-1.45, 
p=0.04).71     
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Considering those with known coronary disease, Chirinos et al studied 297 male 
veterans with a coronary artery stenosis of more than 10%.128  Aortic pressures measured at 
catheterisation were correlated with a composite endpoint of death, MI, stroke, unstable 
angina and revascularisation procedures over a three-year period.  With or without adjusting 
for confounders (including ejection fraction, pulse pressure and heart rate), cAP and cAI 
significantly predicted this composite outcome.  There was a 20% increase in risk for each 
10mmHg rise in augmentation pressure or 10% rise in cAI.  Similar to other studies in this 
field, waveform calibration was performed by invasively-determined pressures rather than 
brachial cuff pressure.  An additional criticism is that for almost 28% of subjects cAI was 
equated to zero as the inflection point in the incident waveform could not be identified.  
 
 In a separate study of 262 patients undergoing percutaneous coronary intervention, 
those reaching the primary endpoint of death, infarct or clinical restenosis had higher heart-
rate adjusted cAI (25.8 ± 10.8 versus 20.2 ± 9.9, p<0.001)129.  Patients with significant 
valvular disease, ejection fraction <35% and atrial fibrillation were excluded, and the 
remainder followed for 24 months.  Multivariate analysis showed adjusted-cAI to be an 
independent predictor of the primary endpoint, above that obtained from clinical risk factors 
and angiographic parameters.  However the absolute numbers of events was small, with 12 
deaths and 17 non-fatal infarcts resulting in large confidence intervals for individual 
endpoints.  Table 1.3 summarizes the major studies discussed above, in particular 
concentrating on the assessment of derived central measures versus standard brachial blood 
pressure.  Despite growing evidence that PWA is an independent marker of risk, the value 
above conventional sphygmomanometry is still unclear. 
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Table 1.3:  Major Studies Assessing Clinical Outcomes Using Radial PWA 
N Population Demographics Variable Endpoints Results Comments Reference 
2403 American-Indians free of overt 
CVD or atrial fibrillation 
Mean age approx 63 
35% male 
47% diabetic 
52% hypertensive 
cPP, per 
10mmHg 
Fatal or non-
fatal CVD 
events 
Adjusted hazard ratio of 1.15 for 
cPP (95% CI 1.07-1.24; p<0.001).  
Hazard ratio for bPP was 1.10 
(1.03-1.18; p<0.01) but not 
significant when included with cPP 
or in the over 62 age-group. 
Specific population with high 
proportion of diabetics. 
Questionable benefit of central 
measurement  in younger age-
group 
72 
Strong 
Heart 
2073 UK hypertensive patients with 3 
or more additional risk markers, 
excluding prior myocardial 
infarct, recent CVD events or 
heart failure 
Age 40-79 
81% male 
24% diabetic 
11% prior CVD 
cPP & cAP, 
per 10mmHg 
CVD events or 
procedures and 
new renal 
impairment 
Adjusted hazard ratio for cPP 1.13 
(1.02-1.26; p=0.03), bPP 1.12 
(1.01-1.24; p=0.03) and cAP 1.21 
(1.01-1.45; p=0.04). 
Very specific entrance criteria. 
Benefit of using central 
measurements over peripheral 
unclear.130 
Post-hoc defined composite 
outcome. 
71 
CAFE-
ASCOT 
262 Austrian percutaneous coronary 
intervention patients, excluding 
ejection fraction <35%, 
moderate or severe valvular 
disease, atrial fibrillation and 
poor quality waveforms 
Mean age 66 
71% male 
23% diabetic 
69% acute coronary 
syndrome 
15% 3-vessel disease 
cAI (cAP/cPP) 
adjusted for 
heart rate of 
75 beats/min 
Death, 
myocardial 
infarction and 
clinical 
restenosis 
cAI was significantly higher in 
those reaching composite or 
individual endpoints.  In 
multivariate analysis, the risk ratio 
per increasing cAI tertile was 1.80 
(1.18-2.76; p<0.01). 
Unlike cAI, bPP was not an 
independent predictor of the 
endpoint.  
Waveforms assessed for 
inclusion by the principal 
investigator. 
129 
cPP, central pulse pressure; bPP, brachial pulse pressure; cAP, central augmentation pressure; cAI, central augmentation index.
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Correlation with Coronary Angiography 
Utilising PWA as an alternative or addition to other assessments of coronary disease 
would appear advantageous, particularly if able to reduce or streamline the need for invasive 
studies.  Coronary angiography is a common procedure and remains the gold standard for 
identifying obstructive CAD.  Hence a number of studies have compared PWA with 
angiographic results. 
In a study of 46 chronic kidney disease patients, cAI increased as more coronary 
vessels were affected.131  This varied group consisted of patients both on and off dialysis and 
post-transplant recipients.  Weber, O’Rourke and colleagues assessed 465 unselected male 
patients undergoing coronary angiography, the only exclusion being significant valvular 
disease.132  12% of their population had non-obstructive (<50% stenosis) or no CAD, 
providing the comparator group.  Significant risk ratios for CAD were identified for the two 
highest quartiles of augmentation index and the per quartile ratio, albeit with large confidence 
intervals.  Interestingly this risk increased after adjustment for confounding factors, 
suggesting that cAI has some degree of independence from these parameters.  Crude odds 
ratio for the highest quartile (cAI>29) versus lowest quartile (cAI< -9) was 4.06 (1.72-9.57) 
with an adjusted odds ratio of 6.91 (1.14-33.70).  Comparing those with and without CAD, 
the values of cAI were 21.5 ± 11.7 versus 17.1 ± 12.0 respectively (p=0.007).  The CAD 
group were older, with a lower diastolic BP, higher pulse pressure and were more likely to be 
taking nitrates, beta-blockers, ACE inhibitors and statins.  Whilst central augmentation 
pressure and index were significant predictors of CAD in the group as a whole, these 
variables lost their significance in sub-group analysis of the over 60 age-group.  Similarly 
although cAP and cAI had weak but significant correlation with the severity of CAD, this 
was also age-dependent.  In older patients (with invariably high augmentation pressure) this 
relationship was absent.  These results highlight that cAI may be useful in assessing the risk 
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of significant CAD, but only in specific populations.  Indeed, if confirmed, they would 
suggest that once arterial distensibility is partially lost (as occurs in normal aging), the 
predictive power of assessment using a distal site, such as the radial artery, is also lost.  
Alternatively cAI could be considered a marker of premature arterial stiffness; once a certain 
level of stiffness has been attained, changes in augmentation are no longer valuable for 
assessing the presence of CAD.  It should also be noted than this study looked at males only.  
The higher AI found in women may diminish the significance of augmentation parameters in 
a mixed population, although this remains to be adequately examined.  
Complementing some of these findings is a study of 184 patients with >50% CAD.133  
In this group, 158 were male, 113 had a history of prior MI and the mean age was 61.  
Central augmentation index derived from radial PWA was not significantly different in 
patients with single, double or three-vessel disease.  The investigators also utilised intima-
media thickness of the carotid artery and ankle-brachial pressure to assess extra-coronary 
atherosclerosis.  Patients with abnormalities in these variables were more likely to have 
higher cAI.  Extra-coronary atherosclerosis may therefore explain some of the increased 
mortality observed in patients with higher augmentation index.   
 
[1.4]  Other Non-invasive Risk Markers 
A number of non-invasive techniques are now available to assess cardiovascular risk 
and in-depth comparisons have previously been published.120, 134-136  Measures of arterial 
stiffness are discussed in clinical guidelines137 and consensus documents74, 100, 138 and should 
not only discriminate between those with and without disease (i.e. appropriate sensitivity and 
specificity) but add incrementally to current evaluation.15  Imaging methods (for example 
magnetic resonance imaging), intima-media thickness (arterial wall ultrasound measurement, 
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usually of the carotid), pulse wave velocity (distance/time, typically carotid-femoral) and 
heart rate variability (measuring sympathetic and vagal modulation of heart rate) are all 
promising alternatives.  Unfortunately resource requirements and operator skills are likely to 
limit the practical application of the former two techniques.  Augmentation properties from 
the carotid artery are independently associated with all-cause and cardiovascular mortality in 
renal failure patients139 and are predictors of myocardial ischaemic threshold in CAD 
patients.140  However for the reasons listed previously, carotid PWA may not be suitable for 
widespread clinical application.     
Ankle-brachial index (ABI) compares systolic BP at the posterior tibial or dosalis 
pedis arteries with brachial pressure using a Doppler probe.  Traditionally used to assess 
peripheral vascular disease, this technique has been extended to more general use as a marker 
of cardiovascular risk.  Meta-analysis of cardiovascular outcomes identified that 10-year 
mortality in men with a low ABI (≤0.90) was 18.7% compared with 4.4% in those with ABI 
in the normal range of 1.11-1.40 (n=24955).  For women (n=23339) corresponding 
mortalities were 12.6% and 4.1%.141  Unfortunately the association of ABI with CVD and 
mortality is not linear but u-shaped with increased risk as ABI rises above 1.40.  
Incompressible peripheral arteries due to calcification of vessel walls are more common in 
patients with peripheral vascular disease and diabetes, confounding risk prediction.  Further, 
ABI can drop substantially during exercise in a third of cases assessed for intermittent 
claudication despite relatively normal resting mesurements.142 
Electron-beam coronary artery calcium scoring can identify calcified atherosclerotic 
coronary plaques and higher levels are independently associated with coronary events in 
symptomatic143 and asymptomatic patients144 as well as those with uncomplicated diabetes.145  
The clinical role and cost-benefit of calcium scoring is still unclear, particularly in light of 
recent developments in multi-slice technology.  Computed tomography scans of the coronary 
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arteries are increasing as a non-invasive screening test for CAD.  Investigations have focused 
on the potential to replace the need for conventional invasive coronary angiography.  The 
technology involved is rapidly progressing and most facilities now have the ability to scan 
using 64-slice machines.  Computed tomography angiography can reliably exclude 
obstructive coronary lesions146, although abnormalities identified still require a second 
radiation dosage in the form of conventional angiographic investigation.147  The risk of 
cancer associated with scanning, even using 64-slice detectors and dose-reduction strategies 
is not negligible.  Cancer risk varies according to the age and sex of the patient as well as the 
anatomical structures scanned and the radiation dose received.  The latter can be expressed as 
effective mean dosage, which is documented as up to 11mSv in a systematic review of 
published data146, compared with <5mSv using conventional angiography.148  Organ-specific 
dosage in simulated models is noted to range from 42 to 91mSv for the lungs and 50 to 
80mSv for the female breast.  Consequentially, lifetime attributable risk of cancer is 
estimated at 0.02% in elderly men ranging to almost 1% for a 20 year-old woman who 
undergoes coronary and aortic arch scanning.149  Proposing these tests as non-invasive is 
therefore difficult to justify, particularly where pre-test probability is low or alternative 
methods are available.  
 
[1.5]  Summary 
Analysis of the radial pulse as a marker of cardiovascular risk has grown in private 
and occupational health clinics although remains largely a research tool in clinical medicine.  
There is good evidence that central pressures derived from the radial artery are independent 
of brachial BP, however whether they are better predictors of cardiovascular risk is more 
controversial.  The available literature suggests that irrespective of baseline risk, there is a 
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fairly uniform 15-20% increased risk in coronary events for every 10mmHg rise in 
augmentation pressure or central pulse pressure.  Clearly there are issues in elderly 
populations, where augmentation is ubiquitously raised and younger age-groups where small 
inflections in the waveform are difficult to identify.  However it could be argued that it is 
precisely in the 40-70 year olds where further stratification of risk is most desirable.   
A major unanswered question is whether PWA, when translated from research into 
clinical practice, would retain a significant prediction for coronary disease despite variability 
in ventricular function, heart rate and medication usage.  Correlation of PWA with other 
accepted risk models such as Framingham in population-based studies has not been as 
substantial as one would hope.150, 151  Existing methods for predicting CAD in symptomatic 
patients are extrapolated from different population-groups or based on small observational 
studies.  The published literature suggests a need for better risk stratification, particularly 
where baseline risk is high and risk factors are already modified.  Biomarkers such as high-
sensitivity CRP and BNP have not substantially added to conventional factors, possibly due 
to the similar pathological pathways in which they determine risk.  Other non-invasive 
methods have shown considerable promise but remain research tools.  Heart rate variability 
(HRV) and pulse wave velocity have the potential for clinical application, once automated 
systems can reduce the technical expertise required whilst maintaining reproducibility and 
reliability.   
Initial data on PWA has been encouraging and the method for obtaining radial 
waveforms is simple and practical.  Whilst unlikely to replace brachial blood pressure 
measurement, PWA has the potential for additional stratification of cardiovascular risk.  
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Chapter 2. Methods 
 
 The data presented in this thesis is derived from the Alternative Risk Markers in 
Coronary Artery Disease (ARM-CAD) study, a prospective observational study of 550 
unselected patients referred for diagnostic coronary angiography. 
 
[2.1]  Concept & Design 
The Study was designed by myself and the co-investigators (Dr David Eccleston and 
Professor Henry Krum) to answer the proposed research questions.  A sample size of 500 was 
initially proposed, although enrolment was extended due to more rapid recruitment than 
anticipated (see Appendix A).  Patients referred for coronary angiography at three centres in 
Melbourne, Australia (2006-8) were eligible for recruitment if angiography was elective and 
not precipitated by an acute coronary syndrome (Table 2.1).  Previous heart transplantation 
was an exclusion criterion at one centre, where transplant recipients had regular scheduled 
angiographic follow-up.   
550 subjects were consecutively enrolled on random days, regardless of reason for 
angiography or co-morbidity.  All patients were assessed prospectively, prior to angiography 
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or coronary intervention (if performed).  Five participants were excluded due to identification 
of a recent acute coronary syndrome and cannulation of the coronary vessels was 
unsuccessful in 3 patients.   
Primary outcome variables are based on results from coronary angiography; the 
absence of any visual lesions (angiographically-normal coronary arteries) and the presence of 
one or more obstructive stenoses.  Secondary outcomes are the extent and severity of 
angiographic disease.  Additionally all participants will be followed up for incident 
cardiovascular events and hospitalisation.  At one year, participants with cardiovascular 
events in the intervening period since initial assessment will be invited for repeat non-
invasive testing.  The majority of patients have also agreed to enter a lifetime follow-up 
cohort as part of the Cardiovascular Longitudinal Evaluation and Assessment of Risk 
Database (CLEAR), a cross-research study set up by the author and based at the Monash 
Centre of Cardiovascular Research & Education in Therapeutics, Melbourne.  Phase 2 of the 
ARM-CAD study is currently recruiting 200 volunteers in a prospective longitudinal study of 
participants with cardiac risk factors but no overt symptoms, to assess the applicability of the 
novel risk markers in a more general population.  In this thesis I report the results of the first 
phase of the ARM-CAD study, a cross-sectional analysis exploring the association of PWA 
with the presence or absence of CAD and identifying its ability to add to conventional risk 
prediction. 
 The author was responsible for all aspects regarding management of the ARM-CAD 
study, including protocol development, day-to-day running of the study, training and 
management of staff, participant recruitment, database management, statistical analysis and 
presentation of results. 
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Table 2.1:  Entrance Criteria for the ARM-CAD Study 
Recruitment Consecutive adult patients referred for elective coronary angiography at three 
cardiac catheter laboratories in Melbourne, Australia 
Inclusion Criteria Adults (18 years or older)  
Male or Female 
Exclusion Criteria Acute coronary syndrome or urgent angiography  
Prior heart transplantation  
Informed consent not obtainable 
 
[2.2]  Ethics & Funding   
The study was approved by the responsible ethics committee for each participating 
institution; Eastern Health Research & Ethics Committee (approved August 2006), the 
Northern Hospital Human Research and Ethics Committee (approved September 2006) and 
the Alfred Hospital Ethics Committee (approved May 2007).  Approval was also granted 
from the Monash University Standing Committee on Ethics in Research Involving Humans 
(October 2006).  Written informed consent was obtained from all participants and the study 
conducted in accordance with the Declaration of Helsinki (updated 2008).  
 Funding consisted of an unrestricted research grant from IM Medical Ltd, Melbourne 
(a supplier of cardiovascular diagnostic devices, including pulse wave analysis) and support 
by the Monash Centre of Cardiovascular Research and Education in Therapeutics, Monash 
University, Melbourne and the Clinical Trials & Evaluation Unit, Royal Brompton & 
Harefield NHS Trust, London.  The ARM-CAD study was investigator initiated, all data rests 
with the principal investigators and there was no commercial involvement with protocol 
design, running of the study, data analysis or manuscript preparation.  
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[2.3]  Site Description 
Three angiographic centres were chosen in Melbourne, Australia and staggered 
recruitment occurred over the first year of the study.  Box Hill Hospital is a metropolitan 
teaching hospital with an established catheter laboratory performing a large number of 
diagnostic coronary angiograms and both acute and elective percutaneous coronary 
interventions (PCI).  The Northern Hospital is situated in suburban Melbourne and for the 
majority of the study only routine diagnostic angiograms were scheduled.  In the last 3 
months of the study, regular elective PCI was also performed.  Finally the Alfred Hospital is 
one of Australia’s major tertiary and quaternary referral centres with on-site cardiac surgery 
and transplantation.  The combination of these three centres contributed to an overall cohort 
that was a good representation of referrals for coronary angiography. 
 
[2.4]  Pilot & Software Testing 
Risk assessments were recorded using a computerised case report form completed by 
the researcher.  A proprietary software package using a standard notebook computer running 
Microsoft Windows (Microsoft Corporation, Redmond) was used to record conventional risk 
factors, relevant patient history, blood pressure and non-invasive testing (Intelliheart®, IM 
Medical Ltd, Melbourne).  The software was modified to incorporate the study-specific 
definitions as per the protocol.  A pilot of 15 healthy volunteers was conducted in September-
October 2006, testing both hardware and software components and evaluating the time 
required for risk assessment.  Following the pilot, substantial modifications were made in 
several areas to improve efficiency and the quality of acquired data. 
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[2.5]  Research Staff & Training 
Seven research staff were trained by the author to obtain radial artery waveforms and 
pulse wave velocity measurements.  Apart from one research student, all were clinical nurses 
with additional research roles.  Training involved two sessions of teaching, followed by 
supervision over the first week of recruitment.  The techniques involved were easily learnt in 
most cases.  An audit of PWA waveform quality was performed at regular intervals and 
additional training instituted where required.  Table 2.2 describes the number and quality of 
PWA waveforms per operator. 
 
Table 2.2:  Quality of Radial Waveforms by Operator 
Operator n (%) Median Quality Index ± IQR 
#1 (Author) 197 (37.1%) 94 ± 10% 
#7 95 (17.9%) 92 ± 11% 
#5 52 (9.8%) 87 ± 15% 
#4 51 (9.6%) 87 ± 17% 
#3 46 (8.7%) 82 ± 12% 
#2 41 (7.7%) 92 ± 5% 
#6 28 (5.3%) 92 ± 7% 
#8 21 (4.0%) 83 ± 14% 
See Figure 2.1 (page 50) for description of quality index. 
 
[2.6]  Data Collection 
Data was collected in a clinical environment, immediately preceding angiography for 
two centres and 2-4 days prior in the third.  The risk assessment protocol consisted of 
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establishing conventional risk factors and medical history, measuring BP and patient 
dimensions, assessing non-invasive risk markers, recording a 12-lead ECG and phlebotomy.  
See Appendix B for a full list of variables and descriptions. 
 
Conventional Risk Markers 
Patients self-reported their prior medical history, diabetes, cardiac symptoms and 
whether they currently smoked or performed regular aerobic exercise on most days of the 
week.  These responses were cross-checked against medical notes and collated electronically 
using customised software.  Family history of CVD was defined as angina, MI, stroke or a 
transient ischemic event in a first-degree relative below the age of 60.  Prior CVD was 
defined as angina, MI, heart failure, PCI, coronary artery bypass graft surgery (CABG), 
stroke or transient ischaemic attack preceding assessment.  Current medications at baseline 
were recorded.  
BP was determined from averaging 2 of 3 resting measurements with the patient in a 
sitting position using a validated oscillometric meter approved by the British Hypertension 
Society (Omron 705/T9P, Omron Healthcare, Japan).  Pulse pressure was the difference 
between the average systolic and diastolic BP and mean arterial pressure was calculated as 
diastolic + ⅓(systolic-diastolic).  BMI was computed as weight in kilograms divided by the 
square of height in metres.  Waist-hip ratio (WHR) was calculated by measuring waist 
circumference (narrowest point between ribs and hips when viewed from the front after 
exhaling) and hip circumference (at the point where the buttocks extend the maximum, when 
viewed from the side).   
Recent blood results for haemoglobin, creatinine and lipid studies (total cholesterol, 
HDL, LDL and triglycerides) were collected from each centre or assessed at the core 
laboratory if unavailable.  Glomerular filtration rate (GFR) was determined by the 
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Modification of Diet in Renal Disease formula, normalised to a body surface area of 
1.73m2.152  High-sensitivity CRP and BNP were analysed by the core laboratory using an 
immunoturbidimetric assay and chemiluminescent micro-particle immunoassay respectively 
with Abbott Architect instrumentation.  High-sensitivity CRP had both upper and lower 
limits of detection and was therefore assessed as a categorical variable using recommended 
cut-points (<1, 1-3, >3 mg/L153 and ≥2mg/L154).  BNP had a skewed distribution and was 
analysed following log-transformation and additionally according to categorical cut-points. 
 
Risk Scores 
Framingham risk scores were derived using a chart-based risk calculator incorporating 
age, systolic BP, total and HDL-cholesterol, presence of diabetes and regular smoking.1  
They give an estimate of ten-year absolute risk of total coronary disease events, including 
angina, recognised and unrecognised MI and coronary deaths.  This prediction is for initial 
coronary events in a free-living population not on medication (i.e. those without clinical 
manifestations of CVD).  The risk algorithm was developed using a population-based sample 
including 2489 men and 2856 women, 30-74 years old at the time of their Framingham Heart 
Study examination in 1971 to 1974.  Information was pooled from the original and offspring 
cohorts with a 12 year follow-up period.  
The SCORE risk tool predicts 10-year fatal CVD, derived from 205178 individuals 
without a history of prior myocardial infarction (high-risk formula used based on total 
cholesterol).2  The SCORE project assembled a pooled dataset of cohort studies from 12 
European countries and includes the same variables as the Framingham algorithm except for 
diabetes.  As diabetic status was not uniformly collected in the SCORE cohorts, a 
multiplication factor of 2 for diabetic men and 4 for diabetic women is suggested. 
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Pulse Wave Analysis 
PWA was obtained using a Millar high-fidelity tonometer and SphygmoCor® 
software (Version 8.0, Atcor Medical, Sydney), a validated commercially-available tool 
which derives central artery pressures from a radial waveform using a generalised transfer 
function.97, 101, 102  Assessment took place prior to coronary angiography with 10-second 
waveforms captured at the radial artery, preferably on the right side, except where the artery 
is obstructed (e.g. by venous cannula) or absent (previous surgery).  The waveform is 
calibrated to the brachial BP as determined above.  An ensemble-averaged waveform is 
automatically generated from the individual pulses over the capture period.  Quality of 
waveforms is determined by the SphygmoCor software and is dependent on variation in pulse 
height, length and diastolic component, shape deviation and change in pressure over time.  
An overall quality index (QI) is generated which broadly defines the ability of individual 
pulses to superimpose (see Figure 2.1).   
Each participant had at least one waveform captured with operators encouraged to 
reach a target QI of 85%.  Where two or more attempts were made to obtain a suitable 
waveform, the best quality was used in analysis, although no minimum level was required for 
inclusion (in keeping with the aims of the study).  Four hundred and nine patients had at least 
two sequential waveforms captured by the same operator in identical environmental 
conditions.  This data forms the basis for the secondary comparative quality analysis where 
the highest quality waveform was compared with another of lower quality.  If more than one 
alternate waveform was available, the comparator was chosen by selecting a waveform where 
QI was 25-35% lower than the best quality recording.  Images of radial pulse waveform 
capture are portrayed in Appendix C. 
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Figure 2.1:  Quality Assessment of Radial Pulse Waveforms 
 
 
 Example of low (A) and high (B) quality waveforms captured sequentially on the same 
individual in identical environmental conditions.  In Figure 1A, pulse height variation=6%, 
variation in diastole=12%, shape deviation=5%, pulse length variation=2% and max 
dp/dt=562.  Corresponding values for Figure 1B are 5%, 4%, 2%, 5% and 595, resulting in 
tighter overlay of pulses and hence better overall quality index. 
 
Heart Rate Variability 
HRV was measured in all participants where a good quality ECG signal was 
obtainable and QRS-width/PR-interval stable for correct acquisition of the RR interval.  
Three leads were used to obtain the ECG signal, placed either centrally on the chest or 
peripherally on the limbs.  Participants were supine, asked to breathe normally and left 
undisturbed during the capture time (mean 5.38 ± 0.52 minutes).  To simulate actual clinical 
use, no attempt was made to control patient or environmental factors (for example coffee and 
alcohol consumption) or to rest the participant prior to HRV capture.  SphygmoCor software 
was used to quantify normal-to-normal RR intervals and deconstruct HRV into component 
frequencies, graphing variance (power) as a function of frequency (power spectral density 
analysis).  Where HRV capture was interrupted, a repeat assessment was performed.  Where 
capture was unsuccessful, leads were placed in the alternate position and a further 2 attempts 
made to record HRV.  In total, 480 participants (89%) had suitable HRV capture. 
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Pulse Wave Velocity 
PWV measurements were instituted in the latter third of the study, following the 
upgrade of the SphygmoCor device to include this function.  Two forms of PWV were 
measured, carotid-radial (n=202) and carotid-femoral (n=163) or both where time permitted 
(n=112).  Calculation of PWV is based on distance/time.  Distance is measured in millimetres 
on the skin surface subtracting the distance of the carotid artery to sternal notch from the 
distance measured between the sternal notch and the peripheral artery of choice.  PWA is 
performed at each arterial site in sequence and the time difference is determined by 
identifying the foot of the pulse waveform in relation to the QRS complex on a simultaneous 
3-lead ECG (see Figure 2.2).   
At least 10 seconds of recording were required for carotid-radial PWV and 20 seconds 
for carotid-femoral.  The algorithm chosen to identify the foot of the waveform was 
intersecting tangents, which describes the point at which a line tangent to the initial upstroke 
of the pressure waveform intersects a horizontal line through the minimum point, suggested 
as the best method in published data.155  The quality of waveforms was not a consideration 
for inclusion in analysis as only the foot of the waveform is used in calculation of PWV.  
Operators were encouraged to obtain multiple sets of waveforms where feasible and overall 
PWV was taken as the average of the two highest quality recordings.  
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Figure 2.2:  Calculation of Pulse Wave Velocity 
 
 
 For each QRS complex over a 10-20 second recording, the difference in time to the foot of 
each waveform is calculated (∆T).  PWV=distance/mean ∆T.  In this example from a 66 year-
old male, PWV distance was 460mm and mean ∆T was 32.6±3.9ms resulting in a carotid-
femoral PWV of 14.1±1.7m/s.  Dashed line indicates the reference point for that particular 
QRS complex and points mark the foot of each waveform. 
 
Resting Electrocardiogram 
12-lead ECGs were recorded using standard techniques with the participant supine 
using a commercially-available portable ECG device (PC-ECG 1200, Norav Medical Ltd, 
Kiryat Bialik).  ECGs were stored electronically, identified only by study number and initials 
and assessed by an independent, blinded cardiologist using a structured ECG evaluation form.  
ECGs were classified as normal or abnormal, the type of abnormality and presence of 
ischaemic features, rhythm abnormalities, left-ventricular hypertrophy and intraventricular 
conduction delay.  Data was entered into the study database using a high-accuracy automated 
content capture system (Teleform) and error fields checked manually.   
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Left-Ventricular Function & Echocardiography 
Left-ventricular (LV) function was primarily determined by contrast ventriculography 
during cardiac catheterisation.  This method has good reproducibility156, correlates well with 
other forms of LV ejection fraction157 but may slightly overestimate LV function.158  Where 
not performed due to contraindications (n=47), data from recent echocardiography was 
substituted.  Data on LV function included a numerical assessment, where made, of ejection 
fraction (typically Simpsons-biplane) and a categorical statement considering function as 
normal or mild/moderate/severe impairment.  Echocardiographic parameters of chamber 
dimensions, ventricular function and valvular disease were recorded in patients where 
available (mean 109 days prior to risk assessment); data on 188 participants was collated 
from clinical reports and electronic databases.  Prospective echocardiography was not 
required for study enrolment. 
 
Coronary Angiography 
Coronary angiography was performed by experienced operators using standardised 
procedures according to international guidelines.  Classification of angiographic stenoses was 
made by the operator after careful review.  In any situation where there was uncertainty about 
classification (8.5%), angiograms were reviewed by the core laboratory.  For quality 
assurance of the angiography report, a random sample of 10% of angiograms at each centre 
were reviewed by two independent, experienced and blinded operators at the angiographic 
core laboratory. 
Angiographically-normal coronary arteries (NCA) were defined as the absence of any 
visual lesion and abnormal angiograms were subsequently classified into minor coronary 
irregularities or obstructive CAD (stenosis of ≥50% in a native major epicardial artery or 
main tributary).  The extent of coronary disease (CAD-score) is described as the number of 
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native vessels diseased, following the scheme published by the Coronary Artery Surgery 
Study Registry159, whereby those with left-main disease have 2 affected vessels in right-
dominant and 3-vessel disease in left-dominant circulations (see Figure 2.3).  In line with 
more recent publications, this scheme was modified to consider lesions of ≥50% and 
additionally we identified patients who had minor (<50%) coronary irregularities and 
represent a higher risk group than those with angiographically-smooth vessels.160, 161   
 
Figure 2.3:  Classification of Obstructive Coronary Artery Lesions 
In a right dominant or unknown circulation, the number of diseased vessels is determined by stenoses in 
the following arteries:  
RCA or PDA ≥50%  1 diseased vessel   
+     
LMCA ≥50%  2 diseased vessels   
or     
LMCA <50%  LAD / 1st or 2nd Diagonal ≥50%  1 diseased vessel 
  LCX / Obtuse Marginals ≥50%  1 diseased vessel 
In left dominance, the number of diseased vessels is determined as follows:  
LMCA ≥50%  3 diseased vessels   
or     
LMCA <50%  LAD / 1st or 2nd Diagonal ≥50%  1 diseased vessel 
  LCX / Obtuse Marginals ≥50%  1 diseased vessel 
  ≥50% in any of:   
     Left atrio-ventricular artery  1 diseased vessel 
     1st, 2nd or 3rd posterolateral branches   
     Left PDA     
RCA, right coronary artery; PDA, posterior descending artery; LMCA, left main coronary artery;              
LAD, left anterior descending; LCX, left circumflex. 
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A limitation of this approach is that all obstructive coronary artery lesions are 
assumed to be equivalent regardless of location.  This does not account for data suggesting 
that isolated right coronary artery stenoses are relatively benign in comparison to disease 
elsewhere.162, 163  To compensate for this limitation, the severity of CAD in patients without 
prior CABG was measured in terms of the Leaman score164 (as modified by the SYNTAX 
group165) which weights luminal narrowing with the usual blood flow of that coronary vessel.  
Leaman scores were then divided into 5 groups; 0, 0-5, 5-10, 10-20 and >20.  Figure 2.4 
illustrates the calculation of extent and severity using two examples. 
 
[2.7]  Data Review & Database Management 
Data was cross-checked by the author to identify incorrect fields and all variables 
investigated individually to identify outliers and errors.  Where data was potentially incorrect 
it was listed as missing and rechecked by the recruiting centre (see below).  Data was 
maintained using Microsoft SQL Server and inspected in Microsoft Office Excel (Microsoft 
Corporation, Redmond) prior to export for statistical analysis. 
 
[2.8]  Missing Data 
Missing data fields were assessed at the end of study recruitment and centres asked to 
retrieve data from medical notes and procedural commentaries.  Three participants were 
missing data on baseline risk factors and were not included in the final analysis.  Only eight 
participants had inadequate or unobtainable PWA waveforms.  An estimate of recent LV 
function was not available for three participants and WHR was incorrectly recorded in eight.  
BNP was not obtained in ten participants (haemolysed and/or clotted specimen) and high-
sensitivity CRP was missing in five (inadequate serum or unsuitable specimen).  
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Figure 2.4:  Coronary Angiogram Scoring for the Extent & Severity of Disease 
 
 
 Example 1:  Panel A demonstrates 80% stenosis of the proximal left anterior descending artery (LAD) 
and 40% stenosis of the left circumflex (LCX)/obtuse marginal (OM).  Panel B shows a 70% stenosis 
in the proximal right coronary artery (RCA).  In this example the patient has obstructive CAD (one or 
more major vessels ≥50%) and the extent score is double-vessel disease.  The modified Leaman score 
weights each stenosis according to coronary flow and degree of obstruction.  In this example the 
severity score is 9 [3.5 (blood flow weighting) x 2 (stenosis weighting, 50-99%) for LAD lesion; 
LCX/OM narrowing is ignored as <50%; 1 x 2 for RCA lesion]. 
Example 2:  Panel C demonstrates an 80% narrowing in the mid-LAD at the second diagonal and two 
tandem stenoses in the OM, both approximately 80%.  Panel D reveals a total occlusion of the 
proximal RCA.  In this example, the patient has obstructive CAD, the extent score is triple-vessel 
disease and the modified Leaman score is 14 [2.5 x 2 for LAD lesion; each OM lesion scores 1 x 2 
(scored separately as more than 3 vessel diameters apart); 1 x 5 (stenosis weighting for total occlusion) 
for RCA]. 
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[2.9]  Statistical Analysis 
All statistical analyses were performed by the author following extensive training in 
regression methods (Master of Public Health module, Monash University, Melbourne).  
Methods were reviewed by Dr Baki Billah and Associate Professor Rory Wolfe (Chief 
Biostatisticians, Department of Epidemiology & Preventive Medicine, Monash University, 
Melbourne) or Winston Banya (Trust Statistician, Royal Brompton & Harefield NHS Trust, 
London). 
Values presented are mean ± standard deviation (SD) or percentage, unless specified.  
Categorical variables are compared with the Chi-squared test and continuous variables with 
two-tailed t-tests or the non-parametric Kruskal-Wallis (Mann-Whitney) test, depending on 
distribution (as determined by histogram, kernel density and kurtosis).  Robust methods were 
utilised, with Fisher’s correction for analyses with low frequency and Satterthwaite's 
modification in t-tests where variance was uneven as identified by a significant F-test.  
Correlations were assessed using Pearson or Spearman coefficients for normal and abnormal 
distributions respectively.  Trends across disease severity were analysed using the non-
parametric Cuzick & Altman test.  The equality of means and variances for comparing two 
methods is assessed using Bland & Altman plots; correlations were calculated using Lin’s 
concordance coefficient and the Bradley-Blackwood F test.  A p-value of <0.05 was 
considered statistically significant; bold type-face in tables indicates significant results.  
Analyses were performed on STATA Intercooled (version 9.2, StataCorp LP, Texas) and 
with custom modules from Garrett166, Ender & Mitchell167 and Nicholas.168   
 
Logistic Regression Models 
Logistic regression is a robust statistical method to predict a dependent variable on the 
basis of other continuous or categorical covariates.  The impact of these predictor variables is 
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usually explained in terms of the odds ratio, where the odds of an event happening is defined 
as the probability that the event occurs divided by the probability that it does not.  Logistic 
regression models were created for each primary outcome variable (NCA and obstructive 
CAD) with crude and adjusted odds ratios presented with 95% confidence intervals.  The pre-
specified analysis plan included the following parameters in multivariate analysis: age, 
gender, smoking, diabetes, prior CVD, chest pain, BMI, BP, cholesterol, GFR, presence of 
LV impairment and medications.  For the PWA analysis, heart rate, haemoglobin, high-
sensitivity CRP and BNP were also included.  Exploratory stepwise models were performed 
using all relevant variables to identify other potential adjusted predictors of CAD and validate 
the multivariate models.  Stepwise models were generated by starting with all variables and 
removing if p>0.1 on likelihood-ratio testing.  A reduced model was generated for PWA 
using this method comprising only common risk factors and PWA; included parameters were 
age, gender, prior CAD, diabetes, BMI, GFR, total and HDL-cholesterol, cAP<24mmHg, 
cPP, beta-blocker, clopidogrel and statin-prescription.  Odds ratios for the secondary 
outcomes (extent and severity of CAD) were determined by ordinal logistic regression.  If the 
proportional odds assumption is not violated, the odds ratio for being in a chosen category or 
higher compared to being in a lower category is the same regardless of which category is 
chosen.  Determinants of PWA quality were also evaluated using an ordered logistic model 
and deciles of quality index. 
 
All multivariate models were assessed for goodness-of-fit using the Hosmer-
Lemeshow chi-squared test and the Bayesian information criterion (BIC’); non-significance 
for the former implies adequate model fit and for the latter more negative values indicate a 
greater likelihood of predicting the observed angiography results (excess variables are 
penalised).  Interactions were investigated for cross-tabulation of all variables in minimal and 
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full models.  Classification of models was assessed in terms of sensitivity, specificity and 
related statistics plus ROC analysis.  
The analysis plan pre-specified a cut-off value for cAP of 24mmHg.  This value was 
determined from our pilot studies and extrapolation of the published literature to our 
population.  The aim was to identify the top quartile of cAP, differentiating patients with 
raised augmentation in excess of standard measures of hypertension.  Subsequent ROC 
analysis confirmed that this was the optimal value to discriminate patients with NCA.  Cut-
off values for HRV variables were not pre-defined but determined using available outcome 
data.  Carotid-femoral PWV of >12m/s was derived from current European guidelines.137 
 
Sample Size 
Statistical calculations of sample size were based on published data from Wang et 
al.169  Patients in this study were divided into those with and without CAD, and matched with 
expected outcome based on risk factors.  As patients in our study were also recruited on a 
referral basis for coronary angiography, we assumed the ratio of high to low risk scores was 
also approximately three.  Using a power of 95% and significance level of 0.05, total sample 
size was calculated at 92 (rounded up to 100 participants) to identify a significant difference 
in cAP between those with and without obstructive angiographic CAD.  Using expected 
groups as absent/present CAD and lowest/highest risk made no statistical difference for 
calculated sample size.  It is generally accepted that sample size should increase by 10% for 
each covariate factor assessed in multivariate regression.  The expected number of variables 
was estimated at 15, therefore requiring a total sample size of 418 [100 x 1.115].  To account 
for medications and changes in baseline risk factors, a minimum sample of 500 was deemed 
necessary.   
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Chapter 3. Conventional Risk Factors 
 
A clear understanding of patient characteristics and baseline risk variables is essential 
to appreciate any potential incremental benefit of novel risk markers.  Further, the literature 
on cardiovascular risk factors is based primarily on primary prevention cohorts which may 
not necessarily apply to cardiology patients.  Extensive risk modification is common prior to 
initial evaluation both in terms of drug therapy as well as lifestyle changes including smoking 
cessation, weight reduction and commencement of regular exercise.  This chapter focuses on 
the ability of risk scores and conventional risk factors to predict the presence, extent and 
severity of angiographic coronary disease.  The value of high-sensitivity CRP and BNP will 
also be examined.  Biomarkers have enjoyed considerable attention in recent years and point-
of-care testing has widened their clinical use.  However despite numerous prospective trials, 
their value in clinical risk stratification is still unclear.  The hypotheses tested are firstly that 
predictive capacity of conventional risk factors is inadequate in contemporary cardiology 
referrals and secondly that biomarkers can aid in clinical determination of CAD risk.  Five-
hundred and thirty-nine patients from the ARM-CAD study were included in this analysis.  
As previously discussed this was a clinical cohort of patients without any major exclusion 
criteria, allowing for an assessment that is applicable to contemporary clinical practice. 
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 Table 3.1 identifies the major outcome criteria assessed on coronary angiography and 
associated LV function data.  An even distribution of NCA, minor irregularities and 
obstructed coronary vessels is noted.  In particular 20.4% had angiographically-smooth 
coronaries and obstructive CAD (the traditional outcome variable for angiography) was 
absent in 39.1%.  As expected, stenosis severity increased with the extent of CAD, both in 
terms of occlusive percentage and effects on blood flow (modified Leaman score).  There 
was a significant trend to worsening of LV function and hypokinetic LV contraction with the 
number of diseased vessels, although discrepancies were noted with regards to the NCA and 
minor irregularity groups.  Overall 18.5% had some degree of impaired LV function. 
 
Table 3.1:  Native Coronary Artery Disease & Left-Ventricular Function 
 Normal Coronary 
Arteries 
Minor 
Coronary 
Irregularities 
Obstructive CAD ( ≥ 50% stenosis) p-value 
for 
trend 
 
Single-vessel 
disease 
2-vessel 
disease 
3-vessel 
disease 
Number (%) 110 (20.4) 101 (18.7) 104 (19.3) 117 (21.7) 107 (19.9) 
 
Most severe left anterior 
descending or diagonal 
artery lesion, % (n=338) 
0 26.5 ± 9.2 63.5 ± 25.0 72.9 ± 26.2 80.6 ± 18.2 <0.001 
Number of proximal 
vessels with ≥70% 
stenosis (n=539) 
0 0 0.21 ± 0.41 0.71 ± 0.74 1.29 ± 1.01 <0.001 
Modified Leaman score 
(n=479) 0 0 4.3 ± 3.0 10.5 ± 5.6 17.2 ± 6.1 <0.001 
Left-ventriculogram 
ejection fraction, % 
(n=246) 
64.2 ± 14.1 65.4 ± 14.0 65.2 ± 11.1 59.3 ± 17.2 55.8 ± 17.1 0.004 
Echocardiographic 
ejection fraction, % 
(n=82) 
57.5 ± 19.4 57.3 ± 13.0 62.1 ± 10.2 57.8 ± 14.5 51.2 ± 15.8 0.092 
Any impairment of LV 
function on LV-gram or 
echo, % (n=536) 
13.8 11.9 12.5 20.7 33.0 <0.001 
Hypokinesis on LV-gram 
or echo, % (n=359) 15.3 9.9 29.0 42.2 52.4 <0.001 
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Treatment recommendation following angiography was medical therapy in 55.7%, 
further investigation in 2.8%, valve replacement (without additional CABG) in 3.9%, PCI in 
21.7% and CABG in 16.0%.  In total, 37.7% of the cohort either had immediate 
revascularisation following angiography, or were referred for PCI or CABG. 
 
[3.1]  Patient Characteristics 
Patient characteristics and cardiac medications are presented in Tables 3.2 and 3.3, 
subdivided according to the presence of obstructive CAD.  As expected, those with 
angiographic CAD were older, more likely to be male and have pre-existing atherosclerotic 
disease.  Symptoms suggestive of coronary disease (or worsening disease in patients with a 
prior history), were the main reason for diagnostic coronary angiography referral; 91.5% of 
patients described either chest pain or dyspnoea.  A positive family history of premature 
CVD was documented in a third of participants and was unrelated to findings on 
angiography.  In comparison, a diagnosis of diabetes conferred a greater than two-fold risk of 
CAD, with diabetics having wider mean pulse pressure (+5.2 mmHg; p<0.01), higher heart 
rate (+3.2 beats/min; p=0.01) and more extensive disease compared to non-diabetics (mean 
2.4 vessels vs. 1.9; p<0.01).  Smoking, a strong predictor in observational cohorts, was less 
frequent in patients with angiographic CAD and there was also a trend to more regular 
exercising in those with disease.  A substantial proportion of patients had other 
cardiovascular co-morbidities including peripheral vascular disease and valvular dysfunction. 
Aspirin, clopidogrel, beta-blockers, calcium channel blockers, nitrates and statins 
were more frequently prescribed in patients with angiographic CAD; these medications were 
adjusted for in all multivariate models described. 
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Table 3.2:  Patient Characteristics by Presence of Angiographic CAD 
 
Table 3.3:  Medication Prescription According to Angiographic CAD 
Medication All No or Non-Obstructive CAD 
Obstructive 
CAD p-value 
Aspirin (%) 71.2 59.2 79.0 <0.001 
Clopidogrel (%) 15.0 6.2 20.7 <0.001 
Warfarin (%) 5.4 6.6 4.6 0.300 
Beta-blockers (%) 45.1 35.6 51.2 <0.001 
Calcium channel blockers (%) 22.6 17.5 25.9 0.023 
RAAS (%) * 54.9 50.7 57.6 0.116 
Diuretic (%) 18.6 17.5 19.2 0.626 
Nitrates (%) 16.5 8.1 22.0 <0.001 
Statins (%) 62.0 50.2 69.5 <0.001 
* RAAS, renin-angiotensin-aldosterone system; includes angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers and aldosterone antagonists. 
Characteristic All No or Non-Obstructive CAD 
Obstructive 
CAD p-value 
Number 539 211 328  
Age (years) 64.7 ± 10.9 61.1 ± 11.3 67.0 ± 9.9 <0.001 
Male gender (%) 67.4 49.3 79.0  <0.001 
Family history of premature CVD (%) 34.7 32.7 36.0 0.436 
Current smoker (%) 16.3 17.5 15.6 0.542 
Regular exercise (%) 38.4 36.0 39.9 0.361 
Chest pain (%) 76.1 70.1 79.9  0.010 
Dyspnoea (%) 63.5 64.0 63.1 0.838 
Prior angina or MI (%)  48.6 27.0 62.5 <0.001 
Prior revascularisation (%) 21.0 4.7 31.4  <0.001 
Peripheral vascular disease (%) 9.7 7.1 11.3 0.109 
Diabetes (%) 21.9 14.2 26.8  0.001 
Aortic or mitral valve disease (%) * 10.6 11.4 10.1 0.628 
* Moderate/severe stenosis or incompetence 
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Measured baseline variables are presented in Table 3.4.  Hypertension (≥140mmHg 
systolic and/or ≥90mmHg diastolic) was present in 55.1% despite each participant being on a 
mean of 1.6 ± 1.1 anti-hypertensive medications.  Correlations between BP and coronary 
disease were confounded by medication usage; in general BP was a poor indicator of the 
presence of CAD.  From the BP indices measured, only pulse pressure was significantly 
increased in patients with obstructive angiographic CAD.  Similarly heart rate and total/LDL-
cholesterol were confounded by prescription of beta-blockers and statins respectively.  Mean 
difference in total cholesterol was 0.84mmol/L between those prescribed and not prescribed 
statins (p<0.001), with no difference in HDL-cholesterol or triglycerides.  The majority of 
patients were overweight with a normal BMI (<25 kg/m2) in only 22.6% and obesity in 
33.5% (BMI>30 kg/m2).  Anaemia, defined as haemoglobin <12g/dL in women and <13g/dL 
in men, was present in 14.7%.  38.6% had normal kidney function (GFR≥90 ml/min), 45.4% 
mild renal impairment (GFR 60-89) and 16.0% moderate or severe renal impairment 
(GFR<60).     
High-sensitivity CRP was <1 mg/L in only 26.6% (low risk as defined by the 
American Heart Association guidelines153) and BNP >100pg/mL in 21.7%, confirming the 
high risk status of this patient cohort.   
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Table 3.4:  Measured Variables by Presence of Angiographic CAD 
Measurement All No or Non-Obstructive CAD 
Obstructive 
CAD p-value 
Brachial systolic BP (mmHg) 143.9 ± 20.8 142.5 ± 20.1 144.9 ± 21.2 0.180 
Brachial diastolic BP (mmHg) 79.5 ± 10.3 80.2 ± 9.6 79.1 ± 10.7 0.224 
Brachial mean pressure (mmHg) 100.5 ± 12.0 100.6 ± 11.2 100.4 ± 12.4 0.842 
Brachial pulse pressure (mmHg) 64.5 ± 18.1 62.3 ± 17.8 65.9 ± 18.1  0.025 
Heart rate (beats/min) 66.0 ± 12.2 68.3 ± 12.0 64.5 ± 12.1 <0.001 
Body mass index (kg/m2) 28.7 ± 5.2 28.9 ± 5.4 28.6 ± 5.0 0.532 
Waist-hip ratio 0.96 ± 0.08 0.94 ± 0.09 0.97 ± 0.07  <0.001 
Lipid values     
     Total cholesterol (mmol/L)  4.60 ± 1.12 4.83 ± 1.11 4.46 ± 1.10 <0.001 
     HDL-cholesterol (mmol/L)  1.22 ± 0.34 1.31 ± 0.38 1.16 ± 0.29  <0.001 
     LDL-cholesterol (mmol/L) 2.52 ± 0.98 2.70 ± 0.96 2.40 ± 0.98 <0.001 
     Triglycerides (mmol/L) 1.84 ± 1.05 1.77 ± 1.03 1.88 ± 1.06 0.239 
Other blood tests     
     Haemoglobin (g/dL) 14.0 ± 1.5 13.9 ± 1.4 14.1 ± 1.5 0.130 
     Creatinine (μmol/L) * 80 ± 28 70 ± 29 82 ± 30 <0.001 
     GFR (ml/min/1.73m2) 83.4 ± 23.2 87.2 ± 22.3 80.8 ± 23.5  0.002 
Biomarkers     
     High-sensitivity CRP ≥2mg/L (%) 49.6 46.7 51.5 0.271 
     High-sensitivity CRP >3mg/L (%) 32.4 31.0 33.3 0.254 
     BNP (pg/mL) * 40 ± 73 32 ± 57 46 ± 81  <0.001 
     BNP >100 pg/mL (%) 21.7 17.1 24.7 0.038 
* Creatinine and BNP presented as median ± interquartile range due to skewed distribution. 
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[3.2]  Conventional Predictors of Coronary Artery Disease 
Framingham and SCORE Risk Models 
Framingham 10-year total coronary disease risk and SCORE 10-year fatal CVD risk 
were significantly associated with obstructive angiographic CAD (odds ratios per 10% 
increase 1.82, 95% CI 1.44-2.33, p<0.001 and 1.62, 1.34-1.95, p<0.001 respectively after 
adjustment for medications).  Mean 10-year risk was 14.0 ± 9.1% for Framingham and 13.2 ± 
15.1% for SCORE, with a non-significant difference of 0.76 ± 12.5% (p=0.318).  Bland-
Altman plots of difference versus average (Figure 3.1) revealed a moderate correlation 
between the two risk calculations (rho-c=0.50, 95% CI 0.44-0.55, p<0.001) although 
discordance was present (F-test=111.90, p<0.0001).  Restricting SCORE to 10-year fatal 
coronary disease made no appreciable difference to the analysis (rho-c=0.53, 0.49-0.58, 
p<0.001).   
 
Figure 3.1:  Bland-Altman Plot Comparing Framingham with SCORE Risk  
 
 
 Bland & Altman 95% limits of agreement are -23.8 and 25.3 (dashed lines). 
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As seen in Figure 3.1, Framingham and SCORE were particularly discordant where 
the baseline risk was high (above an average of 30%).  This was entirely attributable to 
diabetic patients in whom greater differences in the two risk algorithms were noted.  
Correlation between them was reduced by 35% in diabetic compared to non-diabetic patients. 
 
Framingham and SCORE were associated with obstructive CAD in patients with and 
without previous coronary or cerebrovascular disease (Figure 3.2).  Adjusted probability of 
CAD at a Framingham risk of 10% was 0.44 without prior CVD and 0.69 with CVD.  At 
30% 10-year risk, probability was 0.73 and 0.86 respectively (p-value for interaction of 
Framingham and prior CVD=0.727).  Similar values were obtained using the SCORE 
algorithm (p=0.922 for interaction).  As depicted in Figure 3.3, there was a significant trend 
towards higher risk estimates in those with more extensive disease using both Framingham 
and SCORE and this was evident even in those with prior CVD (p<0.01 for all groups).   
 
Figure 3.2:  Probability of CAD According to Framingham and SCORE Risk  
 
 
 Adjusted probability for obstructive CAD in those with (top) and without (bottom) prior CVD, 
comparing Framingham (black, dashed) and SCORE (grey, solid). 
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Figure 3.3:  10-Year Framingham & SCORE Risk by Extent of Angiographic CAD  
 
 
 Box & Whisker plots for 10-year Framingham and SCORE risk by extent of CAD (number of 
diseased vessels) in patients with prior CVD (dark grey) and without (light grey).  Depicted p-
values are for trends across extent of CAD.  NCA, angiographically-normal coronary arteries. 
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Individual Risk Factors: Multivariate Predictors of CAD 
To investigate the predictive components of CAD risk I considered individual 
conventional risk factors and their association with obstructive CAD in univariate and 
multivariate analysis (Table 3.5).  In the fixed multivariate model which included the pre-
specified variables (Model 1) only age, male gender, diabetes, chest pain and previous CVD 
were significant adjusted predictors for the presence of angiographic CAD.  Stepwise 
regression of a much broader range of variables (Model 2) confirmed that smoking, family 
history, hypertension and lipids were not independently associated with obstructive disease.   
 
 Notably the odds ratio for age was unaffected by adjustment for other risk variables, 
reinforcing age as one of the drivers of atherosclerotic risk.  After accounting for age and 
gender, the odds of angiographic disease in patients with prior CVD was halved when 
compared with the univariate association.  Impaired LV function, GFR, WHR and pulse 
pressure were significant univariate predictors of CAD but were not independent of other 
factors in either of the multivariate models. 
 Differences between the fixed and stepwise analyses were of minimal relevance.  In 
the latter model, BP indices, GFR, obesity markers, high sensitivity-CRP and impaired LV 
function did not reach the p<0.1 threshold for inclusion.  As a result chest pain was no longer 
significant with regards to its association with obstructive CAD.  Family history of premature 
CVD approached significance, as did total cholesterol after adjustment for statin use. 
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  Table 3.5:  Univariate and Multivariate Odds Ratios for the Presence of Obstructive CAD 
Variable (unit of increase) 
Univariate Unadjusted  Multivariate Model 1  Multivariate Model 2 
Odds Ratio (95% CI) p-value  Odds Ratio (95% CI) p-value  Odds Ratio (95% CI) p-value 
Age (per 10 years) 1.70 (1.43 - 2.02) <0.001  1.74 (1.34 - 2.27) <0.001  1.79 (1.41 - 2.26) <0.001 
Male gender 3.86 (2.64 - 5.64) <0.001  5.48 (3.36 - 8.92) <0.001  5.28 (3.24 - 8.60) <0.001 
Family history of premature CVD 1.16 (0.80 - 1.67) 0.436      1.55 (0.98 - 2.47) 0.062 
Current smoker 0.87 (0.54 - 1.38) 0.543  1.20 (0.65 - 2.22) 0.561     
Diabetes 2.21 (1.40 - 3.49) 0.001  2.57 (1.44 - 4.60) 0.001  2.71 (1.53 - 4.80) 0.001 
Chest pain 1.69 (1.13 - 2.52) 0.010  1.69 (1.02 - 2.81) 0.043  1.54 (0.93 - 2.55) 0.097 
Prior CVD 4.37 (3.02 - 6.32) <0.001  2.61 (1.65 - 4.12) <0.001  2.63 (1.68 - 4.14) <0.001 
Body mass index (per 1 kg/m2) 0.99 (0.96 - 1.02) 0.553  1.01 (0.96 - 1.05) 0.724     
Waist-hip ratio (per 0.1 unit) 1.64 (1.31 - 2.05) <0.001         
Systolic BP (per 10 mmHg) 1.06 (0.97 - 1.15) 0.180         
Pulse Pressure (per 10 mmHg) 1.12 (1.01 - 1.24) 0.026  0.97 (0.85 - 1.11) 0.653     
GFR (per 10 ml/min) 0.90 (0.83 - 0.97) 0.005  0.95 (0.87 - 1.05) 0.343     
Total cholesterol (per mmol/L) 0.74 (0.63 - 0.87) <0.001  1.22 (0.98 - 1.52) 0.073  1.22 (0.99 - 1.51) 0.064 
HDL-cholesterol (per mmol/L) 0.26 (0.15 - 0.44) <0.001         
High-sensitivity CRP ≥2 mg/L 1.22 (0.86 - 1.72) 0.271  1.18 (0.75 - 1.87) 0.481     
BNP (per log unit) 1.30 (1.13 - 1.50) <0.001  1.19 (0.98 - 1.44) 0.086  1.19 (0.99 - 1.44) 0.071 
Impaired LV function 1.92 (1.19 - 3.11) 0.008  1.18 (0.64 - 2.19) 0.592     
Medications not shown.  Model 1 is a fixed regression of pre-specified variables and Model 2 a stepwise regression at p<0.1. 
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[3.3]  Additional Value of Biomarkers 
In the whole cohort neither high-sensitivity CRP nor BNP added any significant value 
to the prediction of CAD over conventional risk markers.  As demonstrated in Table 3.6, the 
inclusion of biomarkers in the multivariate model did not improve the classification of CAD 
(75.2% correctly classified versus 74.6% in the model without high-sensitivity CRP and 
BNP).  Calibration statistics suggested that including these variables reduced the overall fit of 
the model, as evidenced by the large difference in the Bayesian Information Criterion.  
Further, receiver operator curves comparing the analyses with and without biomarkers were 
visually identical (see Figure 3.4) and statistically no different (chi-squared for difference in 
ROC area was 1.14; p=0.286).   
 
High-sensitivity CRP was noted to have a significant interaction with prior CVD and 
in those patients without prior disease (n=231), the odds ratio for obstructive CAD was 
marginally significant (1.89, 95% CI 1.00-3.57; p=0.049).  Adjusted probability of CAD was 
16% higher in this sub-group when high-sensitivity CRP was ≥2mg/L, whereas for patients 
with prior CVD the probability was reduced non-significantly by 6% (Figure 3.5).  However 
ROC area remained statistically unchanged; 0.788 without high-sensitivity CRP/BNP and 
0.799 with (chi-squared for difference in area=1.52, p=0.217).   
To exclude a masking effect of prolonged hyperlipidaemia, an analysis was performed 
restricting the patient sample to those without prior CVD and LDL-cholesterol below 
3.4mmol/L.  In this sub-group the relationship between high-sensitivity CRP ≥2mg/L and 
obstructive CAD was much stronger, with an adjusted odds ratio of 2.49 (95% CI 1.12-5.51; 
p=0.024; n=173). 
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Table 3.6:  Classification & Model Specification for Multivariate Logistic Models 
Obstructive CAD           
on Angiography 
Framingham 10-
year Coronary 
Disease Risk 
SCORE 10-year 
Fatal CVD Risk 
Multivariate 
Model 
Multivariate 
Model with 
CRP/BNP 
Sensitivity 82.3% 81.7% 83.1% 84.1% 
Specificity 47.4% 51.2% 61.4% 61.3% 
Positive predictive value 70.9% 72.2% 77.0% 77.4% 
Negative predictive value 63.3% 64.3% 70.1% 71.0% 
     
Correctly classified 68.7% 69.8% 74.6% 75.2% 
     
Positive likelihood ratio  1.56 1.67 2.16 2.17 
Negative likelihood ratio  0.37 0.36 0.27 0.26 
Diagnostic odds ratio 4.19 4.68 7.85 8.37 
     
Receiver operator c-statistic 0.739 0.754 0.826 0.829 
     
Goodness of Fit:     
Hosmer-Lemeshow 12.80 (p=0.119) 15.39 (p=0.052) 8.77 (p=0.362) 6.53 (p=0.589) 
BIC’ -49.26 -56.84 -71.04 -55.60 
BIC’ difference 21.78 14.21 referent 15.44 
Positive likelihood ratio (sensitivity/1-specificity) and negative likelihood ratio (1-sensitivity/specificity) describe 
the discriminatory properties of positive and negative test results respectively.  Diagnostic odds ratio 
(positive/negative likelihood ratio) describes the odds of positive test results in participants with CAD compared 
with the odds of positive test results in those without obstructive CAD. 
Goodness of fit tests summarize the overall fit of the multivariate models; for SCORE the Hosmer-Lemeshow chi-
squared statistic approaches significance and suggests there may be a difference in observed and predicted values.  
In all other models the null hypothesis is rejected implying the estimates fit the data at an acceptable level.  The 
Bayesian Information Criterion (BIC’) is a method to compare models; a more negative result implies a better fit 
with excess variables penalised.  A difference of >10 provides very strong evidence for preferring the reference 
model (multivariate analysis of pre-specified variables without biomarkers). 
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Figure 3.4:  Receiver Operator Curves for Obstructive CAD on Angiography 
 
 
Comparison of Framingham risk score (dark grey) and multivariate models with high-sensitivity 
CRP/BNP (light grey) and without (black).  Highly significant difference in ROC areas of 
Framingham versus derived model (chi-squared=24.4; p<0.0001) but no difference with subsequent 
addition of biomarkers (chi-squared=1.14; p=0.286). 
 
Figure 3.5:  Interaction Between C-reactive Protein and Prior CVD 
 
 
 Adjusted probability for obstructive CAD in those with and without prior cardiovascular 
disease, comparing patients with CRP<2mg/L (light grey) and ≥2mg/L (dark grey). 
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[3.4]  Extent & Severity of CAD 
Assessment of the number of diseased vessels and the estimated effect on coronary 
blood flow identified the same 5 variables as independent predictors (age, male gender, 
diabetes, chest pain and previous CVD), with the addition of BNP (Table 3.7).  As in the 
previous analysis, conventional risk factors such as cholesterol, blood pressure and current 
smoking were not independently related to coronary artery lesions in this cohort.   
Note that the extent of CAD includes participants with prior CABG whereas the 
modified Leaman score excludes these patients.  The concordance with each other as well as 
with the primary analysis for the presence of disease, confirms the robustness of the 
multivariate models.  Of particular interest, the variables comprising the full model (including 
high-sensitivity CRP and BNP) only explained 24% of the variability in Leaman scores in an 
exploratory linear regression.  Assuming that a further 50% of variability in coronary disease 
severity is due to genetic predisposition still leaves a large proportion unaccounted for by 
conventional risk factors. 
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Table 3.7:  Multivariate Odds Ratios for the Extent and Severity of CAD 
Variable (unit of increase) 
Extent of CAD Severity of CAD 
Odds Ratio (95% CI) p Odds Ratio (95% CI) p 
Age (per 10 years) 1.66 (1.36 - 2.01) <0.001 1.57 (1.26 - 1.95) <0.001 
Male gender 4.56 (3.13 - 6.64) <0.001 4.41 (2.89 - 6.72) <0.001 
Current smoker 1.26 (0.80 - 1.98) 0.324 1.53 (0.93 - 2.53) 0.095 
Diabetes 1.60 (1.07 - 2.37) 0.021 1.66 (1.08 - 2.57) 0.021 
Chest pain 1.60 (1.09 - 2.34) 0.017 1.92 (1.24 - 2.99) 0.004 
Prior CVD 2.03 (1.42 - 2.91) <0.001 1.72 (1.16 - 2.54) 0.007 
Body mass index (per 1 kg/m2) 0.98 (0.95 - 1.02) 0.374 1.02 (0.99 - 1.06) 0.212 
Pulse Pressure (per 10mmHg) 0.95 (0.86 - 1.04) 0.265 0.97 (0.87 - 1.08) 0.566 
GFR (per 10 ml/min) 0.96 (0.89 - 1.03) 0.221 0.93 (0.86 - 1.01) 0.082 
Total Cholesterol (per 1mmol/L) 1.15 (0.97 - 1.36) 0.103 1.14 (0.95 - 1.37) 0.153 
High-sensitivity CRP ≥2mg/L 1.10 (0.78 - 1.55) 0.576 1.05 (0.72 - 1.52) 0.799 
BNP (per log unit) 1.24 (1.07 - 1.44) 0.004 1.24 (1.05 - 1.45) 0.010 
Impaired LV function 1.33 (0.85 - 2.07) 0.214 1.42 (0.85 - 2.36) 0.180 
Multivariate-adjusted ordered logistic regression for pre-specified variables giving proportional odds ratios (for 
example having diabetes increases the odds of triple-vessel disease compared to less severe CAD by 1.6.  
Similarly the odds increase by 1.6 when comparing zero and minor irregularities with obstructive CAD).  Note 
severity of CAD (using modified Leaman score to weight lesions according to blood flow disturbance) is 
calculated in participants without prior coronary artery bypass surgery (n=467).  Multivariate models are also 
adjusted for medication usage (odds ratios not shown). 
 
 
[3.5]  Discussion 
These data suggest that traditional risk assessment algorithms designed for use in 
asymptomatic patients may also be valuable in predicting angiographic coronary disease in 
those with symptoms and/or established disease.  The key findings were that Framingham 
and SCORE risk estimates were associated with the presence and severity of CAD in a 
population typical of patients referred for cardiology opinion and even in those with prior 
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cardiovascular disease.  The main factors driving risk were the un-modifiable markers such as 
age and gender, with diabetes and prior CVD also significant predictors in multivariate 
analysis.  Assessment of individual risk factors suggests that blood pressure, smoking, 
measures of obesity and lipid profiling were poor discriminators of angiographic CAD.  
Furthermore the addition of high-sensitivity CRP and BNP made little difference to either 
classification of CAD or analysis using receiver operator curves. 
 
Risk scores such as Framingham and SCORE were not designed for this patient 
population nor were they meant to predict the presence of coronary artery lesions.  However 
the variables contained in the algorithms are often part of stratifying risk and determining 
management in patients with a history of CVD or current symptoms of myocardial ischaemia.  
Framingham and SCORE were equivalent in their prediction of angiographic CAD in this 
unselected cohort (Table 3.6).  Model fit was less good for SCORE, an unexpected finding as 
it included a much larger, more recent cohort with a more contemporary distribution of co-
morbidities than Framingham.  However SCORE estimates are for fatal CVD rather than 
events and have also been shown to overestimate disease.170  
Other attempts to establish factors associated with coronary angiography include an 
Australian study by Wang et al. in 1991-2.169  In 594 consecutive participants referred for 
angiography (excluding those with left main disease), smoking dose, ratio of total cholesterol 
to HDL, lipoprotein A, positive family history and hypertension were also found as 
determinants of CAD severity, although major differences exist in the baseline demographics 
compared to our contemporary population.  Statins were prescribed in only 15.2% with mean 
cholesterol over 1 mmol/L higher than the ARM-CAD study.  There were also fewer 
diabetics (11.4%), less obesity (BMI was 1.7 kg/m2 lower) and nearly half were smokers.  
Similarly in a cohort from the Duke Medical Centre (1983-5), smoking was much more 
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prevalent than in our patients, with less diabetes and hypertension.171  I would hypothesize 
that these major changes in lifestyle risk factors contributes to the difference between these 
studies and the present analysis, consistent with the observation that Framingham risk in the 
US population decreased significantly from 1976/1980 to 1988/1994 (although was 
minimally changed from 1988/1994 to 1999/2004).172  
Over 90% of participants in the study were on medications that directly affect cardiac 
risk factors, and there was evidence of social/lifestyle changes in those with CAD which 
could be explained by greater patient awareness and risk factor modification (such as lower 
rates of smoking and total cholesterol).  With regard to BP indices, only pulse pressure was a 
univariate predictor of angiographic outcome but was not independently associated after 
adjustment for medication usage.  Meta-analysis of BP trials in patients without vascular 
disease suggests systolic BP is more informative for mortality prediction than pulse 
pressure.67  However in a population sample that included those with CVD, systolic BP was 
weakly associated with 12-year mortality and only significant in women.25   
 
Despite enthusiasm for assisting in risk-stratification, biomarker testing has rarely 
been shown to add to conventional risk factors46 (although it has been argued that standard 
statistical methods may be inadequate to evaluate new markers173).  We measured high-
sensitivity CRP prior to angiography and found no correlation with angiographic outcomes in 
the whole cohort but a marginally significant association in those without prior CVD.  Recent 
data from the Justification for the Use of Statins in Prevention (JUPITER) study identified 
significant benefit in terms of reduced cardiovascular events and hospitalisation from 
rosuvastatin in healthy patients with elevated CRP but without hyperlipidaemia.154  Analysis 
of the dataset matching the LDL cut-off in JUPITER is concordant with their observations, 
identifying high-sensitivity CRP as an independent predictor of angiographic CAD only in 
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this sub-group.  The poor performance of CRP in hyperlipidaemic patients or those with 
confirmed atherosclerotic lesions may explain its low correlation with angiography, despite 
each being independent markers of long-term risk.50  Thus high-sensitivity CRP may be an 
indicator of unstable atherosclerotic plaques rather than extent of angiographic disease per 
se.174   
BNP was an independent marker of the extent and severity of CAD, even after 
adjustment for impaired left ventricular function.  Similar to CRP, no additional value was 
identified in predicting the presence of disease above conventional risk factors, with super-
imposable receiver operator curves.  Although potentially affected by loading conditions in 
our fasted patients, it does confirm previous reports that BNP is a marker of CAD but not a 
good screening tool.60  BNP may have a role in the stratification of the need for and timing of 
angiography; higher values suggest more severe and extensive disease that may warrant 
earlier investigation and intervention.  Using cut-offs for BNP (>50 pg/ml identified as a 
useful cut-point in conjunction with exercise testing57 and >80 pg/ml in acute coronary 
syndrome patients175) made no discernable difference to outcome models.  
 
Finally comparison of the multivariate models suggested the most parsimonious 
model was that containing the pre-specified variables without biomarkers (Table 3.6).  The 
Bayesian Information Criterion (BIC’) is a useful measure of overall model fit with a lower 
(more negative) number indicating greater likelihood of predicting the observed values.  
Differences in the BIC’ statistic of >10 provides ‘very strong’ evidence for superiority of the 
pre-specified variables compared to Framingham, SCORE or the model including 
biomarkers.176  The mechanism of risk for both high-sensitivity CRP and BNP are already 
described within conventional factors (for example CRP by oxidization of LDL48 and BNP as 
a marker of LV function58).  Therefore we might expect that novel parameters approaching 
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risk stratification using different physiological pathways (such as pulse wave analysis and 
heart rate variability) may add more to standard risk profiling.  Even in the best fitted model, 
the positive and negative likelihood ratios were relatively low, suggesting a need for 
additional independent markers of cardiovascular risk.   
 
Limitations of Analysis 
The ARM-CAD study was an observational cross-sectional evaluation of 
angiography-defined coronary artery disease.  Severity of angiographic CAD is known to 
correlate with long-term mortality8-10 and is associated with reduction in maximal myocardial 
blood flow177 but not necessarily with the culprit lesion in acute coronary syndromes.178  
Patients selected for coronary angiography may have certain biases compared with a general 
cardiology population.  For example, those with known coronary lesions and previous 
revascularisation may have been more likely to be offered angiography which could inflate 
the perceived association with CAD.  Smoking was only recorded in terms of current, patient-
defined use and did not take into account frequency or prior smoking history.  Similarly, 
diabetes status was recorded as a patient-reported variable, although this was corroborated 
with medical notes and medication history. 
 
[3.6]  Summary 
Non-invasive estimation of coronary disease risk is critical in screening symptomatic 
patients and to ascertain the need and priority for coronary angiography.  Framingham and 
SCORE risk models predicted the presence and severity of CAD in an unselected cohort 
referred for angiography, including those with prior cardiovascular disease.  However risk 
factor modification limits the usefulness of blood pressure, lipid profiles and measures of 
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obesity.  Similarly, evaluating B-type natriuretic peptide and high-sensitivity C-reactive 
protein did not improve classification of CAD.  This chapter has also highlighted the low 
sensitivity of existing risk scores in this patient group and the discordance in patients at high 
baseline risk which are under-represented in the Framingham and SCORE populations.  
Conventional risk factor modelling left a large amount of the variance in coronary disease 
severity unexplained.  Markers that further stratify risk beyond conventional factors are 
required to improve diagnostic accuracy and identify patients with and without coronary 
atherosclerosis. 
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Chapter 4. Pulse Wave Analysis & Coronary Disease 
 
This chapter will address the hypothesis that PWA is independently associated with 
coronary artery disease on angiography.  As noted previously, there is a clear clinical need to 
identify those patients with normal coronary artery anatomy who are unnecessarily subjected 
to the potential risks of cardiac catheterisation.  Preliminary analysis suggested that central 
augmentation pressure (at the cut-point of 24 mmHg) was particularly suited for the 
exclusion of NCA and hence the primary outcome for this chapter relates to normal 
coronaries (compared to minor irregularities and more severe CAD) as opposed to obstructive 
versus non-obstructive disease. 
 
Radial pulse waveforms were available in 531 participants of the ARM-CAD study.  
The 8 patients without available waveforms had no significant difference in baseline 
characteristics, although a trend was noticed for a higher rate of prior CVD (87.5% versus 
55.6% in subjects with PWA; p=0.069).  However, there were no differences in the presence, 
extent or severity of CAD on angiography.   
Mean central augmentation pressure was 17.1 ± 10.1mmHg and 125 participants 
(23.5%) had cAP at or above the pre-specified cut-point of 24mmHg.  Mean central (PWA-
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derived) pulse pressure was 52.9 ± 17.8mmHg, 18% lower than the pressure obtained at the 
brachial artery.  Selected baseline variables are presented in Table 4.1, subdivided according 
to identification of normal coronary arteries on angiography.  Variables significantly different 
in those patients without any discernable angiographic disease were similar to those 
differentiating obstructive from non-obstructive CAD (refer to Tables 3.2 and 3.4).  A 
disproportionate percentage of patients with NCA had chest pain, and BMI was higher in this 
group, with a general trend towards reduced BMI as CAD severity worsened (p=0.036).  This 
‘obesity paradox’ has been noted in several studies of patients with CAD in which 
overweight individuals have consistently better survival and lower rates of cardiovascular 
events than those with normal or low BMI.179   
 
In addition to the multivariate regression models described, further models were 
tested with combinations of blood pressure variables and PWA indices (including systolic, 
diastolic, mean and fractional pressures).  The conclusions from all of these analyses, as well 
as both forward and backward stepwise models were similar to that presented below. 
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Table 4.1:  Baseline Characteristics According to Absence of Angiographic CAD 
Characteristic 
Normal coronary 
arteries (n=108) 
Any degree of 
CAD (n=423) 
p-value 
Age (years) 57.8 ± 11.5 66.5 ± 10.0 <0.001 
Male gender (%) 38.9 74.5 <0.001 
Family history of premature CVD (%) 36.1 34.3 0.721 
Current smoker (%) 16.7 16.3 0.929 
Diabetes (%) 12.0 23.9 0.007 
Prior angina or myocardial infarction (%) 25.5 54.6 <0.001 
Peripheral vascular disease (%) 6.5 10.6 0.195 
Chest pain (%) 76.9 75.7 0.794 
Heart rate (beats per minute) 66.9 ± 12.1 62.9 ± 11.6 0.001 
Systolic BP (mmHg) 142.5 ± 18.8 144.5 ± 21.3 0.362 
Peripheral pulse pressure (mmHg) 61.1 ± 16.5 65.5 ± 18.4 0.026 
Body mass index (kg/m2) 29.8 ± 6.0 28.5 ± 4.9 0.033 
GFR (ml/min/1.73m2) 89.9 ± 22.4 81.6 ± 23.5 0.001 
Total cholesterol (mmol/L) 5.02 ± 1.16 4.48 ± 1.08 <0.001 
HDL-cholesterol (mmol/L) 1.35 ± 0.40 1.19 ± 0.31 <0.001 
High-sensitivity CRP (%: <1, 1-3, >3mg/L) 19.4, 47.2, 33.3 28.7, 39.0, 32.3 0.122 
BNP (pg/mL)  22.5 ± 49 43 ± 81 <0.001 
Antiplatelet agent (%) 54.6 79.4 <0.001 
ACE inhibitor/receptor blocker (%) 44.4 57.7 0.014 
Beta-blockers (%) 25.0 49.7 <0.001 
Nitrates (%) 8.3 18.9 0.009 
Statins (%) 42.6 67.4 <0.001 
Data are given as mean ± SD or percentage except for BNP presented as median ± interquartile range. 
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[4.1]  Predictors of Angiographically-Normal Coronary Arteries  
Angiographically-smooth coronaries were identified in 20.4% of participants.  Crude 
odds ratio for cAP<24mmHg (versus cAP≥24mmHg) was 2.00 with 95% CI 1.12-3.54 
(p=0.018).  As anticipated, most conventional risk factors were inversely associated with 
angiographic-NCA in univariate analysis (see Table 4.2).  Notable exceptions were smoking, 
cardiac symptoms, haemoglobin and left-ventricular impairment.  Heart rate and total 
cholesterol were confounded by prescription of beta-blockers and statins respectively.   
Multivariate analysis, with inclusion of all pre-specified variables and adjustment for 
cardiac medications identified only four parameters independently predictive of NCA: 
younger age, female gender, the absence of diabetes and low cAP, as depicted in Figure 4.1.  
Adjusted odds ratio for cAP<24mmHg was 3.37, 1.20-9.49 (p=0.021).  Thus cAP below this 
cut-point increases the odds of NCA by 70%, equivalent to the odds change for diabetes 
(Table 4.2).  Indices of obesity (including waist-hip ratio; data not shown), peripheral BP, 
renal function and lipid studies were not significant indicators of angiographically-normal 
coronaries.   
Low cAP was a better predictor of NCA than high-sensitivity CRP or BNP.  The latter 
biomarkers were also analysed using cut-off values; crude odds ratio for high-sensitivity 
CRP<2mg/L was 1.08 (0.71-1.64; p=0.734), adjusted 1.02 (0.56-1.84; p=0.961) and for 
BNP<100pg/ml crude odds ratio was 2.52 (1.33-4.78; p=0.005), adjusted 1.45 (0.59-3.54; 
p=0.413).  The adjusted analyses included PWA-derived central pressures.  If cAP and cPP 
were excluded from the multivariate model then BNP, adjusted for baseline risk factors and 
even the diagnosis of impaired LV function, was significantly associated with NCA (OR for 
log-unit reduction in BNP was 1.33, 95% CI 1.03-1.71; p=0.031).  This suggests that the 
association of natriuretic peptides with coronary disease is due, in part, to central pressures 
which are more effectively assessed using PWA. 
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Table 4.2:  Univariate & Multivariate Odds Ratios for Identifying Angiographic NCA 
Variable (unit of change) Unadjusted Univariate  Multivariate, Adjusted * 
OR 95% CI p-value  OR 95% CI p-value % change in odds† 
Younger Age (per 10 years) 2.11 1.71 – 2.61 <0.001  2.46 1.74 – 3.48 <0.001 59 
Female gender 4.35 2.81 – 6.75 <0.001  6.62 3.11 – 14.10 <0.001 85 
No prior angina/infarction  3.54 2.20 – 5.70 <0.001  1.79 0.98 – 3.30 0.060 44 
Non-diabetic 2.42 1.30 – 4.49 0.005  3.24 1.38 – 7.62 0.007 69 
Non-smoker 1.00 0.57 – 1.76 0.991      
Free of chest pain 0.98 0.60 – 1.60 0.935      
Lower body mass index (per 1 kg/m2) 0.95 0.92 – 0.99 0.016  0.95 0.90 - 1.00 0.057 -6 
Lower heart rate (per 10 beats/min) 0.75 0.63 – 0.90 0.002      
Reduced peripheral PP (per 10mmHg) 1.16 1.03 – 1.32 0.019      
Reduced central PP (per 10mmHg) 1.18 1.03 – 1.34 0.014      
cAP<24mmHg 2.00 1.12 – 3.54 0.018  3.37 1.20 – 9.49 0.021 70 
Higher haemoglobin (per g/dL) 0.96 0.83 – 1.10 0.533      
Higher GFR (per 10ml/min) 1.16 1.06 – 1.28 0.001      
Lower total cholesterol (per mmol/L) 0.68 0.56 – 0.81 <0.001  1.32 0.99 – 1.77 0.061 24 
Higher HDL-cholesterol (per mmol/L) 3.77 2.07 – 6.86 <0.001      
High-sensitivity CRP (per 1 mg/L category decrease) 0.86 0.65 – 1.13 0.288      
Lower BNP (per log unit)  1.46 1.22 – 1.74 <0.001  1.28 0.99 – 1.66 0.059 -22 
Absence of left-ventricular impairment  1.53 0.85 – 2.78 0.158      
Univariate and multivariate odds ratios for angiographically-normal coronary arteries (medications not shown).  * Only odds ratios (OR) with p<0.1 are displayed.   
† Describes the percentage change in odds for a one-unit change in that variable (for example, a decrease in age of 10 years increases the odds of NCA by 59%). 
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Figure 4.1:  Comparison of Odds Ratios for Normal Coronaries 
 
 
 Multivariate odds ratio presented for fixed regression model as described in Table 4.2. 
 
 
[4.2]  Classification of Angiographic Disease & Value of cAP 
A reduced multivariate model was constructed using PWA plus commonly assessed 
risk factor variables identified in stepwise regression (see Methods section 2.9).  As depicted 
in Figure 4.2, the reduced model was comparable with the full analysis.  Corresponding c-
statistics were 0.869 and 0.876, with no statistical difference noted (chi-squared for 
difference=1.35; p=0.245).  Table 4.3 summarizes the classification statistics for the reduced 
multivariate model.  Specificity was high with only 5.7% misclassified as having NCA when 
coronary disease was actually present.  Positive and negative likelihood ratios were in excess 
of criteria that suggest ‘strong diagnostic evidence’.180   
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Figure 4.2:  ROC Comparison of Full and Reduced Multivariate Models 
 
 
 Receiver operator curves comparing full multivariate model (black) with reduced model (grey) consisting of 
PWA plus commonly assessed risk factor variables only.   
 
Table 4.3:  Classification of NCA using Reduced Multivariate Model 
Receiver operator curve area (c-statistic) 0.866 
Sensitivity 48.2% 
Specificity 94.3% 
Negative predictive value 87.7% 
Positive predictive value 68.4% 
Misclassified as having normal coronaries when disease was present 5.7% 
Correctly classified 84.9% 
Negative likelihood ratio 0.55 
Positive likelihood ratio 8.49 
Diagnostic odds ratio 15.5 
Included variables are age, gender, prior CAD, diabetes, BMI, GFR, total and HDL-cholesterol, 
cAP<24mmHg, cPP, beta-blocker, clopidogrel and statin-prescription.  Hosmer-Lemeshow chi-
squared=5.98 (p=0.649) indicating no significant deviation in observed and predicted values. 
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The value of PWA was also assessed with respect to other baseline risk factors.  
Figure 4.3 demonstrates that cAP<24mmHg doubles the predicted probability of NCA across 
age groups, gender, total cholesterol tertiles, BNP and by diabetic status (all interaction p-
values non-significant).  However the benefit of identifying low cAP was less clear in 
patients with prior angina or MI (interaction p-value=0.037).  This was driven predominantly 
by the MI component of this composite variable (angina interaction p-value=0.371).  Central 
augmentation pressure also successfully reclassified patients in whom conventional risk 
factors incorrectly predicted the presence of CAD.  As noted in Figure 4.4, NCA was present 
in 49 patients (14.0%) with a Framingham risk score of ≥10%.  41 of these (83.7%) were 
correctly identified as having NCA using cAP<24mmHg. 
 
Figure 4.3:  Adjusted Probability of NCA According to cAP & Risk Variables 
 
 
 Probability of normal coronary angiogram comparing cAP<24mmHg (white) with cAP≥24mmHg (grey) 
according to other risk factors.  Each graph is adjusted for all other variables in the regression model. 
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Figure 4.4:  Reclassification Using Central Augmentation Pressure 
 
 
 Classification of angiographically-normal coronary arteries using Framingham 10-year absolute 
event risk of total coronary disease and reclassification by cAP from PWA. 
 
[4.3]  PWA & Extent/Severity of Coronary Artery Disease 
 Central augmentation pressure was also an independent predictor of the extent of 
angiographic coronary disease, in which angiograms were classified into NCA, minor 
irregularities, single vessel, 2-vessel and 3-vessel disease.  As noted in Table 4.4, the 
proportional odds ratio for the extent of CAD for cAP≥24mmHg was 2.17 (95% CI 1.21-
3.89) in adjusted analysis.  Thus the odds ratio of any category of CAD (or combination of 
categories) compared to any higher or lower category was 2.17 when contrasting patients 
above and below the pre-specified cut-off for cAP.  Calibration statistics confirmed that the 
proportional odds assumption was not violated for the final model (chi-squared=45.78; 
p=0.318), 
 As in the analysis for Chapter 3, modified Leaman scores were used as an indicator of 
the severity of lesions in reference to the disturbance in usual coronary blood flow.  Although 
central augmentation pressure was significantly associated with Leaman scores as a 
continuous variable (adjusted OR per 10mmHg was 2.65, 95% CI 1.15-6.12; p=0.022) the 
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cut-off value at 24mmHg was not significant.  The reason for this discrepancy was the 
exclusion from analysis of patients with NCA or minor irregularities (by definition these 
participants have a Leaman score of zero), in whom this cut-off is of particular benefit. 
 
 
Table 4.4:  Multivariate Odds Ratios for the Extent of CAD including PWA 
Variable (unit of increase) Proportional Odds Ratio (95% CI) z-score p-value  
Male gender 4.75 (3.20 - 7.04) 7.75 <0.001  
Age (per 10 years) 1.79 (1.48 - 2.16) 6.05 <0.001  
Prior CVD 2.11 (1.47 - 3.04) 4.04 <0.001  
cAP≥24mmHg 2.17 (1.21 - 3.89) 2.61 0.009  
Diabetes 1.54 (1.03 - 2.31) 2.09 0.037  
Chest pain 1.49 (1.01 - 2.19) 2.02 0.044  
Impaired LV function 1.51 (0.97 - 2.34) 1.84 0.066  
Total Cholesterol (per 1 mmol/L) 1.13 (0.96 - 1.34) 1.48 0.139  
Current smoker 1.21 (0.77 - 1.90) 0.81 0.417  
Central PP (per 10mmHg) 1.00 (0.62 - 1.64) 0.01 0.990  
Peripheral PP (per 10mmHg) 0.84 (0.55 - 1.29) -0.79 0.430  
GFR (per 10ml/min) 0.95 (0.88 - 1.02) -1.34 0.179  
Body mass index (per 1 kg/m2) 0.95 (0.90 - 1.00) -2.13 0.033  
Multivariate-adjusted ordered logistic regression giving proportional odds ratios (for example in patients with 
cAP≥24mmHg compared to those with cAP<24mmHg, the odds of triple-vessel disease compared to less 
severe CAD is 2.17.  Similarly the odds increase by 2.17 when comparing zero and minor irregularities with 
obstructive CAD).  Models are also adjusted for medication usage (odds ratios not shown).  Variables sorted 
by z-score. 
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[4.4]  Pulse Wave Analysis & Risk Factor Variables 
Table 4.5 presents the main variables derived from PWA according to degree of 
angiographic CAD.  Central pulse and augmentation pressures, ejection duration and sub-
endocardial viability ratio were linearly related to the extent of atherosclerotic disease.   
The latter two were highly correlated and not independent of heart rate (r= 0.85, p<0.001 and 
-0.70, p<0.001 respectively).  Variables derived from the peripheral waveform, central 
measures of waveform timing and augmentation index were unrelated to the extent of 
disease.  As demonstrated in Figure 4.5, cAP correlated with peripheral BP and also heart rate 
(although not to the same extent; r= -0.42, p<0.001). 
Women had higher cAP than men; mean 20.0 ± 9.3mmHg versus 15.7 ± 10.3 
(p<0.001) and this was consistent in most patient sub-groups (see Figure 4.6).  Augmentation 
pressure did not differ in diabetics compared to non-diabetics (17.7 ± 10.3mmHg versus 16.9 
± 10.1; p=0.490) but was significantly higher in those with prior angina or MI (18.3 ± 10.7 
versus 16.0 ± 9.5; p=0.018).  In contrast, central pulse pressure did not differ significantly in 
patients with or without prior CAD, was marginally lower in non-diabetics (by 3.72mmHg; 
p=0.049) but similar to cAP was higher in women compared to men (55.4 ± 16.7mmHg 
versus 51.8 ± 18.3; p=0.027).   
Consistent with published data, cAP was linearly associated with age (r= 0.38, 
p<0.001) but cPP and cAI were curvilinear with a marked difference in correlation around the 
age of 50 (see Figure 4.7).  The correlation coefficient for cPP was 0.14 (p=0.289) in patients 
≤50 years old and 0.36 (p<0.001) in those aged over 50. 
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Table 4.5:  PWA-Derived Variables & Angiographic CAD 
PWA Variable 
Normal coronary 
arteries 
Minor coronary 
irregularity 
Single-vessel 
disease 
Two-vessel    
disease 
Three-vessel 
disease 
Quality Index (%) 90 ± 11.5 90 ± 12 91 ± 12 92 ± 10 91 ± 13 
Peripheral augmentation index (%) * 87.1 ± 18.1 89.3 ± 16.2 88.7 ± 15.4 85.5 ± 17.5 91.2 ± 16.9 
Central systolic pressure (mmHg) 131.8 ± 17.9 132.5 ± 20.8 135.3 ± 20.5 134.7 ± 24.0 133.5 ± 20.1 
Central diastolic pressure (mmHg) 82.6 ± 8.4 80.1 ± 10.9 82.1 ± 10.9 80.2 ± 11.7 78.1 ± 9.7 
Central pulse pressure, cPP (mmHg)  49.1 ± 15.5 52.4 ± 18.1 53.3 ± 16.9 54.5 ± 20.2 55.3 ± 17.7 
Time to 1st shoulder, t1 (ms) 105.9 ± 12.6 106.9 ± 12.6 106.8 ± 11.0 106.5 ± 13.5 107.1 ± 14.3 
Time to 2nd shoulder, t2 (ms) 229.8 ± 25.3 231.4 ± 27.2 234.4 ± 22.7 227.4 ± 25.0 234.8 ± 25.9 
Central augmentation pressure, cAP (mmHg)  15.4 ± 9.4 16.7 ± 9.4 17.6 ± 9.2 16.8 ± 11.3 19.1 ± 10.9 
Central augmentation index, cAI (%) † 29.2 ± 13.0 30.5 ± 11.5 30.9 ± 10.2 28.2 ± 11.7 32.4 ± 11.6 
Ejection duration (%) ‡ 35.9 ± 4.6 35.2 ± 4.2 34.3 ± 4.5 34.6 ± 4.8 33.0 ± 4.3 
Sub-endocardial viability ratio (%) § 150.2 ± 31.2 150.4 ± 29.1 157.6 ± 31.5 153.6 ± 33.0 163.9 ± 35.3 
Data are given as means ± SD, except for quality index presented as median ± interquartile range.  * Derived directly from the radial waveform without use of the                      
transfer function.  † cAI = cAP/cPP x 100.  ‡ Time to incisura as a percentage of total waveform time.  § Area under curve; diastole as a percentage of systole.   
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Figure 4.5:  Effect of Heart Rate and Blood Pressure on Augmentation 
 
 
 Scatter plots and linear regression line of central augmentation pressure (cAP) in relation to heart rate (left) 
and brachial systolic blood pressure (right).  Correlation coefficient, r = -0.42 for heart rate (p<0.0001) and 
0.65 for systolic BP (p<0.0001). 
 
Figure 4.6:  Central Augmentation Pressure & Cardiac Risk Factors 
 
 
 Comparison of cAP in males and females by diabetes and prior angina/myocardial infarction using box 
and whisker plots; central black line is the median.  All male versus female comparisons were 
statistically significant except for no prior CAD/diabetic sub-group (p=0.076). 
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Figure 4.7:  Effect of Age on Central Pressure and Augmentation 
 
 
 Scatter plots and locally weighted regression line for PWA variables versus age.  Central augmentation 
pressure (cAP, top) is linear with respect to age but central pulse pressure (cPP, middle) and central 
augmentation index (cAI, bottom) are curvilinear with an inflection around the age of 50. 
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[4.5]  Discussion 
The ARM-CAD study prospectively assessed radial artery PWA in a group of patients 
referred for diagnostic coronary angiography, irrespective of ventricular function and other 
co-morbidities.  The key findings were that identifying cAP<24mmHg using a simple, non-
invasive measurement doubled the predicted probability of angiographically-normal coronary 
arteries, independent of other risk factors.  These findings are clinically important as NCA are 
associated with 10-year survival of 93.6%181 and the risk of coronary death or non-fatal MI is 
the same in these patients as the general population.13   
Current methods used to identify those at high risk of CAD and determine the need 
for coronary angiography include exercise ECG, stress echocardiography and myocardial 
perfusion imaging.  Indirect comparisons of these methods have previously been discussed182; 
each has limitations including variable sensitivity and specificity for exercise ECG183, 
operator-dependence for stress echocardiography and radiation exposure for nuclear imaging. 
Additionally, these tests have reduced accuracy in female patients184 and interpretation is 
complicated by concurrent medication usage, particularly beta-blockers.  A considerable 
number of participants in this study had previously been assessed using these tests but despite 
these costly investigations, 20% had an entirely normal coronary angiogram. 
 
A growing evidence base supports the use of PWA as a marker of long-term vascular 
risk in those without pre-existing CVD, as well as in patients with significant risk factors and 
established coronary disease.  Previous studies correlating PWA variables with coronary 
angiography have confirmed that central pressure augmentation increases with more 
advanced disease in chronic kidney disease patients131 and in male referrals for 
angiography.132  In the latter study by Weber et al, high cAI was associated with the presence 
of obstructive CAD and the severity of disease, although this relationship was absent in 
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patients over the age of 60 years.  Critically, PWA assessment was performed in a single 
centre after coronary angiography, ignoring the hemodynamic effects of cardiac 
catheterisation and procedural medications.  In contrast the ARM-CAD study was not 
restricted by gender, PWA was evaluated prospectively in multiple centres and no exclusions 
were made for valvular disease.  We used cAP as this variable is linear with respect to age, 
whereas cAI and cPP are not113, potentially explaining their inability to independently predict 
CAD in our cohort.  The pre-specified cut-off value of 24mmHg, in combination with 
conventional risk factors, identified NCA with a very high specificity and this was consistent 
across the levels of other risk markers.  Information provided by cAP was independent and 
complementary to these factors as evidenced by the increase in odds ratio following 
multivariate adjustment.  An interaction was only seen in patients with a prior history of 
coronary disease where additional data on risk is seldom required.  Central augmentation 
pressure was also a predictor for the extent and severity of CAD. 
Assessment of new risk markers is frequently discussed in terms of the receiver 
operator curve despite good evidence that the c-statistic, a measure of model discrimination, 
is not a sensitive instrument for calibration and determination of actual risk in well-fitting 
models.173  In the Women’s Health Study, high-sensitivity CRP added only 0.002 to the c-
index despite reclassifying 20% of women into more accurate risk strata.185  Similarly I have 
shown that cAP<24mmHg can successfully reclassify patients in whom conventional risk 
scores incorrectly suggested the presence of CAD and that this benefit was independent of 
high-sensitivity CRP and BNP.  Thus improvement in risk-stratification using PWA has the 
potential for considerable cost savings and could lead to a reduction in unnecessary coronary 
angiograms. 
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Limitations of Analysis 
The aims of this study were to assess the potential clinical use of PWA and therefore 
operators were clinical staff who received only a brief training session.  Nevertheless, each 
operator obtained a large number of waveforms with subsequent effects on quality that may 
not be matched by sporadic use of PWA.  Smoking was only recorded in terms of current use 
and did not take into account frequency or prior smoking history which may have been more 
closely linked to CAD severity.  Visual inspection of contrast angiography can miss coronary 
lesions and potentially very minor stenoses of <30% may have been misclassified as NCA.  
Nevertheless, these patients still have a comparably good prognosis.181   
 
[4.6]  Summary 
Incorrect stratification of cardiovascular risk is common, as evidenced by the high 
proportion of normal angiograms and false-positive stress tests.  Clinicians must carefully 
consider the relative benefits of each test available, accounting for the impact on clinical 
management and factors such as individual suitability and radiation exposure.  PWA, as 
shown in this and previous studies, is easily obtained, independent of standard BP 
measurement, adds to risk prediction based on conventional risk factors and involves no harm 
to the patient.  Identifying low central augmentation pressure in the out-patient setting can 
improve clinical prediction of vascular risk and assist in excluding the presence of coronary 
disease in symptomatic patients. 
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Chapter 5. Clinical Application of Pulse Wave Analysis 
 
The diagnostic value of new tests is frequently overestimated in research-based 
studies as compared with clinical application.  Previous studies investigating PWA have 
considerable exclusion criteria, complicating translation to clinical practice and restricting the 
use of this novel technology.  In comparison, the ARM-CAD study was designed to test the 
clinical applicability of PWA by evaluating an unselected cohort of patients attending 
elective coronary angiography.  Uniquely, this allows an assessment of the effect of co-
morbidities on the quality of waveforms and the subsequent impact on predictive capacity.  
Based on exclusion criteria from other studies (i.e. excluding those with heart failure, 
significant valvular disease or arrhythmias), 24% of ARM-CAD participants would not have 
been enrolled.  For PWA to be accepted in the routine work-up of patients at risk of 
cardiovascular disease, it must retain clinical accuracy despite co-morbid conditions and be 
applied widely without excluding large groups of patients. 
 This chapter reports the effect of radial waveform quality on prediction of 
angiographic CAD to test the hypothesis that PWA is suitable for clinical application.  Two 
methods of analysis are discussed; firstly assessing patient characteristics and co-morbidities 
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with the best waveform obtained and secondly analysing a sub-group with two or more 
sequentially obtained waveforms (see Figure 5.1).   
 
Figure 5.1:  Study Flowchart and Description of Analyses 
 
 
 
[5.1]  Primary Analysis of Best Quality Waveform 
 The best quality waveform was analysed in 531 participants, based on the overall 
quality index (QI) [refer to Figure 2.1, page 50].  Median QI was 91% (IQR 12%), however 
28.3% had QI≤85%, the specified target for waveform quality. 
 
Impact of Risk Factors & Co-Morbidities on Waveform Quality 
Waveform quality was positively correlated with age, systolic BP and pulse pressure 
and inversely correlated with heart rate and BMI (Figure 5.2 & Table 5.1).  However all 
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correlations were weak and less than 0.20.  In an exploratory regression model, age was not 
an independent determinant of QI when adjusted for BMI, BP and heart rate (p=0.101 after 
adjustment).  From the categorical variables, only aortic valve disease, frequent ectopics and 
atrial arrhythmias significantly reduced waveform quality (Table 5.1).  Important variables 
that did not correlate with quality included diabetes, peripheral vascular disease and the 
extent of CAD.  Similarly, neither echocardiographic cardiac dimensions, parameters of LV 
and diastolic function nor BNP were determinants of quality. 
 
 
Figure 5.2:  Quality Index Correlations with Selected Continuous Variables 
 
 
 Scatter plots and linear prediction (grey line) for quality index in relation to age, systolic blood pressure, pulse 
pressure, heart rate, body-mass index and left-ventricular ejection fraction using best quality waveforms.  See 
Table 5.1 for correlation values and significance levels.  n=531 except for ejection fraction (determined on left-
ventriculogram or echocardiography where available, n=297). 
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Table 5.1:  Correlations with Quality of Radial Waveforms 
Continuous 
Variable 
Correlation with   
Quality Index 
(p-value) 
 
Categorical Variable 
Difference in Medians 
for Quality Index  
(p-value*) 
Body-mass index -0.19 (<0.0001)  Atrial arrhythmias:  Yes - No -24.5 (<0.0001) 
Pulse pressure 0.18 (<0.0001)  Frequent ectopic beats:  Yes - No -6.0 (<0.0001) 
Heart rate -0.15 † (0.001)  Mod/Severe Aortic Valve Disease:  Yes - No -2.5 (0.015) 
Systolic BP 0.13 (0.002)  Dilated LV on Echo:  Yes - No -1.5 (0.188) 
E/A ratio -0.13 (0.125)  Peripheral vascular disease:  Yes - No 1.0 (0.266) 
Age 0.12 ‡ (0.004)  LV impairment:  Yes - No 1.0 (0.587) 
Left atrial area -0.10 (0.284)  Diabetes:  Yes - No 0.5 (0.117) 
CAD-score § 0.08 (0.071)  Mod/Severe Mitral Valve Disease:  Yes - No 0.5 (0.685) 
BNP 0.07 (0.127)  High-sensitivity CRP:  >3mg/L - ≤3mg/L 0 (0.059) 
Ejection fraction 0.03 (0.622)  CVD:  Previous - No previous 0 (0.553) 
Cholesterol -0.01 (0.769)  Gender:  Male - Female 0 (0.745) 
Second column shows Spearman correlation coefficients for continuous variables with quality index and significance 
level.  For example, QI increases significantly as systolic BP increases.  Negative values indicate an inverse 
correlation.  See Figure 5.2 for related scatter plots.  Final column shows difference in medians for each categorical 
variable.  For example, median QI was 66.5% (IQR 32%) in those with atrial arrhythmias and 91% (IQR 11%) in 
patients with sinus rhythm resulting in a highly significant reduction in QI of 24.5%. 
* p-value determined using two-sample Wilcoxon rank-sum test.  † Remained significant after adjustment for atrial 
arrhythmias.  ‡ Significant in univariate analysis but not after adjustment for BMI, systolic BP and heart rate.                 
§ Extent of CAD on angiography treated here as continuous variable; similarly non-significant if assessed 
categorically (p=0.193). 
 
Interaction of Quality Index on Coronary Disease Prediction 
Best quality waveforms were sub-divided into those with QI ≤85% or >85% and 
adjusted probability of significant CAD determined for PWA variables.  Median QI was 78% 
(IQR 18%) for the former and 94% (IQR 7%) for the latter (p<0.001).  For cAP, no 
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interaction on predictive capacity was noted according to QI grouping (likelihood ratio 
test=0.18, p for interaction=0.669) as demonstrated in Figure 5.3.  Similarly no statistical 
interaction was identified for cPP in relation to QI (likelihood ratio test=0.72, p for 
interaction=0.396).  This suggests that in patients where a good quality waveform was not 
achievable (for example an overweight patient with high heart rate and valvular disease), 
accurate prediction of coronary disease using PWA is maintained. 
 
Figure 5.3:  Interaction of Quality Index on Coronary Disease Prediction 
 
 
 Adjusted probability of significant angiographic CAD by quality index cut-off of 85%, according to 
5mmHg increments in cAP using best quality waveforms.  No statistical interaction noted between 
QI≤85% and QI>85%.  Adjusted for age, gender, chest pain, diabetes, current smoking, total and 
HDL-cholesterol, systolic BP, beta-blockers, calcium channel blockers, nitrates and statin-use. 
 
Comparison of Measured and Derived Aortic Systolic Pressure as a Function of Quality 
Aortic pressure was measured in a subset of participants during cardiac 
catheterisation.  Peripheral blood pressure was noted to be significantly higher than that 
obtained centrally.  Brachial systolic BP using a conventional sphygmomanometer cuff was 
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7.91 mmHg higher than measured aortic pressure (standard error=1.21; p<0.0001).  In 
comparison, the mean PWA-derived central systolic pressure was 2.70 mmHg lower than 
measured aortic pressure (standard error=1.18; p=0.023).  The 95% confidence interval for 
the difference in means comparing participants with QI>85% and QI≤85% on the best quality 
waveform was -2.68 to 7.23 with a non-significant t-value of 0.902 (p=0.368).  Thus deriving 
central systolic pressure from a non-invasive radial assessment is accurate and waveform 
quality did not affect the transfer function algorithm in systole. 
 
[5.2]  Secondary Comparative Analysis of Sequential Waveforms  
 Multiple radial waveforms were obtained in 409 participants permitting a comparison 
of derived variables and predictive capacity according to quality.  QI was significantly 
reduced in the low quality waveforms from each participant, with a median of 66% (IQR 
20%) versus 92% (IQR 10%) in the high quality waveforms (p<0.001). 
 
Comparison of Derived Central Pressures According to Waveform Quality 
  Figure 5.4 depicts Bland-Altman plots for the difference (high minus low quality) 
versus average results in cPP and cAP.  The vast majority of data points lie within the limits 
of confidence for both variables and were consistent across the pressure range.  Correlation 
values were exceptionally high; rho-c=0.992 for cPP (p<0.001) and 0.960 for cAP (p<0.001).  
High and low quality waveforms were concordant (F-test=2.29, p=0.103 for cPP; F=1.88, 
p=0.154 for cAP, where non-significance implies concordance) and differences between them 
small (average difference 0.23 mmHg for cPP and 0.26 mmHg for cAP). 
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Figure 5.4:  Bland-Altman Plots for cPP and cAP (High versus Low Quality) 
 
 
 n=409 comparing two waveforms (high and low quality) from each participant.  Bland & Altman limits of 
agreement (dashed lines) are -4.54, 4.07 for cPP and -5.75, 5.23 for cAP in mmHg.   
 
 
Prediction of Angiographic CAD According to Waveform Quality  
Table 5.2 demonstrates that high and low quality waveforms had the same power for 
predicting significant CAD on angiography.  Both unadjusted and adjusted odds of 
obstructive CAD were significantly increased for each 10mmHg increase in cPP or cAP 
irrespective of quality.  Further, no difference was observed in ROC classification of disease 
when comparing high and low quality PWA waveforms from the same individual (p-value 
for comparison of ROC area=0.829 for cPP and 0.733 for cAP). 
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Table 5.2:  Odds Ratios for Obstructive CAD using High & Low Quality Waveforms 
Variable Quality 
Unadjusted (per 10mmHg)  Adjusted (per 10mmHg)* 
Odds Ratio for 
Obstructive 
CAD 
95% CI 
for odds 
ratio 
p-
value  
Odds Ratio for 
Obstructive 
CAD 
95% CI 
for odds 
ratio 
p-
value 
cPP 
High 1.22 1.07 - 1.37 0.002  1.36 1.02 - 1.81 0.038 
Low 1.22 1.08 - 1.38 0.002  1.39 1.05 - 1.86 0.023 
cAP 
High 1.32 1.07 - 1.63 0.010  1.56 1.09 - 2.25 0.016 
Low 1.31 1.07 - 1.62 0.011  1.59 1.11 - 2.28 0.011 
* Adjusted for age, gender, current smoking status, total and HDL cholesterol, systolic BP and usage of beta-
blockers, calcium channel blockers, nitrates and statins. 
 
 
[5.3]  Discussion 
As previously discussed, clinical trials using PWA-derived central pressures have 
identified the potential for prediction of cardiovascular risk beyond that obtained from 
peripheral BP.  Unfortunately translating these results to clinical use is complicated by study 
exclusion criteria and the likely reduction in waveform quality associated with application 
outside of research trials.   
These analyses report data from the ARM-CAD study which employed no entry or 
exclusion criteria and is based on a clinical cohort of cardiology patients.  PWA operators 
were all clinical research staff with no previous experience that received only a brief training 
programme.  Average waveform quality was excellent despite the heterogeneous patient 
group studied and time constraints placed on our research nurses (as is likely to occur in 
clinical application).  Analysis of the best available waveform identified that nearly a third of 
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participants had QI less than 85%.  However, the reduction in waveform quality was not 
associated with an observed difference in predicted probability of CAD, nor did it affect the 
accurate generation of PWA-derived central systolic BP. 
 
As expected, waveform quality was reduced in patients with high BMI and low BP, 
indicating more difficult assessment of the radial pulse in those overweight or with low 
volume pulses.  Frequent ectopics or arrhythmias also significantly reduced QI, hampering 
the ability of the software to superimpose individual pulses.  Importantly, waveform quality 
was not associated with age, gender or LV impairment.  The latter is perhaps surprising as 
one might expect patients with poorer ejection fraction to have a lower and more variable 
cardiac output.  However this finding was consistent with the lack of association of QI with 
BNP, which is raised secondary to ventricular wall stress and is a sensitive marker of LV 
dysfunction.58  Moderate or severe aortic regurgitation or stenosis (although not mitral valve 
disease) significantly reduced quality but even this effect was weak and of minimal clinical 
relevance.   
 
In a large subset of the study population, more than one radial waveform was obtained 
at the time of assessment and this permitted a unique evaluation of waveform quality versus 
derived variables with identical environmental conditions and patient-level factors.  I have 
shown that waveforms of low to moderate quality result in similar values for central pulse 
and augmentation pressures.  This may be due to lower amounts of variation in the systolic 
part of the waveform and hence more consistent estimates, as compared to diastole where 
mean pressure was not concordant between high and low quality waveforms (data not 
shown).  A further new finding is that waveforms of moderate quality are equivalent in 
predicting coronary disease on angiography.  The value of these observations is that PWA 
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can be used effectively in a clinical setting without excluding those with co-morbidity and 
with minimal training for staff.  Although good quality waveforms are desirable, ‘perfect’ 
waveform capture is not required.  This could reduce time and cost per patient and widen the 
opportunities for use of this technology in stratifying the risk of vascular disease.   
 
Limitations of Analysis 
There may have been other causes for a reduction in waveform quality that we did not 
assess, for example radial artery calcification and brachial atherosclerosis.  The former has 
been studied in dialysis patients, where femoral calcification was not shown to affect radial-
derived augmentation pressures.186, 187  For the latter, we found no association between QI 
and peripheral vascular disease or previous CVD and brachial atherosclerosis is known to 
correlate highly with disease elsewhere.188  As echocardiography was not available in all 
participants and performed on average some months before PWA assessment, our findings of 
QI correlations with echo parameters require further confirmation.  Left-ventricular function 
was principally assessed immediately following PWA using contrast ventriculography during 
cardiac catheterisation.  Utilising only echo-derived ejection fraction made no difference to 
the conclusion that quality was not dependent on LV function.  Finally the assessment of 
aortic pressures used fluid-filled manometers which are known to be less sensitive than high-
fidelity micro-manometers.  However the purpose of this analysis was not to validate derived 
pressures (as has already been demonstrated previously) but determine the modifying effects 
of waveform quality.   
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[5.4]  Summary 
Pulse wave analysis is a promising tool for establishing cardiovascular risk beyond 
conventional risk markers.  This study establishes, for the first time, that capturing radial 
waveforms is easy to learn and that quality is not related to age, gender or left-ventricular 
function.  In addition, there is no apparent difference between high or moderate quality 
waveforms and their association with the presence of CAD.  PWA-derived systolic pressure 
was similar to that obtained by invasive measurement and substantially closer to true aortic 
pressure than conventional evaluation at the brachial artery.  These findings suggest that 
PWA can successfully be used in patients with major co-morbidities and that reduction in 
waveform quality in the clinical setting will not affect predictive capacity.  More widespread 
application of PWA is now warranted.  
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Chapter 6. Alternative Risk Markers 
 
 The ARM-CAD study also investigated the use of heart rate variability and, in the 
latter stages of the study, pulse wave velocity as additional non-invasive methods for 
assessing the risk of angiographic coronary disease.  Previous literature has shown that HRV 
can successfully identify those at risk of death from CAD and differentiate patients who will 
face a complicated course post-infarction.189-193  Reduced HRV is a better predictor than 
ventricular function of arrhythmic complications, death after MI and death due to progressive 
heart failure.194-196  Low variability is also a predictor for all-cause mortality in those free of 
apparent CAD as well as in congestive heart failure.195, 197, 198  Further, HRV adds to 
prognostic information gained by clinical examination and assessment of myocardial 
function.189  Pulse wave velocity has now entered into clinical guidelines following a number 
of robust observations linking increased aortic wave velocity to the risk of CVD, 
independently of baseline risk factors.137  Increased PWV is now recognised as one of a 
number of factors influencing prognosis as an early index of large artery stiffening199, 200 
although with the caveat that it has a limited availability in clinical practice. 
This chapter will briefly assess the literature for HRV and PWV and assess their 
ability to successfully identify patients with angiographic CAD.  Data from 12-lead resting 
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ECGs will also be evaluated and compared with the 5-minute HRV recording.  Further, the 
hypothesis that PWA is a superior predictor of CAD will be discussed as well as the 
correlations between these alternative risk markers of vascular disease. 
 
[6.1]  Heart Rate Variability 
Data on HRV has been widely published since evidence in the 1980’s that reduced 
variability was an independent predictor of mortality post-MI.  This includes a variety of 
patient-groups, including healthy individuals and those with documented CVD and for 
outcomes such as total mortality, coronary events and incident congestive heart failure.  
Combining participants from the original and offspring Framingham cohorts, Tsuji et al 
recorded an average of 94 minutes of HRV in 2501 subjects free of apparent coronary disease 
at baseline.198    Over a mean follow-up of 3.5 years, 58 cardiac events were documented and 
the adjusted hazard ratio for a standard deviation decrement in log low frequency (LF) HRV 
power was 1.38 (95% CI 1.02-1.85; p=0.034).  Similar hazard ratios were noted for the other 
HRV parameters of total and high frequency (HF) power.  Removing ‘soft’ cardiac events 
(angina and unrecognised myocardial infarcts) increased all hazard ratios and two-thirds of 
events occurred in those with the least variability.  Participants in the lowest tertile of total 
power had an event rate of 13.39 per 1000 person-years of follow-up, compared to 4.08 in the 
middle tertile and 2.08 in the highest.198  
Similar results are noted in patients with prior-MI, where a random 5-minute HRV 
sample in 715 participants of the Multicentre Post-Infarction Program was an excellent 
determinant of all-cause mortality.201  In 226 patients treated with thrombolysis post-infarct 
with an uncomplicated clinical course, non-survivors had significantly lower LF and HF 
power.202  
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Prediction of heart failure and related mortality using HRV has received considerable 
attention due to the importance of autonomic tone in the patho-physiology of heart failure.  
Many studies have confirmed that there is a uniform dampening of all frequencies203, 204, 
although less so in the very-low frequency range due to hypoxia-related chemoreceptor firing 
and changes in the renin-angiotensin system or breathing patterns.205  As the heart fails, a 
reduced response to adrenergic stimulation occurs, secondary to beta-receptor down-
regulation, uncoupling of receptor-G protein complexes and reduced activity of adenyl 
cyclase.206, 207  These effects help to protect against the excessive sympathetic stimulation 
occurring in chronic heart failure as a consequence of central impairment in autonomic 
regulation.  Additionally in animal models, stretch of the sino-atrial node directly reduces 
variance in heart rate.208  Strong correlations have been noted between HRV and ejection 
fraction, particularly in those with ischaemia-related heart failure.209, 210  It is not surprising 
therefore that reduced HRV is one of the best predictors of death due to progressive heart 
failure.195 
Despite these robust observations, we have yet to see HRV enter mainstream use in 
the workup of cardiac patients.  The reasons for this discrepancy are multiple.  Firstly HRV 
has traditional been evaluated through 24-hour Holter recordings, with all the inherent 
problems that accompany it, such as movement artefacts, changes relating to the circadian 
rhythm and technical expertise in translating the results.  Second is the relative lack of 
consistency in the published studies.  Although a joint European/American task-force report 
was published in 1996211, there are still widely different methodologies and types of analysis 
making direct comparison of studies difficult.  Although unable to assess very low frequency 
oscillations, 5-minute HRV has distinct practical advantages to 24-hour evaluation.  
Correlation between them is high during both day and night, with equivalent association to 
mortality post-MI.189   
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Physiology of Heart Rate Variability 
The fundamental concept of HRV is that it reflects changes in the autonomic nervous 
system which can be characterised in different pathological conditions.  The autonomic 
nervous system controls cardiac function via efferent fibres to the vasculature, sino-atrial 
node and myocardium.  Afferent fibres form feedback systems such as the baroreceptor reflex 
(stretch-sensitive mechanoreceptors in the carotid sinus and aortic arch), the direct stretch 
reflex (sensitive to increased atrial volume) and the Bainbridge reflex (responding to higher 
central venous pressure).212  Heart rate itself is determined by the intrinsic firing properties of 
sino-atrial node pacemaker cells, defined by their automaticity.  The autonomic nervous 
system modulates heart rate by the action of sympathetic and parasympathetic fibres on these 
cells, as seen in Figure 6.1.   
Variability in heart rate can be analysed in two ways.  Time domain analysis is a 
statistical evaluation of the interval between successive sinus beats over time.  Power spectral 
density analysis deconstructs HRV into its component frequencies, graphing variance 
(power) as a function of frequency.  HF power (0.15-0.4 Hz) is mediated solely by the 
parasympathetic system213-215, primarily attributable to respiration.203, 216  The physiological 
correlate of LF power (0.04-0.15 Hz) is more contentious and is likely mediated by both 
branches of the autonomic nervous system.214  Sympathetic predominance can cause a 
reduction in low and high frequency HRV as well as total power (i.e. reduced total variance 
in heart rate).211, 217  Figure 6.2 demonstrates the effect of severe CAD on time and frequency 
domains of HRV.   
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Figure 6.1:  Autonomic Nervous System Modulation of Sino-Atrial Node Cells 
 
 
 Release of beta agonists (β) and subsequent binding at B1-adrenoreceptors (β1AR) causes Gs-protein 
stimulation of adenyl cyclise (AC).  The increase in cyclic AMP activates protein kinases  (e.g. PKA) 
resulting in an influx of sodium (Na+), potassium (K+) and calcium (Ca2+) through ‘funny’ channels (f), 
rectifier potassium channels (k) and calcium channels/exchangers (Ca).  The more positive membrane 
potential leads to an increase in spontaneous depolarisation and higher heart rate as demonstrated by the 
sharper incline in Phase 4 of the membrane potential (bottom graph, dark grey).218, 219   
In contrast, binding of vagally-mediated acetylcholine (ACh) to muscarinic receptors (m) causes Gi-protein 
inhibition of adenyl cyclase and an efflux of potassium.  This is amplified by ligand-gated ACh-sensitive 
potassium channels (KAch).  The net effect is relative hyperpolarisation (bottom graph, light grey) and a 
lower heart rate. 
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Figure 6.2:  Time and Frequency Domain Analysis of Heart Rate Variability 
 
 
 Comparative examples of HRV in two 60 year-old male participants, one with angiographically-
smooth coronary arteries (grey) and the other with triple-vessel CAD (black).   
Time domain analysis is displayed in the top panel, graphing R-R intervals between successive pulses 
over time.  A substantial blunting of variability is noted in the patient with CAD (standard deviation 
of R-R intervals=11.4ms and proportion of intervals >50ms=0.9% versus 44.7ms and 4.9% in the 
patient with a normal angiogram).   
Power spectral analysis is displayed in the bottom panel according to HRV frequency.  Substantial 
reduction in power noted at all frequencies in the subject with severe CAD; total power 84ms2 versus 
954ms2, low frequency power (0.04-0.15 Hz) 12ms2 versus 295ms2 and high frequency power (0.15-
0.40 Hz) 17ms2 versus 248ms2. 
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Reproducibility of HRV is generally good220, both for healthy populations221 and 
patients with CAD194, although a variation of up to 12% can be expected222 which in some 
subjects can result in large day-to-day variation.223  More concerning are the complex 
confounding issues relating to both environmental and patient factors.  These include 
respiration, posture and time of HRV recording as well as the impact of coffee and alcohol.  
The most important of these is respiratory frequency; respiratory sinus arrhythmia occurs 
within the HF band and hence HF frequency varies with respiratory rate in situations of 
normal breathing.222  HF power increases as tidal volume increases and conversely increases 
with a slower breathing rate.215, 216  Tilt and standing cause a shift to lower frequencies due to 
increased sympathetic and/or reduced vagal tone214, 216, although this response is blunted in 
patients with CAD.224, 225  Similarly the usual circadian rhythm of autonomic tone is 
diminished in patients with hypertension and CAD.224, 226   
 
Heart Rate Variability in the ARM-CAD Study 
HRV measurement was attempted in all ARM-CAD participants but was 
unsuccessfully captured in 59 participants (11%).  The latter had a higher percentage of LV 
impairment, ischaemic features on ECG and abnormal heart rhythms compared to those 
where HRV was successfully obtained (see Table 6.1).  Only rhythm abnormalities were 
independently associated with the absence of HRV measurement in multivariate analysis 
(odds ratio 2.62, 95% CI 1.44-4.74; p=0.002).  The most important factor limiting the 
acquisition of HRV was atrial fibrillation and/or flutter, which occurred in 2.3% compared 
with 17.5% of participants with and without HRV respectively (p<0.0001).  R-R interval 
capture is unreliable in rapid cardiac rhythms or those without p-waves preceding each QRS 
complex on the electrocardiogram.    
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Table 6.1:  Characteristics of Subjects without HRV Measurement 
Characteristic HRV available HRV not available p-value 
Number 480 59 
 Age (years ± SD) 64.4 ± 11.0 67.0 ± 9.3 0.084 
Male gender 66.8% 71.2% 0.505 
Prior MI 21.7% 25.4% 0.511 
Diabetes 20.8% 30.5% 0.090 
Systolic BP (mmHg ± SD) 143.8 ± 20.9 144.8 ± 20.1 0.750 
Heart rate (beats/min ± SD) 65.7 ± 11.9 68.4 ± 14.1 0.115 
Body mass index (kg/m2 ± SD) 28.7 ± 5.2 28.8 ± 4.7 0.921 
Impaired LV function  16.7% 32.8% * 0.003 
Significant valve disease  10.2% 13.6% 0.430 
Ischaemic ECG † 35.7% 54.4% * 0.006 
Abnormal ECG rhythm ‡ 23.6% 50.9% <0.0001 
Obstructive CAD on angiogram 60.6% 62.7% 0.757 
Number of diseased vessels (mean ± SD) 1.21 ± 1.17 1.29 ± 1.16 0.647 
Comparison of baseline and outcome variables according to availability of adequate HRV measurement.  
No differences in medication usage were noted.  Asterisk (*) indicates that parameter was not independently 
significant in multivariable analysis.  † Pathological Q-waves, ST or T-wave changes on ECG.  ‡ Heart 
block, atrial fibrillation, atrial flutter or frequent ectopics on ECG. 
 
 
In the remaining 480 participants, HRV was analysed in time and frequency domains 
as previously described.  Table 6.2 demonstrates that the majority of ECG and HRV 
parameters were significantly associated with the extent of angiographic CAD (unadjusted 
for baseline risk factors).  Notable exceptions were abnormal ECG rhythms, total HRV power 
and variability in the high frequency (vagal) component.  Figure 6.3 displays the distribution 
of risk factors in participants evaluated with HRV, visually confirming that ECG 
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abnormalities were typically associated with any degree of CAD, whereas reduced low 
frequency HRV power identified those with obstructive disease. 
 
 
Table 6.2:  Electrocardiograms, Heart Rate Variability & Coronary Artery Disease 
Parameter 
Normal 
Coronary 
Arteries 
Minor 
Coronary 
Irregularities 
Obstructive 
CAD                   
(≥ 50% stenosis) 
Trend    
p-value 
Abnormal ECG * 24.5% 42.2% 41.8% 0.006 
Ischaemic ECG † 23.5% 40.0% 38.7% 0.016 
Abnormal ECG rhythm ‡ 20.4% 25.6% 24.1% 0.201 
5-minute heart rate (beats/min ± SD) § 65.2 ± 12.2 63.3 ± 11.5 60.6 ± 10.5 <0.001 
pNN50 (mean % ± SD) # 15.3 ± 21.6 16.6 ± 22.9 11.4 ± 18.4 0.029 
HRV index (log ± SD) 2.04 ± 0.47 1.92 ± 0.55 1.88 ± 0.43 0.003 
Total HRV power (log ms2 ± SD) 6.95 ± 1.39 6.98 ± 1.58 6.75 ± 1.43 0.074 
High Frequency power (log ms2 ± SD) 5.39 ± 1.69 5.56 ± 1.89 5.24 ± 1.78 0.249 
Low Frequency power (log ms2 ± SD) 5.62 ± 1.55 5.47 ± 1.64 5.22 ± 1.58 0.006 
Low Frequency power <250 ms2 ¶ 45.9% 47.8% 63.5% 0.001 
* Any abnormality on 12-lead electrocardiogram.  † Pathological Q-waves, ST or T-wave changes on ECG.            
‡ Heart block, atrial fibrillation, atrial flutter or frequent ectopics on ECG.  § Does not account for use of beta-
blockers.  # Proportion of adjacent sinus R to R intervals differing by more than 50ms.  ¶ Equates to natural log 
value of 5.52. 
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Figure 6.3:  Distribution of Risk Factors, ECG abnormalities and LF Power 
 
 
 
HRV frequency domain parameters did not independently differentiate patients with 
angiographically-normal coronary arteries.  Crude odds ratio for NCA comparing LF 
power≥250ms2 with LF<250ms2 was significant at 1.77 (95% CI 1.13-2.76; p=0.012) but not 
after adjustment for other baseline risk factors (OR 1.65, 0.90-3.04; p=0.106).  Similarly the 
absence of ischaemic features on the 12-lead ECG was associated with NCA in univariate but 
not multivariate analysis.  In contrast, HRV was a strong and independent predictor of the 
presence of obstructive CAD.  Stepwise multivariate analysis and fixed variable regression 
identified a significant association between reduced LF power and obstructive angiographic 
coronary disease (see Table 6.3).  This was not the case for ECG variables.  Adjusted odds 
ratio for LF power<250ms2 was 2.42, 95% CI 1.33-4.38 (p=0.004) in the fixed regression 
model. 
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Table 6.3:  HRV and ECG Variables as Predictors of Obstructive CAD 
 Stepwise multivariate regression 
 
Fixed multivariate regression 
Variable Odds Ratio & 95% CI p-value 
 
Variable Odds Ratio & 95% CI p-value  
Prior MI 6.40 3.08 - 13.3 <0.001 
 
Prior MI 5.67 2.62 - 12.25 <0.001  
Male gender 3.39 2.07 - 5.55 <0.001 
 
Male gender 3.18 1.81 - 5.58 <0.001  
Nitrate 2.99 1.41 - 6.35 0.004 
 
Nitrate 3.03 1.37 - 6.71 0.006  
Clopidogrel 2.19 1.06 - 4.55 0.035 
 
LF power <250 ms2 2.42 1.33 - 4.38 0.004  
LF power <250 ms2 2.15 1.33 - 3.46 0.002 
 
Diabetes 2.11 1.11 - 4.01 0.023  
Diabetes 2.02 1.12 - 3.63 0.019 
 
Age (per 10 years) 1.90 1.45 - 2.50 <0.001  
Chest pain 1.80 1.03 - 3.13 0.038 
 
Heart rate 0.97 0.95 - 1.00 0.026  
Age (per 10 years) 1.72 1.37 - 2.15 <0.001 
 
Abnormal ECG 1.46 0.23 - 9.12 0.686  
Heart rate 0.98 0.95 - 1.00 0.020 
 
Ischaemic ECG  0.96 0.15 - 6.14 0.965  
Table presents adjusted odds ratios for obstructive CAD (≥50% stenosis) in participants with HRV measurement.  Stepwise model determined using a threshold of 
p<0.1.  Fixed model includes age, gender, chest pain, prior MI, prior PCI, diabetes, brachial pulse pressure, BMI, total and HDL cholesterol, GFR, LV impairment, 
moderate/severe aortic valve disease and medications plus ECG and HRV variables.  All significant odds ratio are displayed plus ECG variables for comparison.  
Interactions were noted between gender/chest pain and gender/heart rate although inclusion of interaction terms had no impact on odds ratios for other variables.  
Hosmer-Lemeshow χ2 = 12.05 (p=0.149) for stepwise model and 4.51 (p=0.809) for fixed; non-significance implies adequate model fit. 
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Low Frequency HRV Power and Cardiac Risk Factors 
There were no major interactions of 5-minute LF power with conventional risk factors 
and only a weak correlation with heart rate (see Figure 6.4).  HRV was reduced in diabetics 
compared to non-diabetics (mean log of LF power 5.12 versus 5.42ms2; p=0.033) but not 
affected by gender, smoking or time of assessment.  With regards to the latter, 159 
participants (29.5%) were assessed in the afternoon, but no effect was noted on any HRV 
parameter.   
 
Figure 6.4:  Low Frequency HRV Power & Risk Factor Correlates 
 
 
 Panel A depicts scatter plots of low frequency (LF) power against age, heart rate, pulse 
pressure and body mass index.  Corresponding correlation values are -0.07 (p=0.116), -
0.16 (p=0.001), -0.01 (p=0.858) and -0.06 (p=0.224).  Panel B depicts box and whisker 
plots for LF power according to gender and presence of diabetes. 
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[6.2]  Pulse Wave Velocity 
PWV is a well-studied marker of arterial stiffness and can be rapidly obtained using 
commercial devices (either electrocardiographically-gated or simultaneous oscillometric 
methods).  PWV is determined by measuring the distance between two arterial sites divided 
by the delay in arrival of the pulse waveform (refer to Figure 2.2, page 52).  There is good 
evidence for its use in predicting CAD and cardiovascular mortality131, 200, 227-229, although 
concerns remain in estimating artery length by measuring skin-surface distances.135  
Furthermore, the relationship between age and pulse wave velocity is not linear113 and there 
are also multiple methods available for determining the foot of the pulse waveform.  These all 
have implications when attempting individual risk prediction.  There is mounting evidence 
that pulse wave analysis and velocity are not interchangeable and may represent endothelial 
dysfunction in different ways.230-232  Guidelines have now incorporated the use of aortic PWV 
for assessing the risk of vascular disease with a threshold of 12m/s suggested as an indicator 
of central artery dysfunction in middle-aged hypertensives.137 
 
Pulse Wave Velocity in the ARM-CAD Study 
Pulse wave velocities from the carotid-radial (CRPWV) and carotid-femoral (CFPWV) 
arterial sites were measured in a subset of the ARM-CAD study population during the latter 
part of recruitment.  These give estimates of brachial and aortic PWV respectively.  Mean 
CRPWV was 7.35 ± 1.34m/s (n=202) and mean CFPWV 10.2 ± 2.89m/s (n=163).  Both were 
assessed sequentially in 112 participants.  As noted in Figure 6.5, correlation between them 
was significant but less substantial than expected (Spearman-rho=0.260, p=0.006).   
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Figure 6.5:  Brachial-Aortic Pulse Wave Velocity Correlation 
 
 
 Scatter plot and linear regression line for correlation between aortic (carotid-femoral) and 
brachial (carotid-radial) pulse wave velocity. 
 
 
Reduced aortic (but not brachial) PWV was associated with the absence of CAD on 
angiography in univariate analysis.  Crude odds ratio for normal coronary angiography per 
1m/s reduction in velocity was 1.13 for CRPWV (95% CI 0.87-1.47; p=0.373) and 1.31 for 
CFPWV (1.10-1.57; p=0.003).  However CFPWV was not independent of other baseline risk 
factors; adjusted OR for NCA was 1.39 (0.95-2.03; p=0.093).  Similarly the dichotomous 
variable CFPWV>12m/s was significant in univariate but not multivariate analysis.  
Neither aortic nor brachial PWV were associated with the presence of obstructive CAD, as is 
evident from Table 6.4 which displays summary statistics according to the extent of 
angiographic disease. 
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Table 6.4:  Pulse Wave Velocity & Extent of Angiographic CAD 
 
Carotid-Radial PWV  Carotid-Femoral PWV 
N Mean ± SD  N Mean ± SD  >12m/s 
Normal Coronary Arteries 42 7.19 ± 1.11  33 8.81 ± 1.85 6.1% 
Minor Coronary Irregularities 35 7.59 ± 1.45  27 10.65 ± 3.95 22.2% 
Single-vessel disease 39 7.39 ± 1.21  35 10.16 ± 2.89 25.7% 
Two-vessel disease 43 7.55 ± 1.49  40 11.03 ± 2.76 32.5% 
Three-vessel disease 43 7.10 ± 1.42  28 10.11 ± 2.43 17.9% 
 
Correlation & Reproducibility Estimates for Pulse Wave Velocity 
Both aortic and brachial PWV significantly increased as systolic BP increased, 
although their correlation with other baseline risk factors was noticeably discordant (Table 
6.5).  Aortic PWV was highly correlated with age and moderately correlated with ventricular 
dysfunction whereas brachial PWV was statistically associated with heart rate and BMI.  On 
average, carotid-femoral velocity was 1.0m/s greater in men than women (95% confidence 
interval for difference 0.05-1.93; p=0.004) but CRPWV was similar (mean difference 0.1m/s; 
p=0.607).   
Two sequential estimates of PWV were obtained in the majority of participants for 
both brachial and aortic PWV.  Comparison of results identified good intra-observer 
reproducibility; for CRPWV average difference (± SD) between measurements was 0.01 ± 
0.95m/s and for CFPWV 0.12 ± 1.44m/s.  There was no evidence of discordance for either 
variable (Bradley-Blackwood F-test=0.023, p=0.977 and 0.892, p=0.412 respectively). 
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Table 6.5:  Pulse Wave Velocity & Correlation with Baseline Risk Factors 
PWV type 
Spearman Correlation Coefficient (p-value) 
Age Systolic BP Heart rate BMI Log of BNP 
Carotid-Radial 
(Brachial PWV) 
0.05 (p=0.519) 0.24 (p=0.001) 0.29 (p<0.001) 0.19 (p=0.008) -0.07 (p=0.353) 
Carotid-Femoral 
(Aortic PWV) 0.55 (p<0.001) 0.34 (p<0.001) 0.10 (p=0.201) -0.03 (p=0.677) 0.23 (p=0.004) 
 
 
[6.3]  Discussion 
This chapter has illustrated the major clinical issues associated with 5-minute analysis 
of heart rate variability and electrocardiographically-gated pulse wave velocity measurement.  
Although neither test was able to differentiate the absence of CAD on angiography, LF power 
of HRV was a strong and independent predictor of obstructive CAD.  Unlike PWV, HRV did 
not exhibit correlation with conventional risk factors and was superior to standard 12-lead 
electrocardiograms.  
 
Heart Rate Variability 
These analyses are concordant with published literature that suggests symptomatic 
patients with evidence of ischaemia have substantially reduced HRV.  Compared with 
healthy age-matched controls, 24-hour time and frequency variables were significantly lower 
in 65 patients being evaluated for suspected CAD.233  All participants had a positive exercise 
stress test or known CAD, with no prior history of MI and normal ventricular function.  
Hayano et al have published two studies correlating HRV with angiographic severity.  Both 
studies recruited elective angiography patients without a history of acute infarction, heart 
failure, valve disease, arrhythmias, diabetes or renal failure and all medications were stopped.  
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In the first study, 5-minute HRV was recorded in 56 participants with controlled breathing at 
15 breaths per minute.234  Power in low and high frequencies was progressively lower as the 
severity of coronary disease worsened.  In their second study, the author’s classified 
angiograms with a coronary atheroma score (multiplying extent of atheroma with mean 
plaque size) and a severity score evaluating the proportional reduction in luminal diameter.  
In 80 patients, 10-minute age and sex-adjusted HF power was significantly correlated with 
both the extent of CAD (r= -0.43; p<0.0001) and severity of coronary disease (r= -0.30; 
p=0.007).235  There was no relation to the presence or site of previous infarcts, LV ejection 
fraction or end-diastolic pressure.  Lower HRV frequencies were not associated with CAD, 
although similar to their first study, these patients were asked to breathe in time to a 
metronome.  As discussed this amplifies the response in higher frequency variability. 
Smaller experimental studies have added key data on the mechanisms of HRV 
reduction.  Recording 5-minute HRV in 31 patients with chest pain and a positive angiogram 
(≥70% stenosis of at least one artery), Petretta et al found no difference between single, 
double and three-vessel disease.236  However patients with severe CAD had a substantially 
greater increase in LF and the ratio of LF to HF at the peak effects of dipyridamole on stress-
testing.  After dipyridamole there was a direct correlation between LF power and the wall 
motion score index, suggesting this marker of sympathetic activation corresponds to active 
ischaemia. 
Heart rate itself is a well documented marker of mortality.237, 238  A higher heart rate 
decreases the duration of diastole, diminishing left-ventricular filling and coronary artery 
perfusion.  It also causes disruption of atherosclerotic plaques, promoting thrombus formation 
and myocardial infarction.239, 240  Despite a progressive increase in overall mortality with 
heart rate in the Framingham cohort, the proportion of deaths specifically due to 
cardiovascular disease was not different at any given heart rate.241  An excess of non-
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cardiovascular deaths at higher heart rates illustrates the poor specificity of heart rate as a 
marker of coronary disease.   
 
Measuring HRV was simple, non-invasive and unobtrusive, even in the setting of the 
catheter laboratory.  Unlike previous studies, no prior restrictions were placed on participants 
(such as a prolonged resting period) and no attempt was made to control breathing.  Our 
results highlight that HRV is a potential tool for clinical use and not solely for research 
studies.  Further, the short duration of measurement has specific advantages in addition to 
practical considerations, including the assessment of HRV following changes in management 
and drug therapies.  HRV is a sensitive marker of modulation in the autonomic nervous 
system, as demonstrated in the experiment depicted in Figure 6.6 which simulated 
sympathetic stimulation in a healthy participant during the ARM-CAD pilot study.  Even a 
relatively minor sympathetic stress (in this case subtraction whilst standing) can be identified 
using these techniques.  However not all patients are suitable as evidenced by the inability to 
capture HRV in 11% of study participants.  The primary cause was rhythm abnormalities, 
including not only atrial arrhythmias but also frequent ectopic beats.  In contrast only 8 
patients (1.5%) were unable to be assessed using radial PWA. 
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518 ms2
70 ms2
491 ms2
402 ms2
Low Frequency HRV Power (0.04-0.15 Hz)
High Frequency HRV Power (0.15-0.4 Hz)
Figure 6.6:  Effect of Sympathetic Stress on Heart Rate Variability 
 Resting; Supine      Mental arithmetic test; Standing 
 
            
 
 
 
 
 
 Sequential 5-minute HRV measurements in a healthy male aged 28 (ARM-CAD pilot study).  
On the left the subject is resting in a supine position whilst on the right the subject is standing 
whilst performing a mental arithmetic task.  The latter stimulates sympathetic outflow and 
results in a reduction in overall HRV as well as a diminution in high frequencies (lower vagal 
tone).   
 
 
Pulse Wave Velocity 
The sub-study data on PWV has confirmed the benefit of aortic (carotid-femoral) over 
brachial (carotid-radial) PWV in a clinical cohort of patients.  Brachial velocity was unrelated 
to coronary atherosclerosis, compatible with data in autopsy cases where brachial 
atherosclerosis did not correlate with disease in the left anterior descending artery in subjects 
over the age of 50.188  Similarly, brachial-ankle PWV had a relatively weak correlation with 
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the severity of CAD in 205 patients scheduled for coronary angiography (r=0.20; p=0.004).242  
CRPWV is known to linearly increase with age in healthy normotensives but to a much lesser 
degree than aortic PWV, presumably due to the muscular nature of the brachial artery.113  In 
contrast, the ARM-CAD study examined a co-morbid patient group (predominantly with 
hypertension) and found no association of age to brachial PWV and a strengthened 
correlation with aortic PWV. 
 Despite being a predictor of CAD in univariate analysis, CFPWV was not independent 
of other baseline risk factors.  This is contrary to published data suggesting that aortic PWV 
is independent of factors such as age, BP and diabetes, although the majority of studies have 
examined either healthy individuals or populations with low rates of risk factor prevalence.  
In a Danish population sample of 1678 subjects (excluding those with prior MI or stroke), a 
standard deviation increase in CFPWV had a hazard ratio of 1.17 (95% CI 1.04-1.32; p<0.05) 
for the composite cardiovascular end point.  This analysis was adjusted for sex, age, BMI, 
mean arterial pressure, current smoking and alcohol intake.  However the standard deviation 
increase was relatively large (3.4m/s), 18% greater than the ARM-CAD study despite 
examining a less heterogeneous group.  Laurent et al studied a cohort of 1980 hypertensive 
patients and identified a hazard ratio of 2.35 for cardiovascular mortality (95% CI 1.76-3.14; 
p<0.001) for each 5m/s increase in CFPWV.199  The population included participants with 
cardiovascular risk factors but only 9% had a history of previous CVD.  Diabetes was present 
in 6% of their population and mean age was 50.  As evidenced by the results presented in this 
thesis, extrapolation of data to higher-risk populations is not warranted.  Indeed, our results 
are consistent with post-mortem studies of the presence and distribution of atherosclerosis.  In 
304 deceased elderly subjects, aortic PWV (a median of 3.5 years prior to death) was only 
weakly correlated with an index of total atherosclerosis (r=0.32; p<0.001).  Correlation was 
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even less substantial if coronary stenoses alone were considered (r=0.19; p<0.005), a value 
very similar to that obtained in the ARM-CAD study (r=0.20; p=0.009). 
 Intra-observer reproducibility for PWV was good and similar to other published 
data243, which also identifies low inter-observer differences.109  However the procedure for 
obtaining waveforms at the carotid and femoral arteries was technically difficult and 
occasionally uncomfortable for participants.  Although no adverse events were reported in the 
ARM-CAD study, the potential exists for vagally-mediated hypotension and disruption of 
carotid artery plaques.  Finally the disadvantages of this particular PWV method should be 
considered, in particular the potential for measurement error.  Calibration of the waveform 
requires brachial BP evaluation and skin-surface measurement is used to calculate the 
distance between arterial sites.  Imprecision in either of these measurements could introduce 
substantial error.  Newer techniques involving simultaneous oscillometric evaluation in all 
four limbs are now available244, although these provide estimates of total body PWV rather 
than aortic velocity.245 
 
Limitations of Analysis 
To simulate clinical application of HRV, no attempt was made to control 
environmental factors prior to recording.  In ideal conditions, we would therefore expect the 
relationship between HRV and coronary disease to be even stronger.  Correct capture of sinus 
R-R intervals is dependent on automatic algorithms in the SphygmoCor software.  Patients 
with irregular cardiac rhythms and broad bundle branch blocks often fail to capture sufficient 
R-R intervals for estimation of HRV.  However this situation is certainly preferable to 
existing manual methods of assessing acceptable sections of 24-hour ECG recordings. 
Sample size for PWV was considerably smaller than for PWA or HRV as these 
measurements were additions to the protocol in the latter stages of the study.  Nevertheless, 
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the number of observations is large in comparison to other published studies in this 
population.  As noted above, potential sources of error include blood pressure calibration of 
the pressure waveform and the distance measured between the arterial sites.  To reduce the 
former, three measurements of BP were taken (preferably on the right arm whilst sitting) and 
the average of the second and third used for waveform calibration.  For measurement of 
distance, operators were trained to measure from a fixed point (the sternal notch) and re-
measure if the arterial site changed or became uncomfortable for the patient.  
 
 
[6.4]  Comparison of Risk Markers 
The ARM-CAD study included detailed measurements of pulse wave analysis, heart 
rate variability and pulse wave velocity with baseline recording of conventional risk 
predictors and biomarkers.  It represents one of the largest cohorts in symptomatic patients 
and allows a unique comparison of the value of these novel markers in a clinical population.  
Table 6.6 provides a comparison for the two primary outcomes, NCA and obstructive CAD 
on angiography.  
For prediction of angiographically-normal coronaries, cAP from pulse wave analysis 
was the only novel risk marker to retain significance in multivariate analysis.  Note that 
although BNP was significantly associated with NCA, it lost significance once central 
pressures from PWA were included in the model.  Further, the odds ratio displayed for cAP 
includes adjustment for risk factors included in the Framingham and SCORE algorithms.  
Central augmentation pressure and low frequency HRV power were independently associated 
with obstructive CAD.  At the cut-points specified, the latter was statistically a better 
predictor and both were superior as compared to ECG variables, PWV, high-sensitivity CRP 
and BNP.  
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An additional method to assess and compare these risk markers is their inter-
relationship and independence from each other.  As depicted in Figure 6.6, correlations 
between the main variables examined in this thesis are generally weak.  The exception was 
PWV, which showed significant and moderate correlation with all markers apart from HRV.  
This supports the finding that PWV was not independently associated with CAD and hence 
cannot be recommended for risk stratification in symptomatic patients at high baseline risk of 
vascular disease.  PWA and HRV variables were entirely independent from each other, 
strengthening the potential for combined use as physiologically-distinct predictors of 
coronary disease.   
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Table 6.6:  Comparison of Odds Ratios for Primary Angiographic Outcomes 
Risk variable 
Normal Coronary Angiogram 
 
Obstructive CAD Independent 
of PWA Unit OR 95% CI z-score p-value   Unit OR 95% CI z-score p-value 
Framingham 10-year  
  risk of CAD 
10% decrease 2.36 1.60 - 3.48 4.36 <0.001 
 
10% increase 1.74 1.34 - 2.26 4.19 <0.001  
SCORE 10-year risk  
  of fatal CVD 
10% decrease 2.36 1.61 - 3.47 4.37 <0.001 
 
10% increase 1.64 1.33 - 2.01 4.66 <0.001  
PWA central augmentation 
  pressure (cAP) 
<24mmHg 3.37 1.20 - 9.49 2.30 0.021 
 
≥24mmHg 2.28 1.01 - 5.12 1.99 0.047 n/a 
HRV low frequency  
  spectral power (LF) 
≥250ms2 1.67 0.92 - 3.02 1.69 0.091 
 
<250ms2 2.33 1.43 - 3.80 3.39 0.001  
Carotid-femoral pulse  
  wave velocity (CFPWV) 
1m/s decrease 1.39 0.95 - 2.03 1.68 0.093 
 
1m/s increase 0.95 0.76 - 1.19 -0.43 0.670  
Ischaemic features  
  on resting ECG 
Absent 1.83 1.00 - 3.37 1.95 0.051 
 
Present 1.17 0.73 - 1.85 0.65 0.515  
High-sensitivity C-reactive  
  protein (CRP) 
<2mg/L 1.12 0.63 - 2.00 0.38 0.704 
 
≥2mg/L 1.25 0.78 - 2.00 0.94 0.345  
B-type natriuretic  
  peptide (BNP) 
log unit decrease 1.32 1.02 - 1.71 2.13 0.033 
 
log unit increase 1.23 1.00 - 1.50 1.99 0.046  
Table presents multivariate odds ratios, adjusted for relevant baseline risk factors.   
Last column denotes if variable remained significant after cAP and cPP from PWA were included in the multivariate model. 
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Figure 6.7:  Scatter Plot Matrix of Risk Markers 
 
 
 Cross-correlation scatter plots for major risk markers in the ARM-CAD Study.  Note that plots 
exclude patients with BNP<10pg/mL (lower limit of detection) and those with SCORE risk above 
50%.  Pearson correlation coefficient depicted only where correlation was statistically significant. 
 
In terms of practical application, the technique to acquire radial pulse waveforms was 
easy to learn, suitable for clinical use and caused no harm or inconvenience to the patient.  
The process to obtain PWA requires standard BP measurement using a brachial cuff, 
followed by a 10-second waveform capture at the radial artery using a pressure transducer 
placed on the skin surface (see Appendix C).  A number of patients commented that pictorial 
representation of BP was useful in understanding the nature of hypertension, more so than the 
(arbitrary) numbers representing systolic and diastolic BP.  PWA may therefore have a role in 
education and successful patient-centred modification of risk factors.  
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 In contrast, the concept of HRV was not well understood by participants of the ARM-
CAD study and remains a tool predominantly for medical professionals.  HRV was easily 
obtained over a 5-minute period with the patient in a supine position, but restricted to those 
where the software could identify successive sinus R-R intervals.  Pulse wave velocity was 
evaluated using a sequential dual-arterial method gated to the electrocardiogram.  Good 
quality waveforms were difficult to achieve, although reproducibility was surprisingly within 
acceptable limits.  Patients were required to sit at 45 degrees with the neck extended and to 
expose the groin area.  Obtaining accurate carotid and femoral waveforms was occasionally 
uncomfortable, particularly where a steady pressure was required to capture waveforms in 
patients with deep arteries or excess soft tissue.  Conversely waveform capture was also 
difficult in thin patients where the arterial site was mobile and not tethered to surrounding 
tissues. 
 Electrocardiograms are the most widely used diagnostic tests in cardiology and yet 
data on their performance as a screening test is inconsistent and mainly based on white 
middle-aged males.31  Availability in the clinical setting is ubiquitous and application for risk 
stratification is only limited in cases of transient abnormalities missed during ECG capture 
and incorrect lead placement.  As noted in a prospective emergency department observational 
study, variability in chest lead position can be substantial, particularly for women.246  Vertical 
and horizontal displacement of lead position has been associated with clinically-significant 
changes in ECG interpretation, even by experienced cardiologists.247  Biomarkers, such as 
BNP and high-sensitivity CRP require phlebotomy and at present need specific handling 
procedures in core laboratories, although multi-marker point-of-care tests are now beginning 
to enter clinical use.  Interpretation of results is often dependent on the population studied and 
despite numerous large studies, none have entered general clinical use for stratification of 
coronary disease apart from markers of acute infarction such as troponins. 
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Chapter 7. Conclusions 
 
 The ARM-CAD Study was designed to assess the use of novel markers of vascular 
risk in a clinical setting and establish their incremental value to conventional risk prediction.  
Five-hundred and fifty participants were evaluated in a prospective, protocol-driven 
observational study, with only prior cardiac transplantation as an exclusion criterion.  The 
absence of major criteria for recruitment provides a unique clinical perspective and allows a 
better estimate of the true applicability of these tests.  This thesis has explored the potential of 
PWA, a simple non-invasive marker of central artery stiffness, in relation to risk algorithms, 
biomarkers and other novel tools such as heart rate variability and pulse wave velocity.  
 Central pressures are implicated in the pathogenesis of CAD as well as being markers 
of disease burden.  Enhanced systolic augmentation can lead to increased afterload (with 
subsequent ventricular hypertrophy) and diminish diastolic filling of coronary arteries.  
Conversely, the same atherosclerotic processes involved in CAD can lead to vascular 
abnormalities in the large central arteries, causing increased pulse wave velocity and a greater 
magnitude of wave reflection.  Although observational studies are unable to delineate cause 
and effect, the ARM-CAD study has provided an important platform from which to study the 
effects of CAD and incident cardiovascular events on arterial pressure waves.  
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Hypothesis 1:  Prediction of the presence of CAD using conventional risk factors is 
inadequate in contemporary cardiology referrals due to patient heterogeneity and 
modification of risk factors 
 Extensive risk factor modification was noted in this patient population, consistent 
with attempts by general practitioners and patients to attenuate risk, as well as successful 
secondary prevention in those with prior CVD.  Conventional risk markers such as systolic 
BP, serum cholesterol, family history and smoking were unrelated to the presence, extent or 
severity of CAD.  Surprisingly, both Framingham and SCORE risk algorithms predicted 
angiographic coronary disease, despite derivation from cohorts free of CAD at baseline.  
However their ability to accurately classify patients was relatively poor.  10% of patients with 
a high Framingham score (>20%) had angiographically-normal coronary arteries and 
conversely 45% with a Framingham score of <10% had obstructive CAD.  These results 
highlight the poor predictive power, in this population, of the conventional risk factors 
incorporated within the risk algorithms.  A multivariate model containing additional factors 
such as BMI, chest pain and prior history of CVD was a better discriminator of disease.  Even 
with these variables, diagnostic accuracy was not substantial, supporting this hypothesis and 
suggesting the need for additional markers of atherosclerotic disease.   
 
Hypothesis 2:  High-sensitivity CRP and BNP can aid in clinical determination of the 
risk of coronary artery disease 
 Previous data on biochemical markers has identified that tests such as high-sensitivity 
CRP and BNP are independently associated with cardiovascular outcomes and CAD.  
Evidence for successful clinical application is substantially less extensive.  Rare examples 
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where biomarkers perform well in addition to conventional risk factors include trials using 
BNP as a screening tool for heart failure and the JUPITER study showing the value of high-
sensitivity CRP in patients without hyperlipidaemia.  I hypothesised that biomarkers may 
have benefit in this patient-group as a result of modification of other risk factors.  However, 
no advantage was noted in the use of biomarkers for the ARM-CAD cohort as a whole.  
Indeed for prediction of obstructive CAD the addition of high-sensitivity CRP and BNP 
reduced the calibration statistics for the multivariate model.  Consistent with the JUPITER 
data, high-sensitivity CRP did independently predict angiographic disease in patients without 
elevated LDL and no prior history of CVD.  Patients in this sub-group with a high-sensitivity 
CRP of 2mg/L or greater had a similar increase in the odds of obstructive CAD as a 15-year 
increase in age.  For all other patients (68% of the cohort), high-sensitivity CRP was not 
associated with angiographic CAD.   
In comparison, BNP was a predictor of NCA and obstructive disease despite adding 
little to the receiver operator curve.  Confirming previous studies, the association of BNP 
with angiographic disease was independent of baseline risk factors and the presence of 
known LV dysfunction.  A new finding in the ARM-CAD study was that BNP was not 
independent of PWA-derived central pressures.  In coronary artery disease, BNP is proposed 
as a surrogate marker of ventricular wall tension and neurohormonal activation secondary to 
reversible ischaemia or myocardial necrosis.58  Mechanistically, these processes are related to 
changes in central artery pressure and hence including more direct measurements (as 
provided by PWA) may have diminished their association with coronary disease.  The 
hypothesis that biomarkers can aid in clinical determination of CAD risk was therefore not 
upheld by the ARM-CAD data, particularly when novel techniques such as PWA are 
considered.    
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Hypothesis 3:  PWA is independently associated with the presence of arterial disease on 
coronary angiography  
Central augmentation pressure, in combination with standard risk factors, 
differentiated patients with angiographically-normal coronary arteries and was linearly 
associated with the extent of coronary disease.  Low cAP was a strong predictor of NCA and 
the only modifiable risk variable independent of other baseline factors and medications.  
Crude odds ratio for cAP<24mmHg (versus cAP≥24mmHg) was 2.00 (95% CI 1.12-3.54; 
p=0.018) and adjusted odds ratio was 3.37 (1.20-9.49; p=0.021).  The latter included 
adjustment for brachial and central pulse pressure, other conventional risk factors, 
inflammatory processes (using high-sensitivity CRP) and left-ventricular impairment 
(identified by left-ventriculography and BNP).  Identifying low cAP was equivalent in 
predictive power to that observed for diabetes.  It also successfully reclassified patients with 
angiographically-smooth coronary arteries that were predicted a high likelihood of significant 
CAD based on conventional scores.  cAP<24mmHg was an important determinant of NCA 
irrespective of age group, gender, cholesterol or LV function.  An interaction was only noted 
in patients with prior MI in whom, as expected, the probability of obstructive CAD was 
already around 90%. 
 
Hypothesis 4:  PWA can be used in a clinical setting despite variation in waveform 
quality due to patient co-morbidity 
 The ARM-CAD study identified that training of previously inexperienced operators 
was relatively simple and that patients were comfortable with the method of waveform 
recording.  Existing publications support good reproducibility for PWA but no data was 
previously available on waveform quality, the impact of co-morbid conditions or their effects 
 139 
on predictive capacity for CVD.  Due to the open recruitment strategy, almost a quarter of 
participants had cardiac co-morbidities that would have excluded them from assessment 
based on criteria from other studies.  In fact the majority of these exclusion criteria (such as 
heart failure and valvular disease) had little impact on waveform quality.  Moderate quality 
waveforms resulted in almost identical values of central pulse and augmentation pressure as 
high quality recordings and no impact was noted on the prediction of angiographic coronary 
disease.  The difference in measured aortic systolic pressure at the time of angiography and 
that derived from the radial artery waveform was minimal and was also unaffected by 
waveform quality.  These features suggest that PWA is suitable for application in an out-
patient setting and would make a useful addition to existing methods of clinical evaluation.  
 
Hypothesis 5:  PWA is a superior predictor of CAD as compared with heart rate 
variability, pulse wave velocity and the resting electrocardiogram 
 Heart rate variability and pulse wave velocity are two additional markers of 
cardiovascular risk that seek to define atherosclerotic disease through alternative pathological 
pathways.  Frequency analysis of HRV is analogous to assessing the balance in autonomic 
tone and is a sensitive indicator of sympathetic activity.  Measurement using an automated 
five-minute technique has simplified recording and analysis considerably, allowing HRV to 
be considered as a potential clinical tool.  In the data presented, low HRV was a strong 
predictor of obstructive CAD but did not identify NCA.  Further, 11% of the study population 
were unable to be evaluated with HRV, principally due to ectopic beats and atrial 
arrhythmias.   
In comparison, although PWV and ECG variables were significantly associated with 
CAD in univariate analysis they were not independent of other baseline risk factors.  Similar 
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to PWA, wave velocity is a marker of arterial stiffness, although arterial wave reflections and 
ventricular output are thought to predominantly account for the former.  The method for 
assessing aortic (carotid-femoral) PWV requires a technically difficult measurement at the 
carotid artery, discomfort for the patient and the potential for complications.  Resting ECGs 
are easy to obtain in the hospital environment and pain-free but require trained reviewers and 
have poor sensitivity for detecting coronary disease.   
The assessment of PWA during the ARM-CAD study has confirmed that this novel 
risk marker is promising, practical and superior to other non-invasive techniques, whilst able 
to measure physiological domains of cardiovascular risk that are not included in conventional 
risk models. 
 
Future Work 
This thesis has explored the clinical role and applicability of pulse wave analysis as a 
non-invasive marker of coronary atherosclerosis.  Three manuscripts have been submitted to 
leading journals and data has been presented at four international conferences (refer to 
Appendix D).  Future planned work includes further investigation of the ARM-CAD cohort 
as well as the testing of new hypotheses generated from this thesis.   
Phase 2 of the ARM-CAD study is currently underway, recruiting an additional 200 
participants to establish if the conclusions presented here can apply to a population at a 
different baseline risk and with respect to cardiovascular outcomes.  Additionally all ARM-
CAD participants will be followed up longitudinally to assess the relationship of PWA with 
cardiovascular mortality, hospitalisation and non-fatal events.  A number of sub-studies are 
also in progress and new proposals in discussion to extend and develop the work presented.  
These include a full evaluation of heart rate variability and the potential for combined 
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assessment with PWA.  As noted in the analyses, both were independent risk markers that 
showed no inter-correlation, assessing vascular risk using different physiological pathways.  
The generation of a risk model, integrating these two novel methods for the clinical 
assessment of symptomatic patients would be an important step forward and will require a 
validation cohort of patients referred for coronary angiography.  Other sub-studies in 
preparation include a comparative analysis of peripheral, carotid and central pressures in the 
pathogenesis of atherosclerotic disease and the effects of anxiety and depression on PWA and 
HRV (using data collected with the Hospital and Anxiety and Depression Scale, HADS). 
Mechanistically, it is important to understand the components of augmentation 
pressure and the method by which these are related to vascular compliance.  The concept of 
reservoir pressure, in effect a surrogate for total large artery compliance, may account for 
many of the changes seen in systolic pressure augmentation, returning wave magnitude and 
the generation of forward and backward waves in the arterial circulation.  A collaborative 
project is underway to measure reservoir pressure in this dataset.  This presents an exciting 
opportunity to gain new knowledge about the physiology of arterial pressure and the impact 
of heart failure, valve disease and other clinical co-morbidities.   
Finally, I plan to extend this research into new directions, including the assessment of 
patients with acute coronary syndromes to identify those at risk of post-ischaemic (and post-
revascularisation) myocardial dysfunction.  This project is in the proposal stages and would 
involve a combined observational and randomised trial design to investigate if central artery 
pressure waveforms in patients with myocardial ischaemia can identify those who might 
benefit from active intervention.  The hypothesis tested is that nebivolol, a beta-1 selective 
adrenergic blocker with unique nitric-oxide vasodilatory properties, has the potential to 
improve contractility and reduce reperfusion injury in patients with high PWA-derived 
central augmentation pressure.  
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Appendix A. ARM-CAD Study Recruitment 
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Appendix B. Variable Descriptors 
 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
D
at
ab
as
e Patient identifier  pid G, cont  
D
em
og
ra
ph
ic
s (
co
nt
) Prior cardiovascular disease  cvd G, cat 
Initials  initials A, str  Prior CVD, not incl PCI/CABG  cvdnor G, cat 
Site of assessment  site A, cat  Family history of premature CVD  fh A, cat 
Date of assessment  date A, cont  Family history of premature angina  fh_angina A, cat 
Time of assessment  time A, cont  Family history of premature MI  fh_mi A, cat 
Assessed in afternoon  pm G, cat  Family history of premature stroke  fh_stroke A, cat 
Non-invasive tests performed  scor_types G, cat  Family history of premature TIA  fh_tia A, cat 
Data/outcome merge  merge G, cat  Current smoker  smoking A, cat 
Blood test database merge  bloods_update G, cat  Regular aerobic exercise  exercise A, cat 
Operator comments  comments A, str       
CLEAR recruitment  clear A, cat  
M
ed
ic
at
io
ns
 Aspirin  aspirin A, cat 
      Clopidogrel  clopidogrel A, cat 
D
em
og
ra
ph
ic
s Date of birth  date_of_birth A, cont  Warfarin  warfarin A, cat 
Age years age10 A, cont  Beta-blockers (not 3rd generation)  beta A, cat 
Age >50  age50 G, cat  Carvedilol  carvedilol A, cat 
Age >65  age65 G, cat  All beta-blockers  all_beta A, cat 
Age grouping <60, 60-69, 70+ age_groups G, cat  ACE inhibitor/Angiotensin receptor blocker  acei A, cat 
Male gender  male A, cat  Calcium channel blocker  ccb A, cat 
Diagnosis of diabetes  dm A, cat  Diuretic  diuretic A, cat 
History of hypertension or medications  ht A, cat  Aldosterone antagonist  aldo A, cat 
Diagnosis of angina  angina A, cat  Nitrate  nitrate A, cat 
Diagnosis of myocardial infarction  mi A, cat  Nicorandil  nicorandil A, cat 
Angina or MI  cad A, cat  Digoxin  digoxin A, cat 
Prior transient ischaemic attack  tia A, cat  Amiodarone  amiodarone A, cat 
Prior stroke  stroke A, cat  Statin  statin A, cat 
Chronic heart failure  chf A, cat  Fibrate  fibrate A, cat 
Prior revascularisation  revasc A, cat  Renin-angiotensin-aldosterone system drugs  raas G, cat 
Prior percutaneous intervention  pci A, cat  Number of anti-hypertensives  antihyp G, cat 
Prior coronary artery bypass  cabg A, cat  Antiplatelet usage  antiplat G, cat 
Peripheral vascular disease  pvd A, cat       
A = assessed; G = generated; cat = categorical; cont = continuous; str = string variable 
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 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
Sy
m
pt
om
s Chest pain  cp A, cat  
H
ea
rt 
 ra
te
 
Heart rate (from BP monitor) beats/min hr A, cont 
Dyspnoea  sob A, cat  Heart rate grouping  hr_group G, cat 
Chest pain or dyspnoea  cpsob G, cat  Heart rate (from PWA) beats/min hr_pwa A, cont 
Chest pain and dyspnoea  cp_sob G, cat  5-minute heart rate (from HRV) beats/min hr_hrv A, cont 
Dizziness  diz A, cat       
Blackouts  blk A, cat  
B
lo
od
 T
es
ts Haemoglobin g/L hb A, cont 
HADS Anxiety score  hads_a A, cont  Haemoglobin g/dL hb2 G, cont 
HADS Depression score  hads_d A, cont  Hb<12 in women, <13 in men  anaemia G, cat 
Total HADS score  hads A, cont  Creatinine mmol/L creat A, cont 
Significant Anxiety/Depression  hads_sig G, cat  Creatinine micromol/L creat2 G, cont 
Somewhat or Significant Anxiety/Depression  hads_somesig G, cat  Estimated glomerular filtration rate ml/min/1.73m2 gfr G, cont 
      Stages of Kidney Disease (by eGFR)  gfr_cat G, cat 
M
ea
su
re
m
en
ts
 Height cm height A, cont  eGFR<90  lowgfr G, cat 
Weight kg weight A, cont  Total Cholesterol mmol/L chol A, cont 
Body mass index kg/m2 bmi G, cont  Total Cholesterol (US units) mg/dL chol_us G, cont 
Body mass index grouping <25, 25-30, >30 kg/m2 bmi_groups G, cat  Total Cholesterol tertiles  chol_us_tert G, cat 
Waist circumference cm waist A, cont  High-density lipoprotein cholesterol mmol/L hdl A, cont 
Hip circumference cm hip A, cont  High-density lipoprotein cholesterol (US) mg/dL hdl_us G, cont 
Waist-hip ratio  whr G, cont  Low-density lipoprotein cholesterol mmol/L ldl A, cont 
Waist-hip ratio grouping ≤0.94, 0.94-1, ≥1 whr_groups G, cat  Low-density lipoprotein cholesterol (US) mg/dL ldl_us G, cont 
      Triglycerides mmol/L tg A, cont 
B
lo
od
 P
re
ss
ur
e Brachial systolic BP mmHg p_sp A, cont  Cholesterol/HDL ratio  chol_hdl G, cont 
Brachial systolic BP quartiles  sbpq G, cat       
Brachial diastolic BP mmHg p_dp A, cont  
B
N
P B-type natriuretic peptide pg/mL bnp A, cont 
Brachial pulse pressure mmHg p_pp G, cont  BNP below detection limit <10pg/mL bnp_low A, cat 
Brachial pulse pressure >70  p_pp70 G, cat  BNP (<10 averaged at 5pg/mL)  bnp2 G, cont 
Brachial mean arterial pressure mmHg p_map G, cont  Natural Log of BNP  ln_bnp2 G, cont 
Brachial fractional pulse pressure  p_fpp G, cont  BNP grouping <50, 50-100, ≥100 bnp_group G, cat 
High peripheral systolic BP (≥140mmHg)  highsbp G, cat  BNP ≥80pg/mL  bnp_hi80 G, cat 
High peripheral diastolic BP (≥90mmHg)  highdbp G, cat  BNP >100pg/mL  bnp_hi100 G, cat 
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 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
C
R
P High-sensitivity C-reactive protein mg/L crp A, cont  
Pu
ls
e 
W
av
e 
A
na
ly
si
s (
co
nt
) Peripheral augmentation index 2 † % p_ai2 A, cont 
High-sensitivity CRP above detection limit >9.4 mg/L crp_hi A, cat  Peripheral augmentation index 3 ‡ % p_ai3 A, cont 
High-sensitivity CRP below detection limit <0.1 mg/L  A, cat  Pulse pressure amplification ratio % ppampratio A, cont 
High-sensitivity CRP ≥1mg/L  crp_hi1 G, cat  Central systolic BP mmHg c_sp A, cont 
High-sensitivity CRP ≥2mg/L  crp_hi2 G, cat  Central diastolic BP mmHg c_dp A, cont 
High-sensitivity CRP >3mg/L  crp_hi3 G, cat  Central pulse pressure mmHg c_pp A, cont 
High-sensitivity CRP grouping <1, 1-3, >3 crp_group G, cat  Central pulse pressure >50mmHg  cpp50 G, cat 
      Central pulse pressure quartiles  cppq G, cat 
Pu
ls
e 
W
av
e 
A
na
ly
si
s Radial PWA measured  pwa G, cat  Peripheral-central pulse pressure mmHg pc_ppdiff G, cont 
PWA operator  operator A, cat  Central mean arterial pressure mmHg c_map G, cont 
Date and time of PWA assessment  datetime A, cont  Central fractional pulse pressure  c_fpp G, cont 
Arterial site  sub_type A, cat  Mean central pressure during systole mmHg c_mps A, cont 
Quality index % operator_index A, cont  Mean central pressure during diastole mmHg c_mpd A, cont 
Quality index >85%  qi85 G, cat  Pressure at 1st shoulder of central waveform mmHg c_p1 A, cont 
Quality index deciles  qi10 G, cat  Pressure at 2nd shoulder of central waveform mmHg c_p2 A, cont 
Inconclusive (software-derived)  pwa_inconc A, cat  Time to 1st shoulder of central waveform ms c_t1 A, cont 
Quality index: Max pressure change  p_max_dpdt A, cont  Time to 2nd shoulder of central waveform ms c_t2 A, cont 
Quality index: Average pulse height  p_qc_ph A, cont  Maximal pulse height above diastolic BP mmHg c_ph A, cont 
Quality index: Pulse height variation  p_qc_phv A, cont  End systolic pressure of central waveform mmHg c_esp A, cont 
Quality index: Pulse length variation  p_qc_plv A, cont  Central augmentation pressure § mmHg c_ap A, cont 
Quality index: Diastolic variation  p_qc_dv A, cont  Central AP, adjusted to heart rate of 75 mmHg c_ap_hr75 A, cont 
Quality index: Shape deviation  p_qc_sdev A, cont  Central AP >24mmHg  cap24 G, cat 
Peripheral waveform pressure at 1st shoulder mmHg p_p1 A, cont  Central augmentation index 1 # % c_ai A, cont 
Peripheral waveform pressure at 2nd shoulder mmHg p_p2 A, cont  Central AI, adjusted to heart rate of 75 % c_ai_hr75 A, cont 
Time to 1st shoulder of peripheral waveform ms p_t1 A, cont  Central augmentation index 2 ¶ % c_ai2 G, cont 
Time to 2nd shoulder of peripheral waveform ms p_t2 A, cont  Systolic pressure time index  c_tti A, cont 
End systolic pressure of peripheral waveform mmHg p_esp A, cont  Diastolic pressure time index  c_dti A, cont 
Peripheral augmentation pressure mmHg p_ap A, cont  Sub-endocardial viability ratio % sevr A, cont 
Peripheral augmentation index * % p_ai A, cont  Absolute ejection duration ms ed A, cont 
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 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
PW
A
 (c
on
t) Ejection duration (diastole/systole) % ed_percent A, cont  
H
ea
rt 
R
at
e 
V
ar
ia
bi
lit
y 
(c
on
t) Natural log of HRV triangular index  ln_tri~_index G, cont 
Time of Reflectance ms aotr A, cont  Total HRV frequency power ms2 tp G, cat 
[all PWA variables repeated for 2nd waveform]    Total power ≤5000ms2  tp_5000 G, cat 
Difference in central AP, high-low quality mmHg ap_diff G, cont  Total power ≤600ms2  tp600 G, cat 
Mean central AP, high and low quality mmHg ap_mean G, cont  Natural log of total power  ln_tp G, cont 
Difference in central PP, high-low quality mmHg pp_diff A, cont  Low frequency power ms2 lf A, cont 
Mean central PP, high and low quality mmHg pp_mean G, cont  Log of low frequency power  ln_lf G, cont 
      Log of low frequency power - tertiles  lf250 G, cat 
H
ea
rt 
R
at
e 
V
ar
ia
bi
lit
y HRV not measured  nohrv G, cat  Low frequency power <250ms2  ln_lf_tert G, cat 
HRV start time  start_time A, cont  Normalised LF power (proportion of total) % lf_n A, cont 
HRV end time  end_time A, cont  Maximal LF power ms2 lf_max A, cont 
HRV capture time min capture_time G, cont  High frequency power ms2 hf A, cont 
Number of recorded pulses  number_pulses A, cont  Log of high frequency power  ln_hf G, cont 
Mean R-R interval ms mean A, cont  Normalised HF power (proportion of total) % hf_n A, cont 
Minimum R-R interval ms minimum A, cont  Maximal HF power ms2 hf_max A, cont 
Maximum R-R interval ms maximum A, cont  LF:HF ratio  ratio A, cont 
Range of R-R intervals ms range A, cont  Natural log of LF:HF ratio  ln_ratio G, cont 
Log of R-R interval range  ln_range G, cont  Maximum spectral power ms2 spec_max A, cont 
Ratio of maximum to minimum R-R interval  max_min A, cont  Natural log of maximum spectral power  ln_spec_max G, cont 
Standard deviation of R-R intervals ms sd A, cont  Total HRV frequency power ms2 tp G, cat 
Square root of R-R intervals SD  sq_sd G, cont       
Most frequent R-R interval ms mode A, cont  
Pu
ls
e 
W
av
e 
V
el
oc
ity
 Carotid-radial PWV measurement 1 m/s pwv_cr1 A, cont 
Number of consecutive R-R intervals >50ms  nn50 A, cont  Carotid-radial PWV measurement 1 SD m/s pwverr_cr1 A, cont 
Proportion of R-R intervals >50ms % pnn50 A, cont  Carotid-radial PWV measurement 2 m/s pwv_cr2 A, cont 
Root mean square of R-R interval differences  rmssd A, cont  Carotid-radial PWV measurement 2 SD m/s pwverr_cr2 A, cont 
Natural log of RMSSD  ln_rmssd G, cont  Carotid-femoral PWV measurement 1 m/s pwv_cf1 A, cont 
HRV index   hrv_index A, cont  Carotid-femoral PWV measurement 1 SD m/s pwverr_cf1 A, cont 
Natural log of HRV index  ln_hrv_index G, cont  Carotid-femoral PWV measurement 2 m/s pwv_cf2 A, cont 
HRV triangular index ms triangular_index A, cont  Carotid-femoral PWV measurement 2 SD m/s pwverr_cf2 A, cont 
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 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
PW
V
 (c
on
t) Mean carotid-radial PWV m/s crpwv G, cont  
El
ec
tro
ca
rd
io
gr
am
 (c
on
t) Paced  ecg_paced A, cat 
Natural log of mean carotid-radial PWV m/s ln_crpwv G, cont  Intraventricular conduction delay  ecg_bbb A, cat 
Mean carotid-femoral PWV m/s cfpwv G, cont  Other ECG classification  ecg_other A, cat 
Natural log of mean carotid-femoral PWV  ln_cfpwv G, cont  Comments for ECG classification  ecg_othertext A, str 
Mean carotid-femoral PWV >12m/s  cfpwv12 G, cat  ECG rhythm  ecgrhythm A, cat 
Difference in carotid-radial PWV (1st-2nd) m/s crpwv_diff G, cont  ECG rhythm abnormality  ecgr_abn A, cat 
Difference in carotid-femoral PWV (1st-2nd) m/s cfpwv_diff G, cont  Sinus rhythm  ecgr_sinus A, cat 
      Atrial or ventricular ectopics  ecgr_ectopics A, cat 
R
is
k 
A
lg
or
ith
m
s Total points on Framingham Risk Score  framtotal G, cont  Atrial fibrillation or flutter  ecgr_af A, cat 
Framingham 10-year coronary disease risk % framrisk G, cont  Heart block  ecgr_hb A, cat 
Framingham risk ≥20%  framrisk_20 G, cat  Other rhythm  ecgr_other A, cat 
Framingham risk ≥10%  framrisk_10 G, cat  Comments for ECG rhythm  ecgr_othertext A, str 
SCORE risk calculation CVD  scorerisk10cvd G, cont  LV hypertrophy  ecglvh A, cat 
SCORE risk calculation CAD  scorerisk10chd G, cont  Type of bundle branch block  ecgbbbtype A, cat 
SCORE 10-year risk of fatal CVD % score G, cont  ST or T-wave changes  ecg_isch G, cat 
SCORE risk adjusted for diabetes % score_dm G, cont  Q waves, ST or T-wave changes  ecg_isch2 G, cat 
Mean of Framingham & SCORE % risk_mean G, cont  ECG reporter identification  ecgreporter_id A, str 
Difference in Framingham & SCORE % risk_diff G, cont  ECG reporter initials  ecgreporter_init A, str 
           
El
ec
tro
ca
rd
io
gr
am
 Atrial or ventricular ectopics (>5 over 5-min)  ectopics G, cat  
A
ng
io
gr
ap
hy
 Date of coronary angiography  angio_date A, cont 
Ectopics or atrial arrhythmias  arrhyth G, cat  Angiogram comments  angio_comment A, str 
Atrial fibrillation/flutter  atrialf G, cat  Reviewed by core laboratory  de_review G, cat 
Abnormal ECG  ecgabn A, cat  Coronary artery dominance right, left dominance A, cat 
Type of ECG abnormality  ecgabnormality A, str  Stenosis % in LMCA % lmca A, cont 
Pathological Q waves  ecg_q A, cat  Minor irregularities within LMCA  lmca_min A, cat 
ST elevation  ecg_ste A, cat  Stenosis within existing stent in LMCA  lmca_pci A, cat 
ST depression  ecg_std A, cat  Ostial/bifurcation lesion of LMCA  lmca_ost A, cat 
T wave changes  ecg_t A, cat  Most severe LAD/Diagonal lesion % ladmax G, cont 
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 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
A
ng
io
gr
ap
hy
 (c
on
t) Stenosis % LAD1 % lad1 A, cont  
A
ng
io
gr
ap
hy
 (c
on
t) Minor irregularities, RCA1  rca1min A, cat 
Location of stenosis for LAD1  lad1loc A, cat  Stenosis within existing stent, RCA1  rca1pci A, cat 
Minor irregularities, LAD1  lad1min A, cat  Stenosis % RCA2 % rca2 A, cont 
Stenosis within existing stent, LAD1  lad1pci A, cat  Location of stenosis for RCA2  rca2loc A, cat 
LAD1 ostial/bifurcation lesion  lad1ost A, cat  Minor irregularities, RCA2  rca2min A, cat 
Stenosis % LAD2 % lad2 A, cont  Stenosis within existing stent, RCA2  rca2pci A, cat 
Location of stenosis for LAD2  lad2loc A, cat  Stenosis % RCA3 % rca3 A, cont 
Minor irregularities, LAD2  lad2min A, cat  Location of stenosis for RCA3  rca3loc A, cat 
Stenosis within existing stent, LAD2  lad2pci A, cat  Minor irregularities, RCA3  rca3min A, cat 
LAD2 ostial/bifurcation lesion  lad2ost A, cat  Stenosis within existing stent, RCA3  rca3pci A, cat 
Stenosis % LAD3 % lad3 A, cont  Stenosis % Graft1 % graft1 A, cont 
Location of stenosis for LAD3  lad3loc A, cat  Minor irregularities within Graft1  graft1min A, cat 
Minor irregularities, LAD3  lad3min A, cat  Graft1 type  graft1type A, cat 
Stenosis within existing stent, LAD3  lad3pci A, cat  Location of stenosis in Graft1  graft1loc A, cat 
LAD3 ostial/bifurcation lesion  lad3ost A, cat  Stenosis within existing stent in Graft1  graft1pci A, cat 
Stenosis % LCX1 % lcx1 A, cont  Stenosis % Graft2 % graft2 A, cont 
Location of stenosis for LCX1  lcx1loc A, cat  Minor irregularities within Graft2  graft2min A, cat 
Minor irregularities, LCX1  lcx1min A, cat  Graft2 type  graft2type A, cat 
Stenosis within existing stent, LCX1  lcx1pci A, cat  Location of stenosis in Graft2  graft2loc A, cat 
Stenosis % LCX2 % lcx2 A, cont  Stenosis within existing stent in Graft2  graft2pci A, cat 
Location of stenosis for LCX2  lcx2loc A, cat  Stenosis % Graft3 % graft3 A, cont 
Minor irregularities, LCX2  lcx2min A, cat  Minor irregularities within Graft3  graft3min A, cat 
Stenosis within existing stent, LCX2  lcx2pci A, cat  Graft3 type  graft3type A, cat 
Stenosis % LCX3 % lcx3 A, cont  Location of stenosis in Graft3  graft3loc A, cat 
Location of stenosis for LCX3  lcx3loc A, cat  Stenosis within existing stent in Graft3  graft3pci A, cat 
Minor irregularities, LCX3  lcx3min A, cat  Stenosis % Graft4 % graft4 A, cont 
Stenosis within existing stent, LCX3  lcx3pci A, cat  Minor irregularities within Graft4  graft4min A, cat 
Stenosis % RCA1 % rca1 A, cont  Graft4 type  graft4type A, cat 
Location of stenosis for RCA1  rca1loc A, cat  Location of stenosis in Graft4  graft4loc A, cat 
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 Variable Unit Abbrev Type   Variable Unit Abbrev Type 
A
ng
io
gr
ap
hy
 (c
on
t) Extent of native vessel CAD  cadscore G, cat  
 
Measured-derived systolic BP mmHg sbpdiff G, cont 
Obstructive CAD (1 or more ≥50% stenosis)  sigcad G, cat  Measured-derived diastolic BP mmHg dbpdiff G, cont 
Number of obstructed coronary systems  nvd G, cat  Measured-derived pulse pressure mmHg ppdiff G, cont 
Any degree of native vessel CAD  anycad G, cat       
Angiographically-normal coronary arteries  nocad G, cat  
Ec
ho
ca
rd
io
gr
ap
hy
 Date of echocardiography  echo_date A, cont 
No of proximal CAD lesions ≥70%  proxcad G, cat  Left atrial radius cm elarad A, cont 
1 or more proximal CAD lesions ≥70%  sig_proxcad G, cat  Left atrial area cm2 elaarea A, cont 
SYNTAX-modified Leaman score (excludes 
prior CABG)  leaman G, cont  Left atrial area >20cm
2  elaarea_cat A/G, cat 
Leaman score in those with obstructive CAD  leaman2 G, cont  Right atrial area cm2 eraarea A, cont 
Natural log of Leaman2  ln_leaman2 G, cont  Right atrial area >20cm2  eraarea_cat A/G, cat 
Categorical Leaman scores 0, 0-5, 5-10, 10-20, 20+ leaman_cat G, cat  LV diastolic dimension cm elvdia A, cont 
Treatment Recommendation  recom A, cat  LV systolic dimension cm elvsys A, cont 
PCI, CABG, valve replacement or further 
investigation  recomb1 G, cat  Intraventricular septum width cm eivs A, cont 
Revascularisation required  recomb2 G, cat  Posterior wall dimension cm epw A, cont 
      LV mass index g/m2 elvmass A, cont 
Le
ft-
V
en
tri
cu
lo
gr
am
 Impairment of LV systolic function  lvimp A, cat  Aortic root diameter cm earoot A, cont 
LV ejection fraction on LV-gram % lvef A, cont  Doppler: Peak Mitral E   epeak_e A, cont 
LV end-diastolic pressure mmHg lvedp A, cont  Doppler: Peak Mitral A  epeak_a A, cont 
Hypokinesis on LVgram  lvhypokin A, cat  E/A ratio  eea G, cont 
Aortic systolic BP mmHg aosbp A, cont  E/E-prime ratio  e_e1 A, cont 
Aortic diastolic BP mmHg aodbp A, cont  Fractional shortening % efs A, cont 
Aortic pulse pressure (aosbp - aodbp) mmHg aopp G, cont  Ejection Fraction % eef A, cont 
LV systolic pressure (pre) mmHg lvpresys A, cont  Mean aortic valve gradient mmHg eavgrad A, cont 
LV systolic pressure (post) mmHg lvpostsys A, cont  Aortic stenosis severity <25, 25-40, >40 eavgrad_cat A, cat 
LV diastolic pressure (pre) mmHg lvpredia A, cont  Aortic valve area cm2 eavarea A, cont 
LV diastolic pressure (post) mmHg lvpostdia A, cont  Aortic valve regurgitation None, mild, mod, severe eavreg A, cat 
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 Variable Unit Abbrev Type   
Ec
ho
ca
rd
io
gr
ap
hy
 (c
on
t) Any aortic valve disease  avalve G, cat   
Moderate or severe aortic valve disease  asigvalve G, cat   
Mitral valve gradient mmHg emvgrad A, cont   
Mitral stenosis severity <5, 5-10, >10 emvgrad_cat A, cat   
Mitral valve area cm2 emvarea A, cont   
Mitral valve regurgitation None, mild, mod, severe emvreg A, cat   
Any mitral valve disease  mvalve G, cat   
Moderate or severe mitral valve disease  msigvalve G, cat   
Any aortic or mitral valve disease  anyvalve G, cat   
Moderate or severe aortic/mitral valve disease  anysigvalve G, cat  Legend 
Abnormal LV size  elvsize A, cat   
Severity of LV impairment None, mild, mod, severe elvimp A, cat  A = assessed 
Impaired LV function  elvimp_yn A, cat  G = generated 
LV dilatation  elvd A, cat  cat = categorical 
LV hypertrophy  elvh A, cat  cont = continuous 
Abnormal RV size  ervsize A, cat  str = string variable 
Impaired RV function  ervimp A, cat   
RV dilatation  ervd A, cat  *  p_ap/p_pp 
RV hypertrophy  ervh A, cat  †  p_p2 - p-dp / p_p1 - p_dp 
Location of hypokinesis  ehypokin_loc A, str  ‡  p_p2/p_p1 
Hypokinesis present  ehypokin G, cat  §  c_p2 - c_p1 
Impaired diastole/relaxation  edhf A, cat  #  c_ap/c_pp 
Impaired LV function on LV-gram / echo if 
missing  lvimp_yn G, cat 
 ¶  c_p2/c_p1 
Ejection fraction using LV-gram / echo if 
missing % ef_overall G, cont 
  
Hypokinesis on LV-gram / echo if missing  hypokin G, cat   
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Appendix C. Obtaining Radial Pulse Waveforms 
 
                 
 
Left:  Millar tonometer and conventional oscillometric blood pressure meter. 
Other images:  Research nurse Elizabeth Jenkins performing radial pulse wave analysis on two participants. 
[photographic permissions on file] 
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